id	sid	tid	token	lemma	pos
cord-334454-cqaado3u	1	1	key	key	NN
cord-334454-cqaado3u	1	2	:	:	:
cord-334454-cqaado3u	2	1	cord-334454-cqaado3u	cord-334454-cqaado3u	NNP
cord-334454-cqaado3u	2	2	authors	author	NNS
cord-334454-cqaado3u	2	3	:	:	:
cord-334454-cqaado3u	2	4	Leal	Leal	NNP
cord-334454-cqaado3u	2	5	,	,	,
cord-334454-cqaado3u	2	6	Rodolfo	Rodolfo	NNP
cord-334454-cqaado3u	2	7	Oliveira	Oliveira	NNP
cord-334454-cqaado3u	2	8	;	;	:
cord-334454-cqaado3u	2	9	Gil	Gil	NNP
cord-334454-cqaado3u	2	10	,	,	,
cord-334454-cqaado3u	3	1	Solange	Solange	NNP
cord-334454-cqaado3u	3	2	title	title	NN
cord-334454-cqaado3u	3	3	:	:	:
cord-334454-cqaado3u	4	1	The	the	DT
cord-334454-cqaado3u	4	2	Use	Use	NNP
cord-334454-cqaado3u	4	3	of	of	IN
cord-334454-cqaado3u	4	4	Recombinant	recombinant	JJ
cord-334454-cqaado3u	4	5	Feline	Feline	NNP
cord-334454-cqaado3u	4	6	Interferon	Interferon	NNP
cord-334454-cqaado3u	4	7	Omega	Omega	NNP
cord-334454-cqaado3u	4	8	Therapy	Therapy	NNP
cord-334454-cqaado3u	4	9	as	as	IN
cord-334454-cqaado3u	4	10	an	an	DT
cord-334454-cqaado3u	4	11	Immune	Immune	NNP
cord-334454-cqaado3u	4	12	-	-	HYPH
cord-334454-cqaado3u	4	13	Modulator	modulator	NN
cord-334454-cqaado3u	4	14	in	in	IN
cord-334454-cqaado3u	4	15	Cats	Cats	NNPS
cord-334454-cqaado3u	4	16	Naturally	naturally	RB
cord-334454-cqaado3u	4	17	Infected	infect	VBN
cord-334454-cqaado3u	4	18	with	with	IN
cord-334454-cqaado3u	4	19	Feline	feline	JJ
cord-334454-cqaado3u	4	20	Immunodeficiency	Immunodeficiency	NNP
cord-334454-cqaado3u	4	21	Virus	Virus	NNP
cord-334454-cqaado3u	4	22	:	:	:
cord-334454-cqaado3u	4	23	New	new	JJ
cord-334454-cqaado3u	4	24	Perspectives	Perspectives	NNPS
cord-334454-cqaado3u	4	25	date	date	NN
cord-334454-cqaado3u	4	26	:	:	:
cord-334454-cqaado3u	4	27	2016	2016	CD
cord-334454-cqaado3u	4	28	-	-	SYM
cord-334454-cqaado3u	4	29	10	10	CD
cord-334454-cqaado3u	4	30	-	-	SYM
cord-334454-cqaado3u	4	31	27	27	CD
cord-334454-cqaado3u	4	32	journal	journal	NN
cord-334454-cqaado3u	4	33	:	:	:
cord-334454-cqaado3u	5	1	Vet	Vet	NNP
cord-334454-cqaado3u	5	2	Sci	Sci	NNP
cord-334454-cqaado3u	5	3	DOI	DOI	NNP
cord-334454-cqaado3u	5	4	:	:	:
cord-334454-cqaado3u	5	5	10.3390	10.3390	CD
cord-334454-cqaado3u	5	6	/	/	SYM
cord-334454-cqaado3u	5	7	vetsci3040032	vetsci3040032	NNP
cord-334454-cqaado3u	5	8	sha	sha	NNP
cord-334454-cqaado3u	5	9	:	:	:
cord-334454-cqaado3u	6	1	8041d586dc357d38fb7e13f528d400a14ae64b8d	8041d586dc357d38fb7e13f528d400a14ae64b8d	NNP
cord-334454-cqaado3u	6	2	doc_id	doc_id	CD
cord-334454-cqaado3u	6	3	:	:	:
cord-334454-cqaado3u	6	4	334454	334454	CD
cord-334454-cqaado3u	6	5	cord_uid	cord_uid	NNS
cord-334454-cqaado3u	6	6	:	:	:
cord-334454-cqaado3u	7	1	cqaado3u	cqaado3u	NNP
cord-334454-cqaado3u	8	1	Type	type	NN
cord-334454-cqaado3u	8	2	I	-PRON-	PRP
cord-334454-cqaado3u	8	3	interferons	interferon	NNS
cord-334454-cqaado3u	8	4	(	(	-LRB-
cord-334454-cqaado3u	8	5	IFNs	IFNs	NNP
cord-334454-cqaado3u	8	6	)	)	-RRB-
cord-334454-cqaado3u	8	7	are	be	VBP
cord-334454-cqaado3u	8	8	well	well	RB
cord-334454-cqaado3u	8	9	-	-	HYPH
cord-334454-cqaado3u	8	10	known	know	VBN
cord-334454-cqaado3u	8	11	cytokines	cytokine	NNS
cord-334454-cqaado3u	8	12	that	that	WDT
cord-334454-cqaado3u	8	13	,	,	,
cord-334454-cqaado3u	8	14	among	among	IN
cord-334454-cqaado3u	8	15	their	-PRON-	PRP$
cord-334454-cqaado3u	8	16	main	main	JJ
cord-334454-cqaado3u	8	17	functions	function	NNS
cord-334454-cqaado3u	8	18	,	,	,
cord-334454-cqaado3u	8	19	are	be	VBP
cord-334454-cqaado3u	8	20	key	key	JJ
cord-334454-cqaado3u	8	21	components	component	NNS
cord-334454-cqaado3u	8	22	of	of	IN
cord-334454-cqaado3u	8	23	the	the	DT
cord-334454-cqaado3u	8	24	host	host	NN
cord-334454-cqaado3u	8	25	immune	immune	JJ
cord-334454-cqaado3u	8	26	response	response	NN
cord-334454-cqaado3u	8	27	against	against	IN
cord-334454-cqaado3u	8	28	viral	viral	JJ
cord-334454-cqaado3u	8	29	infections	infection	NNS
cord-334454-cqaado3u	8	30	.	.	.
cord-334454-cqaado3u	9	1	Due	due	IN
cord-334454-cqaado3u	9	2	to	to	IN
cord-334454-cqaado3u	9	3	its	-PRON-	PRP$
cord-334454-cqaado3u	9	4	immune	immune	JJ
cord-334454-cqaado3u	9	5	modulation	modulation	NN
cord-334454-cqaado3u	9	6	properties	property	NNS
cord-334454-cqaado3u	9	7	,	,	,
cord-334454-cqaado3u	9	8	they	-PRON-	PRP
cord-334454-cqaado3u	9	9	are	be	VBP
cord-334454-cqaado3u	9	10	commonly	commonly	RB
cord-334454-cqaado3u	9	11	used	use	VBN
cord-334454-cqaado3u	9	12	in	in	IN
cord-334454-cqaado3u	9	13	the	the	DT
cord-334454-cqaado3u	9	14	therapeutic	therapeutic	JJ
cord-334454-cqaado3u	9	15	approach	approach	NN
cord-334454-cqaado3u	9	16	of	of	IN
cord-334454-cqaado3u	9	17	various	various	JJ
cord-334454-cqaado3u	9	18	retroviral	retroviral	JJ
cord-334454-cqaado3u	9	19	infections	infection	NNS
cord-334454-cqaado3u	9	20	,	,	,
cord-334454-cqaado3u	9	21	namely	namely	RB
cord-334454-cqaado3u	9	22	human	human	JJ
cord-334454-cqaado3u	9	23	immunodeficiency	immunodeficiency	NN
cord-334454-cqaado3u	9	24	virus	virus	NN
cord-334454-cqaado3u	9	25	(	(	-LRB-
cord-334454-cqaado3u	9	26	HIV	HIV	NNP
cord-334454-cqaado3u	9	27	)	)	-RRB-
cord-334454-cqaado3u	9	28	and	and	CC
cord-334454-cqaado3u	9	29	feline	feline	JJ
cord-334454-cqaado3u	9	30	immunodeficiency	immunodeficiency	NN
cord-334454-cqaado3u	9	31	virus	virus	NN
cord-334454-cqaado3u	9	32	(	(	-LRB-
cord-334454-cqaado3u	9	33	FIV	FIV	NNP
cord-334454-cqaado3u	9	34	)	)	-RRB-
cord-334454-cqaado3u	9	35	.	.	.
cord-334454-cqaado3u	10	1	In	in	IN
cord-334454-cqaado3u	10	2	HIV	HIV	NNP
cord-334454-cqaado3u	10	3	infection	infection	NN
cord-334454-cqaado3u	10	4	,	,	,
cord-334454-cqaado3u	10	5	it	-PRON-	PRP
cord-334454-cqaado3u	10	6	has	have	VBZ
cord-334454-cqaado3u	10	7	been	be	VBN
cord-334454-cqaado3u	10	8	shown	show	VBN
cord-334454-cqaado3u	10	9	that	that	IN
cord-334454-cqaado3u	10	10	IFN	IFN	NNP
cord-334454-cqaado3u	10	11	therapy	therapy	NN
cord-334454-cqaado3u	10	12	limits	limit	VBZ
cord-334454-cqaado3u	10	13	early	early	JJ
cord-334454-cqaado3u	10	14	viral	viral	JJ
cord-334454-cqaado3u	10	15	replication	replication	NN
cord-334454-cqaado3u	10	16	,	,	,
cord-334454-cqaado3u	10	17	particularly	particularly	RB
cord-334454-cqaado3u	10	18	useful	useful	JJ
cord-334454-cqaado3u	10	19	on	on	IN
cord-334454-cqaado3u	10	20	post	post	JJ
cord-334454-cqaado3u	10	21	-	-	JJ
cord-334454-cqaado3u	10	22	exposure	exposure	JJ
cord-334454-cqaado3u	10	23	prophylaxis	prophylaxis	NN
cord-334454-cqaado3u	10	24	.	.	.
cord-334454-cqaado3u	11	1	In	in	IN
cord-334454-cqaado3u	11	2	veterinary	veterinary	JJ
cord-334454-cqaado3u	11	3	medicine	medicine	NN
cord-334454-cqaado3u	11	4	,	,	,
cord-334454-cqaado3u	11	5	recombinant	recombinant	JJ
cord-334454-cqaado3u	11	6	feline	feline	JJ
cord-334454-cqaado3u	11	7	interferon	interferon	NN
cord-334454-cqaado3u	11	8	omega	omega	NN
cord-334454-cqaado3u	11	9	(	(	-LRB-
cord-334454-cqaado3u	11	10	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	11	11	-	-	HYPH
cord-334454-cqaado3u	11	12	ω	ω	CD
cord-334454-cqaado3u	11	13	)	)	-RRB-
cord-334454-cqaado3u	11	14	was	be	VBD
cord-334454-cqaado3u	11	15	the	the	DT
cord-334454-cqaado3u	11	16	first	first	JJ
cord-334454-cqaado3u	11	17	interferon	interferon	NN
cord-334454-cqaado3u	11	18	licensed	license	VBN
cord-334454-cqaado3u	11	19	for	for	IN
cord-334454-cqaado3u	11	20	use	use	NN
cord-334454-cqaado3u	11	21	in	in	IN
cord-334454-cqaado3u	11	22	cats	cat	NNS
cord-334454-cqaado3u	11	23	.	.	.
cord-334454-cqaado3u	12	1	Several	several	JJ
cord-334454-cqaado3u	12	2	studies	study	NNS
cord-334454-cqaado3u	12	3	have	have	VBP
cord-334454-cqaado3u	12	4	recently	recently	RB
cord-334454-cqaado3u	12	5	shown	show	VBN
cord-334454-cqaado3u	12	6	that	that	IN
cord-334454-cqaado3u	12	7	this	this	DT
cord-334454-cqaado3u	12	8	compound	compound	NN
cord-334454-cqaado3u	12	9	seems	seem	VBZ
cord-334454-cqaado3u	12	10	to	to	TO
cord-334454-cqaado3u	12	11	stimulate	stimulate	VB
cord-334454-cqaado3u	12	12	the	the	DT
cord-334454-cqaado3u	12	13	innate	innate	JJ
cord-334454-cqaado3u	12	14	immunity	immunity	NN
cord-334454-cqaado3u	12	15	,	,	,
cord-334454-cqaado3u	12	16	decreasing	decrease	VBG
cord-334454-cqaado3u	12	17	clinical	clinical	JJ
cord-334454-cqaado3u	12	18	signs	sign	NNS
cord-334454-cqaado3u	12	19	and	and	CC
cord-334454-cqaado3u	12	20	co	co	NNS
cord-334454-cqaado3u	12	21	-	-	NNS
cord-334454-cqaado3u	12	22	infections	infection	NNS
cord-334454-cqaado3u	12	23	in	in	IN
cord-334454-cqaado3u	12	24	naturally	naturally	RB
cord-334454-cqaado3u	12	25	FIV	fiv	NN
cord-334454-cqaado3u	12	26	-	-	HYPH
cord-334454-cqaado3u	12	27	infected	infect	VBN
cord-334454-cqaado3u	12	28	cats	cat	NNS
cord-334454-cqaado3u	12	29	.	.	.
cord-334454-cqaado3u	13	1	More	More	JJR
cord-334454-cqaado3u	13	2	than	than	IN
cord-334454-cqaado3u	13	3	summarizing	summarize	VBG
cord-334454-cqaado3u	13	4	the	the	DT
cord-334454-cqaado3u	13	5	main	main	JJ
cord-334454-cqaado3u	13	6	conclusions	conclusion	NNS
cord-334454-cqaado3u	13	7	about	about	IN
cord-334454-cqaado3u	13	8	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	13	9	-	-	HYPH
cord-334454-cqaado3u	13	10	ω	ω	NN
cord-334454-cqaado3u	13	11	in	in	IN
cord-334454-cqaado3u	13	12	cats	cat	NNS
cord-334454-cqaado3u	13	13	,	,	,
cord-334454-cqaado3u	13	14	this	this	DT
cord-334454-cqaado3u	13	15	review	review	NN
cord-334454-cqaado3u	13	16	emphasizes	emphasize	VBZ
cord-334454-cqaado3u	13	17	the	the	DT
cord-334454-cqaado3u	13	18	immune	immune	JJ
cord-334454-cqaado3u	13	19	-	-	HYPH
cord-334454-cqaado3u	13	20	modulation	modulation	NN
cord-334454-cqaado3u	13	21	properties	property	NNS
cord-334454-cqaado3u	13	22	of	of	IN
cord-334454-cqaado3u	13	23	IFN	IFN	NNP
cord-334454-cqaado3u	13	24	therapy	therapy	NN
cord-334454-cqaado3u	13	25	,	,	,
cord-334454-cqaado3u	13	26	opening	open	VBG
cord-334454-cqaado3u	13	27	new	new	JJ
cord-334454-cqaado3u	13	28	perspectives	perspective	NNS
cord-334454-cqaado3u	13	29	for	for	IN
cord-334454-cqaado3u	13	30	its	-PRON-	PRP$
cord-334454-cqaado3u	13	31	use	use	NN
cord-334454-cqaado3u	13	32	in	in	IN
cord-334454-cqaado3u	13	33	retroviral	retroviral	JJ
cord-334454-cqaado3u	13	34	infections	infection	NNS
cord-334454-cqaado3u	13	35	.	.	.
cord-334454-cqaado3u	14	1	Either	either	CC
cord-334454-cqaado3u	14	2	in	in	IN
cord-334454-cqaado3u	14	3	FIV	fiv	NN
cord-334454-cqaado3u	14	4	-	-	HYPH
cord-334454-cqaado3u	14	5	infected	infect	VBN
cord-334454-cqaado3u	14	6	cats	cat	NNS
cord-334454-cqaado3u	14	7	or	or	CC
cord-334454-cqaado3u	14	8	in	in	IN
cord-334454-cqaado3u	14	9	HIV	HIV	NNP
cord-334454-cqaado3u	14	10	individuals	individual	NNS
cord-334454-cqaado3u	14	11	,	,	,
cord-334454-cqaado3u	14	12	type	type	NN
cord-334454-cqaado3u	14	13	I	-PRON-	PRP
cord-334454-cqaado3u	14	14	IFNs	ifns	VBP
cord-334454-cqaado3u	14	15	seem	seem	VBP
cord-334454-cqaado3u	14	16	to	to	TO
cord-334454-cqaado3u	14	17	induce	induce	VB
cord-334454-cqaado3u	14	18	an	an	DT
cord-334454-cqaado3u	14	19	innate	innate	JJ
cord-334454-cqaado3u	14	20	immune	immune	JJ
cord-334454-cqaado3u	14	21	-	-	HYPH
cord-334454-cqaado3u	14	22	modulation	modulation	NN
cord-334454-cqaado3u	14	23	and	and	CC
cord-334454-cqaado3u	14	24	should	should	MD
cord-334454-cqaado3u	14	25	not	not	RB
cord-334454-cqaado3u	14	26	be	be	VB
cord-334454-cqaado3u	14	27	overlooked	overlook	VBN
cord-334454-cqaado3u	14	28	as	as	IN
cord-334454-cqaado3u	14	29	a	a	DT
cord-334454-cqaado3u	14	30	therapeutic	therapeutic	JJ
cord-334454-cqaado3u	14	31	option	option	NN
cord-334454-cqaado3u	14	32	in	in	IN
cord-334454-cqaado3u	14	33	retroviral	retroviral	JJ
cord-334454-cqaado3u	14	34	infections	infection	NNS
cord-334454-cqaado3u	14	35	.	.	.
cord-334454-cqaado3u	15	1	In	in	IN
cord-334454-cqaado3u	15	2	clinical	clinical	JJ
cord-334454-cqaado3u	15	3	practice	practice	NN
cord-334454-cqaado3u	15	4	,	,	,
cord-334454-cqaado3u	15	5	the	the	DT
cord-334454-cqaado3u	15	6	initial	initial	JJ
cord-334454-cqaado3u	15	7	therapeutic	therapeutic	JJ
cord-334454-cqaado3u	15	8	approach	approach	NN
cord-334454-cqaado3u	15	9	in	in	IN
cord-334454-cqaado3u	15	10	cats	cat	NNS
cord-334454-cqaado3u	15	11	suspected	suspect	VBN
cord-334454-cqaado3u	15	12	of	of	IN
cord-334454-cqaado3u	15	13	retroviral	retroviral	JJ
cord-334454-cqaado3u	15	14	infections	infection	NNS
cord-334454-cqaado3u	15	15	is	be	VBZ
cord-334454-cqaado3u	15	16	always	always	RB
cord-334454-cqaado3u	15	17	supportive	supportive	JJ
cord-334454-cqaado3u	15	18	and	and	CC
cord-334454-cqaado3u	15	19	symptomatic	symptomatic	JJ
cord-334454-cqaado3u	15	20	.	.	.
cord-334454-cqaado3u	16	1	When	when	WRB
cord-334454-cqaado3u	16	2	the	the	DT
cord-334454-cqaado3u	16	3	diagnosis	diagnosis	NN
cord-334454-cqaado3u	16	4	of	of	IN
cord-334454-cqaado3u	16	5	retroviral	retroviral	JJ
cord-334454-cqaado3u	16	6	infection	infection	NN
cord-334454-cqaado3u	16	7	is	be	VBZ
cord-334454-cqaado3u	16	8	established	establish	VBN
cord-334454-cqaado3u	16	9	,	,	,
cord-334454-cqaado3u	16	10	antivirals	antiviral	NNS
cord-334454-cqaado3u	16	11	and	and	CC
cord-334454-cqaado3u	16	12	immune	immune	JJ
cord-334454-cqaado3u	16	13	modulators	modulator	NNS
cord-334454-cqaado3u	16	14	can	can	MD
cord-334454-cqaado3u	16	15	be	be	VB
cord-334454-cqaado3u	16	16	considered	consider	VBN
cord-334454-cqaado3u	16	17	on	on	IN
cord-334454-cqaado3u	16	18	short	short	JJ
cord-334454-cqaado3u	16	19	-	-	HYPH
cord-334454-cqaado3u	16	20	and	and	CC
cord-334454-cqaado3u	16	21	long	long	JJ
cord-334454-cqaado3u	16	22	-	-	HYPH
cord-334454-cqaado3u	16	23	term	term	NN
cord-334454-cqaado3u	16	24	management	management	NN
cord-334454-cqaado3u	16	25	.	.	.
cord-334454-cqaado3u	17	1	Taking	take	VBG
cord-334454-cqaado3u	17	2	into	into	IN
cord-334454-cqaado3u	17	3	account	account	NN
cord-334454-cqaado3u	17	4	that	that	IN
cord-334454-cqaado3u	17	5	most	most	JJS
cord-334454-cqaado3u	17	6	of	of	IN
cord-334454-cqaado3u	17	7	these	these	DT
cord-334454-cqaado3u	17	8	drugs	drug	NNS
cord-334454-cqaado3u	17	9	are	be	VBP
cord-334454-cqaado3u	17	10	licensed	license	VBN
cord-334454-cqaado3u	17	11	for	for	IN
cord-334454-cqaado3u	17	12	use	use	NN
cord-334454-cqaado3u	17	13	in	in	IN
cord-334454-cqaado3u	17	14	humans	human	NNS
cord-334454-cqaado3u	17	15	,	,	,
cord-334454-cqaado3u	17	16	there	there	EX
cord-334454-cqaado3u	17	17	is	be	VBZ
cord-334454-cqaado3u	17	18	a	a	DT
cord-334454-cqaado3u	17	19	lack	lack	NN
cord-334454-cqaado3u	17	20	of	of	IN
cord-334454-cqaado3u	17	21	well	well	RB
cord-334454-cqaado3u	17	22	-	-	HYPH
cord-334454-cqaado3u	17	23	controlled	control	VBN
cord-334454-cqaado3u	17	24	clinical	clinical	JJ
cord-334454-cqaado3u	17	25	trials	trial	NNS
cord-334454-cqaado3u	17	26	in	in	IN
cord-334454-cqaado3u	17	27	cats	cat	NNS
cord-334454-cqaado3u	17	28	and	and	CC
cord-334454-cqaado3u	17	29	their	-PRON-	PRP$
cord-334454-cqaado3u	17	30	efficacy	efficacy	NN
cord-334454-cqaado3u	17	31	is	be	VBZ
cord-334454-cqaado3u	17	32	not	not	RB
cord-334454-cqaado3u	17	33	entirely	entirely	RB
cord-334454-cqaado3u	17	34	clear	clear	JJ
cord-334454-cqaado3u	17	35	[	[	-LRB-
cord-334454-cqaado3u	17	36	1	1	CD
cord-334454-cqaado3u	17	37	,	,	,
cord-334454-cqaado3u	17	38	2	2	CD
cord-334454-cqaado3u	17	39	]	]	-RRB-
cord-334454-cqaado3u	17	40	.	.	.
cord-334454-cqaado3u	18	1	Nowadays	nowadays	RB
cord-334454-cqaado3u	18	2	,	,	,
cord-334454-cqaado3u	18	3	there	there	EX
cord-334454-cqaado3u	18	4	are	be	VBP
cord-334454-cqaado3u	18	5	no	no	DT
cord-334454-cqaado3u	18	6	antivirals	antiviral	NNS
cord-334454-cqaado3u	18	7	licensed	license	VBN
cord-334454-cqaado3u	18	8	for	for	IN
cord-334454-cqaado3u	18	9	use	use	NN
cord-334454-cqaado3u	18	10	in	in	IN
cord-334454-cqaado3u	18	11	veterinary	veterinary	JJ
cord-334454-cqaado3u	18	12	medicine	medicine	NN
cord-334454-cqaado3u	18	13	with	with	IN
cord-334454-cqaado3u	18	14	the	the	DT
cord-334454-cqaado3u	18	15	exception	exception	NN
cord-334454-cqaado3u	18	16	of	of	IN
cord-334454-cqaado3u	18	17	several	several	JJ
cord-334454-cqaado3u	18	18	immune	immune	JJ
cord-334454-cqaado3u	18	19	modulators	modulator	NNS
cord-334454-cqaado3u	18	20	,	,	,
cord-334454-cqaado3u	18	21	which	which	WDT
cord-334454-cqaado3u	18	22	have	have	VBP
cord-334454-cqaado3u	18	23	concurrent	concurrent	JJ
cord-334454-cqaado3u	18	24	antiviral	antiviral	JJ
cord-334454-cqaado3u	18	25	properties	property	NNS
cord-334454-cqaado3u	18	26	.	.	.
cord-334454-cqaado3u	19	1	Therefore	therefore	RB
cord-334454-cqaado3u	19	2	,	,	,
cord-334454-cqaado3u	19	3	all	all	PDT
cord-334454-cqaado3u	19	4	the	the	DT
cord-334454-cqaado3u	19	5	truly	truly	RB
cord-334454-cqaado3u	19	6	antiviral	antiviral	JJ
cord-334454-cqaado3u	19	7	compounds	compound	NNS
cord-334454-cqaado3u	19	8	used	use	VBN
cord-334454-cqaado3u	19	9	in	in	IN
cord-334454-cqaado3u	19	10	dogs	dog	NNS
cord-334454-cqaado3u	19	11	and	and	CC
cord-334454-cqaado3u	19	12	cats	cat	NNS
cord-334454-cqaado3u	19	13	are	be	VBP
cord-334454-cqaado3u	19	14	those	those	DT
cord-334454-cqaado3u	19	15	licensed	license	VBN
cord-334454-cqaado3u	19	16	for	for	IN
cord-334454-cqaado3u	19	17	use	use	NN
cord-334454-cqaado3u	19	18	in	in	IN
cord-334454-cqaado3u	19	19	humans	human	NNS
cord-334454-cqaado3u	19	20	,	,	,
cord-334454-cqaado3u	19	21	namely	namely	RB
cord-334454-cqaado3u	19	22	in	in	IN
cord-334454-cqaado3u	19	23	HIV	HIV	NNP
cord-334454-cqaado3u	19	24	therapies	therapy	NNS
cord-334454-cqaado3u	19	25	[	[	-LRB-
cord-334454-cqaado3u	19	26	1	1	CD
cord-334454-cqaado3u	19	27	]	]	-RRB-
cord-334454-cqaado3u	19	28	[	[	-LRB-
cord-334454-cqaado3u	19	29	2	2	CD
cord-334454-cqaado3u	19	30	]	]	-RRB-
cord-334454-cqaado3u	19	31	[	[	-LRB-
cord-334454-cqaado3u	19	32	3	3	CD
cord-334454-cqaado3u	19	33	]	]	-RRB-
cord-334454-cqaado3u	19	34	.	.	.
cord-334454-cqaado3u	20	1	On	on	IN
cord-334454-cqaado3u	20	2	the	the	DT
cord-334454-cqaado3u	20	3	other	other	JJ
cord-334454-cqaado3u	20	4	hand	hand	NN
cord-334454-cqaado3u	20	5	,	,	,
cord-334454-cqaado3u	20	6	interestingly	interestingly	RB
cord-334454-cqaado3u	20	7	,	,	,
cord-334454-cqaado3u	20	8	the	the	DT
cord-334454-cqaado3u	20	9	administration	administration	NN
cord-334454-cqaado3u	20	10	of	of	IN
cord-334454-cqaado3u	20	11	antivirals	antiviral	NNS
cord-334454-cqaado3u	20	12	in	in	IN
cord-334454-cqaado3u	20	13	cats	cat	NNS
cord-334454-cqaado3u	20	14	has	have	VBZ
cord-334454-cqaado3u	20	15	been	be	VBN
cord-334454-cqaado3u	20	16	frequently	frequently	RB
cord-334454-cqaado3u	20	17	documented	document	VBN
cord-334454-cqaado3u	20	18	due	due	IN
cord-334454-cqaado3u	20	19	to	to	IN
cord-334454-cqaado3u	20	20	the	the	DT
cord-334454-cqaado3u	20	21	fact	fact	NN
cord-334454-cqaado3u	20	22	that	that	IN
cord-334454-cqaado3u	20	23	FIV	fiv	NN
cord-334454-cqaado3u	20	24	-	-	HYPH
cord-334454-cqaado3u	20	25	infected	infect	VBN
cord-334454-cqaado3u	20	26	cats	cat	NNS
cord-334454-cqaado3u	20	27	are	be	VBP
cord-334454-cqaado3u	20	28	commonly	commonly	RB
cord-334454-cqaado3u	20	29	used	use	VBN
cord-334454-cqaado3u	20	30	as	as	IN
cord-334454-cqaado3u	20	31	HIV	HIV	NNP
cord-334454-cqaado3u	20	32	experimental	experimental	JJ
cord-334454-cqaado3u	20	33	models	model	NNS
cord-334454-cqaado3u	20	34	.	.	.
cord-334454-cqaado3u	21	1	Even	even	RB
cord-334454-cqaado3u	21	2	if	if	IN
cord-334454-cqaado3u	21	3	antivirals	antiviral	NNS
cord-334454-cqaado3u	21	4	have	have	VBP
cord-334454-cqaado3u	21	5	shown	show	VBN
cord-334454-cqaado3u	21	6	a	a	DT
cord-334454-cqaado3u	21	7	low	low	JJ
cord-334454-cqaado3u	21	8	efficacy	efficacy	NN
cord-334454-cqaado3u	21	9	in	in	IN
cord-334454-cqaado3u	21	10	cats	cat	NNS
cord-334454-cqaado3u	21	11	and	and	CC
cord-334454-cqaado3u	21	12	can	can	MD
cord-334454-cqaado3u	21	13	induce	induce	VB
cord-334454-cqaado3u	21	14	significant	significant	JJ
cord-334454-cqaado3u	21	15	toxic	toxic	JJ
cord-334454-cqaado3u	21	16	effects	effect	NNS
cord-334454-cqaado3u	21	17	,	,	,
cord-334454-cqaado3u	21	18	several	several	JJ
cord-334454-cqaado3u	21	19	of	of	IN
cord-334454-cqaado3u	21	20	them	-PRON-	PRP
cord-334454-cqaado3u	21	21	are	be	VBP
cord-334454-cqaado3u	21	22	used	use	VBN
cord-334454-cqaado3u	21	23	on	on	IN
cord-334454-cqaado3u	21	24	the	the	DT
cord-334454-cqaado3u	21	25	management	management	NN
cord-334454-cqaado3u	21	26	of	of	IN
cord-334454-cqaado3u	21	27	retroviral	retroviral	JJ
cord-334454-cqaado3u	21	28	infections	infection	NNS
cord-334454-cqaado3u	21	29	[	[	-LRB-
cord-334454-cqaado3u	21	30	1	1	CD
cord-334454-cqaado3u	21	31	,	,	,
cord-334454-cqaado3u	21	32	2	2	CD
cord-334454-cqaado3u	21	33	,	,	,
cord-334454-cqaado3u	21	34	4	4	CD
cord-334454-cqaado3u	21	35	]	]	-RRB-
cord-334454-cqaado3u	21	36	.	.	.
cord-334454-cqaado3u	22	1	Among	among	IN
cord-334454-cqaado3u	22	2	them	-PRON-	PRP
cord-334454-cqaado3u	22	3	,	,	,
cord-334454-cqaado3u	22	4	the	the	DT
cord-334454-cqaado3u	22	5	RT	RT	NNP
cord-334454-cqaado3u	22	6	inhibitors	inhibitor	NNS
cord-334454-cqaado3u	22	7	/	/	SYM
cord-334454-cqaado3u	22	8	nucleoside	nucleoside	JJ
cord-334454-cqaado3u	22	9	analogues	analogue	NNS
cord-334454-cqaado3u	22	10	are	be	VBP
cord-334454-cqaado3u	22	11	the	the	DT
cord-334454-cqaado3u	22	12	most	most	RBS
cord-334454-cqaado3u	22	13	common	common	JJ
cord-334454-cqaado3u	22	14	.	.	.
cord-334454-cqaado3u	23	1	The	the	DT
cord-334454-cqaado3u	23	2	majority	majority	NN
cord-334454-cqaado3u	23	3	are	be	VBP
cord-334454-cqaado3u	23	4	nucleoside	nucleoside	JJ
cord-334454-cqaado3u	23	5	analogues	analogue	NNS
cord-334454-cqaado3u	23	6	which	which	WDT
cord-334454-cqaado3u	23	7	,	,	,
cord-334454-cqaado3u	23	8	acting	act	VBG
cord-334454-cqaado3u	23	9	as	as	IN
cord-334454-cqaado3u	23	10	anti	anti	JJ
cord-334454-cqaado3u	23	11	-	-	NNS
cord-334454-cqaado3u	23	12	metabolites	metabolite	NNS
cord-334454-cqaado3u	23	13	,	,	,
cord-334454-cqaado3u	23	14	are	be	VBP
cord-334454-cqaado3u	23	15	"	"	``
cord-334454-cqaado3u	23	16	false	false	JJ
cord-334454-cqaado3u	23	17	substrates	substrate	NNS
cord-334454-cqaado3u	23	18	"	"	''
cord-334454-cqaado3u	23	19	that	that	WDT
cord-334454-cqaado3u	23	20	bind	bind	VBP
cord-334454-cqaado3u	23	21	to	to	IN
cord-334454-cqaado3u	23	22	RT	RT	NNP
cord-334454-cqaado3u	23	23	enzyme	enzyme	NN
cord-334454-cqaado3u	23	24	and	and	CC
cord-334454-cqaado3u	23	25	block	block	VB
cord-334454-cqaado3u	23	26	its	-PRON-	PRP$
cord-334454-cqaado3u	23	27	activity	activity	NN
cord-334454-cqaado3u	23	28	[	[	-LRB-
cord-334454-cqaado3u	23	29	4	4	CD
cord-334454-cqaado3u	23	30	]	]	-RRB-
cord-334454-cqaado3u	23	31	.	.	.
cord-334454-cqaado3u	24	1	Other	other	JJ
cord-334454-cqaado3u	24	2	antivirals	antiviral	NNS
cord-334454-cqaado3u	24	3	that	that	WDT
cord-334454-cqaado3u	24	4	can	can	MD
cord-334454-cqaado3u	24	5	be	be	VB
cord-334454-cqaado3u	24	6	used	use	VBN
cord-334454-cqaado3u	24	7	in	in	IN
cord-334454-cqaado3u	24	8	retroviral	retroviral	JJ
cord-334454-cqaado3u	24	9	infections	infection	NNS
cord-334454-cqaado3u	24	10	are	be	VBP
cord-334454-cqaado3u	24	11	antagonists	antagonist	NNS
cord-334454-cqaado3u	24	12	/	/	,
cord-334454-cqaado3u	24	13	homologous	homologous	JJ
cord-334454-cqaado3u	24	14	of	of	IN
cord-334454-cqaado3u	24	15	receptors	receptor	NNS
cord-334454-cqaado3u	24	16	,	,	,
cord-334454-cqaado3u	24	17	namely	namely	RB
cord-334454-cqaado3u	24	18	byciclams	byciclams	NNP
cord-334454-cqaado3u	24	19	such	such	JJ
cord-334454-cqaado3u	24	20	as	as	IN
cord-334454-cqaado3u	24	21	plerixafor	plerixafor	NN
cord-334454-cqaado3u	24	22	and	and	CC
cord-334454-cqaado3u	24	23	AMD	AMD	NNP
cord-334454-cqaado3u	24	24	3100	3100	CD
cord-334454-cqaado3u	24	25	,	,	,
cord-334454-cqaado3u	24	26	which	which	WDT
cord-334454-cqaado3u	24	27	bind	bind	VBP
cord-334454-cqaado3u	24	28	either	either	DT
cord-334454-cqaado3u	24	29	to	to	IN
cord-334454-cqaado3u	24	30	viruses	virus	NNS
cord-334454-cqaado3u	24	31	(	(	-LRB-
cord-334454-cqaado3u	24	32	homologous	homologous	JJ
cord-334454-cqaado3u	24	33	)	)	-RRB-
cord-334454-cqaado3u	24	34	or	or	CC
cord-334454-cqaado3u	24	35	to	to	IN
cord-334454-cqaado3u	24	36	cell	cell	NN
cord-334454-cqaado3u	24	37	-	-	HYPH
cord-334454-cqaado3u	24	38	receptors	receptor	NNS
cord-334454-cqaado3u	24	39	(	(	-LRB-
cord-334454-cqaado3u	24	40	antagonists	antagonist	NNS
cord-334454-cqaado3u	24	41	)	)	-RRB-
cord-334454-cqaado3u	24	42	,	,	,
cord-334454-cqaado3u	24	43	inhibiting	inhibit	VBG
cord-334454-cqaado3u	24	44	the	the	DT
cord-334454-cqaado3u	24	45	virus	virus	NN
cord-334454-cqaado3u	24	46	-	-	HYPH
cord-334454-cqaado3u	24	47	cell	cell	NN
cord-334454-cqaado3u	24	48	interaction	interaction	NN
cord-334454-cqaado3u	24	49	.	.	.
cord-334454-cqaado3u	25	1	With	with	IN
cord-334454-cqaado3u	25	2	the	the	DT
cord-334454-cqaado3u	25	3	exception	exception	NN
cord-334454-cqaado3u	25	4	of	of	IN
cord-334454-cqaado3u	25	5	several	several	JJ
cord-334454-cqaado3u	25	6	drugs	drug	NNS
cord-334454-cqaado3u	25	7	,	,	,
cord-334454-cqaado3u	25	8	these	these	DT
cord-334454-cqaado3u	25	9	compounds	compound	NNS
cord-334454-cqaado3u	25	10	are	be	VBP
cord-334454-cqaado3u	25	11	strongly	strongly	RB
cord-334454-cqaado3u	25	12	selective	selective	JJ
cord-334454-cqaado3u	25	13	for	for	IN
cord-334454-cqaado3u	25	14	HIV	HIV	NNP
cord-334454-cqaado3u	25	15	,	,	,
cord-334454-cqaado3u	25	16	meaning	mean	VBG
cord-334454-cqaado3u	25	17	that	that	IN
cord-334454-cqaado3u	25	18	they	-PRON-	PRP
cord-334454-cqaado3u	25	19	are	be	VBP
cord-334454-cqaado3u	25	20	not	not	RB
cord-334454-cqaado3u	25	21	used	use	VBN
cord-334454-cqaado3u	25	22	in	in	IN
cord-334454-cqaado3u	25	23	veterinary	veterinary	JJ
cord-334454-cqaado3u	25	24	medicine	medicine	NN
cord-334454-cqaado3u	25	25	[	[	-LRB-
cord-334454-cqaado3u	25	26	4	4	CD
cord-334454-cqaado3u	25	27	]	]	-RRB-
cord-334454-cqaado3u	25	28	.	.	.
cord-334454-cqaado3u	26	1	Taking	take	VBG
cord-334454-cqaado3u	26	2	part	part	NN
cord-334454-cqaado3u	26	3	in	in	IN
cord-334454-cqaado3u	26	4	the	the	DT
cord-334454-cqaado3u	26	5	group	group	NN
cord-334454-cqaado3u	26	6	of	of	IN
cord-334454-cqaado3u	26	7	"	"	``
cord-334454-cqaado3u	26	8	immune	immune	JJ
cord-334454-cqaado3u	26	9	therapy	therapy	NN
cord-334454-cqaado3u	26	10	"	"	''
cord-334454-cqaado3u	26	11	,	,	,
cord-334454-cqaado3u	26	12	by	by	IN
cord-334454-cqaado3u	26	13	definition	definition	NN
cord-334454-cqaado3u	26	14	,	,	,
cord-334454-cqaado3u	26	15	immune	immune	JJ
cord-334454-cqaado3u	26	16	modulators	modulator	NNS
cord-334454-cqaado3u	26	17	are	be	VBP
cord-334454-cqaado3u	26	18	compounds	compound	NNS
cord-334454-cqaado3u	26	19	that	that	WDT
cord-334454-cqaado3u	26	20	interfere	interfere	VBP
cord-334454-cqaado3u	26	21	with	with	IN
cord-334454-cqaado3u	26	22	the	the	DT
cord-334454-cqaado3u	26	23	immune	immune	JJ
cord-334454-cqaado3u	26	24	system	system	NN
cord-334454-cqaado3u	26	25	.	.	.
cord-334454-cqaado3u	27	1	They	-PRON-	PRP
cord-334454-cqaado3u	27	2	are	be	VBP
cord-334454-cqaado3u	27	3	commonly	commonly	RB
cord-334454-cqaado3u	27	4	used	use	VBN
cord-334454-cqaado3u	27	5	in	in	IN
cord-334454-cqaado3u	27	6	different	different	JJ
cord-334454-cqaado3u	27	7	clinical	clinical	JJ
cord-334454-cqaado3u	27	8	situations	situation	NNS
cord-334454-cqaado3u	27	9	,	,	,
cord-334454-cqaado3u	27	10	particularly	particularly	RB
cord-334454-cqaado3u	27	11	in	in	IN
cord-334454-cqaado3u	27	12	canine	canine	JJ
cord-334454-cqaado3u	27	13	and	and	CC
cord-334454-cqaado3u	27	14	feline	feline	JJ
cord-334454-cqaado3u	27	15	viral	viral	JJ
cord-334454-cqaado3u	27	16	infections	infection	NNS
cord-334454-cqaado3u	27	17	.	.	.
cord-334454-cqaado3u	28	1	It	-PRON-	PRP
cord-334454-cqaado3u	28	2	is	be	VBZ
cord-334454-cqaado3u	28	3	believed	believe	VBN
cord-334454-cqaado3u	28	4	that	that	IN
cord-334454-cqaado3u	28	5	immune	immune	JJ
cord-334454-cqaado3u	28	6	modulators	modulator	NNS
cord-334454-cqaado3u	28	7	restore	restore	VBP
cord-334454-cqaado3u	28	8	several	several	JJ
cord-334454-cqaado3u	28	9	functions	function	NNS
cord-334454-cqaado3u	28	10	of	of	IN
cord-334454-cqaado3u	28	11	the	the	DT
cord-334454-cqaado3u	28	12	immune	immune	JJ
cord-334454-cqaado3u	28	13	system	system	NN
cord-334454-cqaado3u	28	14	,	,	,
cord-334454-cqaado3u	28	15	allowing	allow	VBG
cord-334454-cqaado3u	28	16	a	a	DT
cord-334454-cqaado3u	28	17	better	well	JJR
cord-334454-cqaado3u	28	18	management	management	NN
cord-334454-cqaado3u	28	19	of	of	IN
cord-334454-cqaado3u	28	20	opportunistic	opportunistic	JJ
cord-334454-cqaado3u	28	21	infections	infection	NNS
cord-334454-cqaado3u	28	22	and	and	CC
cord-334454-cqaado3u	28	23	a	a	DT
cord-334454-cqaado3u	28	24	better	well	JJR
cord-334454-cqaado3u	28	25	clinical	clinical	JJ
cord-334454-cqaado3u	28	26	recovery	recovery	NN
cord-334454-cqaado3u	28	27	.	.	.
cord-334454-cqaado3u	29	1	Some	some	DT
cord-334454-cqaado3u	29	2	of	of	IN
cord-334454-cqaado3u	29	3	these	these	DT
cord-334454-cqaado3u	29	4	compounds	compound	NNS
cord-334454-cqaado3u	29	5	can	can	MD
cord-334454-cqaado3u	29	6	even	even	RB
cord-334454-cqaado3u	29	7	have	have	VB
cord-334454-cqaado3u	29	8	a	a	DT
cord-334454-cqaado3u	29	9	direct	direct	JJ
cord-334454-cqaado3u	29	10	antiviral	antiviral	JJ
cord-334454-cqaado3u	29	11	effect	effect	NN
cord-334454-cqaado3u	29	12	[	[	-LRB-
cord-334454-cqaado3u	29	13	4	4	CD
cord-334454-cqaado3u	29	14	]	]	-RRB-
cord-334454-cqaado3u	29	15	.	.	.
cord-334454-cqaado3u	30	1	In	in	IN
cord-334454-cqaado3u	30	2	between	between	IN
cord-334454-cqaado3u	30	3	the	the	DT
cord-334454-cqaado3u	30	4	well	well	RB
cord-334454-cqaado3u	30	5	-	-	HYPH
cord-334454-cqaado3u	30	6	known	know	VBN
cord-334454-cqaado3u	30	7	immune	immune	JJ
cord-334454-cqaado3u	30	8	modulators	modulator	NNS
cord-334454-cqaado3u	30	9	,	,	,
cord-334454-cqaado3u	30	10	interferons	interferon	NNS
cord-334454-cqaado3u	30	11	(	(	-LRB-
cord-334454-cqaado3u	30	12	IFNs	IFNs	NNP
cord-334454-cqaado3u	30	13	)	)	-RRB-
cord-334454-cqaado3u	30	14	will	will	MD
cord-334454-cqaado3u	30	15	be	be	VB
cord-334454-cqaado3u	30	16	further	further	RB
cord-334454-cqaado3u	30	17	discussed	discuss	VBN
cord-334454-cqaado3u	30	18	,	,	,
cord-334454-cqaado3u	30	19	mainly	mainly	RB
cord-334454-cqaado3u	30	20	due	due	IN
cord-334454-cqaado3u	30	21	to	to	IN
cord-334454-cqaado3u	30	22	its	-PRON-	PRP$
cord-334454-cqaado3u	30	23	current	current	JJ
cord-334454-cqaado3u	30	24	use	use	NN
cord-334454-cqaado3u	30	25	in	in	IN
cord-334454-cqaado3u	30	26	retroviral	retroviral	JJ
cord-334454-cqaado3u	30	27	infections	infection	NNS
cord-334454-cqaado3u	30	28	.	.	.
cord-334454-cqaado3u	31	1	Interferons	interferon	NNS
cord-334454-cqaado3u	31	2	(	(	-LRB-
cord-334454-cqaado3u	31	3	IFNs	ifn	NNS
cord-334454-cqaado3u	31	4	)	)	-RRB-
cord-334454-cqaado3u	31	5	are	be	VBP
cord-334454-cqaado3u	31	6	key	key	JJ
cord-334454-cqaado3u	31	7	components	component	NNS
cord-334454-cqaado3u	31	8	of	of	IN
cord-334454-cqaado3u	31	9	the	the	DT
cord-334454-cqaado3u	31	10	host	host	NN
cord-334454-cqaado3u	31	11	immune	immune	JJ
cord-334454-cqaado3u	31	12	system	system	NN
cord-334454-cqaado3u	31	13	,	,	,
cord-334454-cqaado3u	31	14	being	be	VBG
cord-334454-cqaado3u	31	15	particularly	particularly	RB
cord-334454-cqaado3u	31	16	relevant	relevant	JJ
cord-334454-cqaado3u	31	17	in	in	IN
cord-334454-cqaado3u	31	18	viral	viral	JJ
cord-334454-cqaado3u	31	19	infections	infection	NNS
cord-334454-cqaado3u	31	20	[	[	-LRB-
cord-334454-cqaado3u	31	21	5	5	CD
cord-334454-cqaado3u	31	22	]	]	-RRB-
cord-334454-cqaado3u	31	23	.	.	.
cord-334454-cqaado3u	32	1	The	the	DT
cord-334454-cqaado3u	32	2	large	large	JJ
cord-334454-cqaado3u	32	3	family	family	NN
cord-334454-cqaado3u	32	4	of	of	IN
cord-334454-cqaado3u	32	5	IFNs	ifn	NNS
cord-334454-cqaado3u	32	6	can	can	MD
cord-334454-cqaado3u	32	7	be	be	VB
cord-334454-cqaado3u	32	8	divided	divide	VBN
cord-334454-cqaado3u	32	9	into	into	IN
cord-334454-cqaado3u	32	10	different	different	JJ
cord-334454-cqaado3u	32	11	types	type	NNS
cord-334454-cqaado3u	32	12	.	.	.
cord-334454-cqaado3u	33	1	Type	type	NN
cord-334454-cqaado3u	33	2	I	-PRON-	PRP
cord-334454-cqaado3u	33	3	IFNs	ifn	NNS
cord-334454-cqaado3u	33	4	are	be	VBP
cord-334454-cqaado3u	33	5	the	the	DT
cord-334454-cqaado3u	33	6	most	most	RBS
cord-334454-cqaado3u	33	7	studied	study	VBN
cord-334454-cqaado3u	33	8	ones	one	NNS
cord-334454-cqaado3u	33	9	as	as	IN
cord-334454-cqaado3u	33	10	they	-PRON-	PRP
cord-334454-cqaado3u	33	11	are	be	VBP
cord-334454-cqaado3u	33	12	commonly	commonly	RB
cord-334454-cqaado3u	33	13	used	use	VBN
cord-334454-cqaado3u	33	14	for	for	IN
cord-334454-cqaado3u	33	15	therapeutic	therapeutic	JJ
cord-334454-cqaado3u	33	16	purposes	purpose	NNS
cord-334454-cqaado3u	33	17	.	.	.
cord-334454-cqaado3u	34	1	Among	among	IN
cord-334454-cqaado3u	34	2	their	-PRON-	PRP$
cord-334454-cqaado3u	34	3	major	major	JJ
cord-334454-cqaado3u	34	4	functions	function	NNS
cord-334454-cqaado3u	34	5	,	,	,
cord-334454-cqaado3u	34	6	type	type	NN
cord-334454-cqaado3u	34	7	I	-PRON-	PRP
cord-334454-cqaado3u	34	8	IFNs	ifns	VBP
cord-334454-cqaado3u	34	9	increase	increase	NN
cord-334454-cqaado3u	34	10	and	and	CC
cord-334454-cqaado3u	34	11	sensitize	sensitize	VB
cord-334454-cqaado3u	34	12	the	the	DT
cord-334454-cqaado3u	34	13	immune	immune	JJ
cord-334454-cqaado3u	34	14	system	system	NN
cord-334454-cqaado3u	34	15	towards	towards	IN
cord-334454-cqaado3u	34	16	the	the	DT
cord-334454-cqaado3u	34	17	microbial	microbial	JJ
cord-334454-cqaado3u	34	18	recognition	recognition	NN
cord-334454-cqaado3u	34	19	[	[	-LRB-
cord-334454-cqaado3u	34	20	6	6	CD
cord-334454-cqaado3u	34	21	]	]	-RRB-
cord-334454-cqaado3u	34	22	,	,	,
cord-334454-cqaado3u	34	23	establishing	establish	VBG
cord-334454-cqaado3u	34	24	an	an	DT
cord-334454-cqaado3u	34	25	important	important	JJ
cord-334454-cqaado3u	34	26	link	link	NN
cord-334454-cqaado3u	34	27	between	between	IN
cord-334454-cqaado3u	34	28	innate	innate	NN
cord-334454-cqaado3u	34	29	and	and	CC
cord-334454-cqaado3u	34	30	acquired	acquire	VBN
cord-334454-cqaado3u	34	31	immunity	immunity	NN
cord-334454-cqaado3u	34	32	[	[	-LRB-
cord-334454-cqaado3u	34	33	7	7	CD
cord-334454-cqaado3u	34	34	]	]	-RRB-
cord-334454-cqaado3u	34	35	.	.	.
cord-334454-cqaado3u	35	1	Furthermore	furthermore	RB
cord-334454-cqaado3u	35	2	,	,	,
cord-334454-cqaado3u	35	3	they	-PRON-	PRP
cord-334454-cqaado3u	35	4	have	have	VBP
cord-334454-cqaado3u	35	5	different	different	JJ
cord-334454-cqaado3u	35	6	anti	anti	JJ
cord-334454-cqaado3u	35	7	-	-	JJ
cord-334454-cqaado3u	35	8	viral	viral	JJ
cord-334454-cqaado3u	35	9	properties	property	NNS
cord-334454-cqaado3u	35	10	,	,	,
cord-334454-cqaado3u	35	11	blocking	block	VBG
cord-334454-cqaado3u	35	12	viral	viral	JJ
cord-334454-cqaado3u	35	13	replication	replication	NN
cord-334454-cqaado3u	35	14	and	and	CC
cord-334454-cqaado3u	35	15	inducing	induce	VBG
cord-334454-cqaado3u	35	16	apoptosis	apoptosis	NN
cord-334454-cqaado3u	35	17	of	of	IN
cord-334454-cqaado3u	35	18	infected	infected	JJ
cord-334454-cqaado3u	35	19	cells	cell	NNS
cord-334454-cqaado3u	35	20	[	[	-LRB-
cord-334454-cqaado3u	35	21	8	8	CD
cord-334454-cqaado3u	35	22	]	]	-RRB-
cord-334454-cqaado3u	35	23	[	[	-LRB-
cord-334454-cqaado3u	35	24	9	9	CD
cord-334454-cqaado3u	35	25	]	]	-RRB-
cord-334454-cqaado3u	35	26	[	[	-LRB-
cord-334454-cqaado3u	35	27	10	10	CD
cord-334454-cqaado3u	35	28	]	]	-RRB-
cord-334454-cqaado3u	35	29	[	[	-LRB-
cord-334454-cqaado3u	35	30	11	11	CD
cord-334454-cqaado3u	35	31	]	]	-RRB-
cord-334454-cqaado3u	35	32	.	.	.
cord-334454-cqaado3u	36	1	In	in	IN
cord-334454-cqaado3u	36	2	human	human	JJ
cord-334454-cqaado3u	36	3	immunodeficiency	immunodeficiency	NN
cord-334454-cqaado3u	36	4	virus	virus	NN
cord-334454-cqaado3u	36	5	(	(	-LRB-
cord-334454-cqaado3u	36	6	HIV	HIV	NNP
cord-334454-cqaado3u	36	7	)	)	-RRB-
cord-334454-cqaado3u	36	8	,	,	,
cord-334454-cqaado3u	36	9	the	the	DT
cord-334454-cqaado3u	36	10	therapeutic	therapeutic	JJ
cord-334454-cqaado3u	36	11	use	use	NN
cord-334454-cqaado3u	36	12	of	of	IN
cord-334454-cqaado3u	36	13	IFNs	ifn	NNS
cord-334454-cqaado3u	36	14	has	have	VBZ
cord-334454-cqaado3u	36	15	been	be	VBN
cord-334454-cqaado3u	36	16	assessed	assess	VBN
cord-334454-cqaado3u	36	17	in	in	IN
cord-334454-cqaado3u	36	18	various	various	JJ
cord-334454-cqaado3u	36	19	in	in	IN
cord-334454-cqaado3u	36	20	vitro	vitro	FW
cord-334454-cqaado3u	36	21	and	and	CC
cord-334454-cqaado3u	36	22	in	in	IN
cord-334454-cqaado3u	36	23	vivo	vivo	NNP
cord-334454-cqaado3u	36	24	studies	study	NNS
cord-334454-cqaado3u	36	25	.	.	.
cord-334454-cqaado3u	37	1	In	in	IN
cord-334454-cqaado3u	37	2	vitro	vitro	FW
cord-334454-cqaado3u	37	3	,	,	,
cord-334454-cqaado3u	37	4	it	-PRON-	PRP
cord-334454-cqaado3u	37	5	was	be	VBD
cord-334454-cqaado3u	37	6	proven	prove	VBN
cord-334454-cqaado3u	37	7	that	that	IN
cord-334454-cqaado3u	37	8	IFNs	ifn	NNS
cord-334454-cqaado3u	37	9	are	be	VBP
cord-334454-cqaado3u	37	10	able	able	JJ
cord-334454-cqaado3u	37	11	to	to	TO
cord-334454-cqaado3u	37	12	restrict	restrict	VB
cord-334454-cqaado3u	37	13	HIV	HIV	NNP
cord-334454-cqaado3u	37	14	replication	replication	NN
cord-334454-cqaado3u	37	15	inducing	induce	VBG
cord-334454-cqaado3u	37	16	an	an	DT
cord-334454-cqaado3u	37	17	antiviral	antiviral	JJ
cord-334454-cqaado3u	37	18	state	state	NN
cord-334454-cqaado3u	37	19	and	and	CC
cord-334454-cqaado3u	37	20	preventing	prevent	VBG
cord-334454-cqaado3u	37	21	viral	viral	JJ
cord-334454-cqaado3u	37	22	infection	infection	NN
cord-334454-cqaado3u	37	23	[	[	-LRB-
cord-334454-cqaado3u	37	24	12	12	CD
cord-334454-cqaado3u	37	25	,	,	,
cord-334454-cqaado3u	37	26	13	13	CD
cord-334454-cqaado3u	37	27	]	]	-RRB-
cord-334454-cqaado3u	37	28	.	.	.
cord-334454-cqaado3u	38	1	In	in	IN
cord-334454-cqaado3u	38	2	vivo	vivo	NN
cord-334454-cqaado3u	38	3	,	,	,
cord-334454-cqaado3u	38	4	despite	despite	IN
cord-334454-cqaado3u	38	5	the	the	DT
cord-334454-cqaado3u	38	6	HIV	HIV	NNP
cord-334454-cqaado3u	38	7	's	's	POS
cord-334454-cqaado3u	38	8	evasion	evasion	NN
cord-334454-cqaado3u	38	9	mechanisms	mechanism	NNS
cord-334454-cqaado3u	38	10	,	,	,
cord-334454-cqaado3u	38	11	IFNs	ifn	NNS
cord-334454-cqaado3u	38	12	seem	seem	VBP
cord-334454-cqaado3u	38	13	to	to	TO
cord-334454-cqaado3u	38	14	play	play	VB
cord-334454-cqaado3u	38	15	an	an	DT
cord-334454-cqaado3u	38	16	important	important	JJ
cord-334454-cqaado3u	38	17	protective	protective	JJ
cord-334454-cqaado3u	38	18	role	role	NN
cord-334454-cqaado3u	38	19	against	against	IN
cord-334454-cqaado3u	38	20	HIV	HIV	NNP
cord-334454-cqaado3u	38	21	infection	infection	NN
cord-334454-cqaado3u	38	22	in	in	IN
cord-334454-cqaado3u	38	23	seronegative	seronegative	JJ
cord-334454-cqaado3u	38	24	individuals	individual	NNS
cord-334454-cqaado3u	38	25	exposed	expose	VBN
cord-334454-cqaado3u	38	26	to	to	IN
cord-334454-cqaado3u	38	27	the	the	DT
cord-334454-cqaado3u	38	28	virus	virus	NN
cord-334454-cqaado3u	38	29	[	[	-LRB-
cord-334454-cqaado3u	38	30	14	14	CD
cord-334454-cqaado3u	38	31	,	,	,
cord-334454-cqaado3u	38	32	15	15	CD
cord-334454-cqaado3u	38	33	]	]	-RRB-
cord-334454-cqaado3u	38	34	.	.	.
cord-334454-cqaado3u	39	1	Moreover	moreover	RB
cord-334454-cqaado3u	39	2	,	,	,
cord-334454-cqaado3u	39	3	its	-PRON-	PRP$
cord-334454-cqaado3u	39	4	therapeutic	therapeutic	JJ
cord-334454-cqaado3u	39	5	administration	administration	NN
cord-334454-cqaado3u	39	6	showed	show	VBD
cord-334454-cqaado3u	39	7	a	a	DT
cord-334454-cqaado3u	39	8	durable	durable	JJ
cord-334454-cqaado3u	39	9	suppression	suppression	NN
cord-334454-cqaado3u	39	10	of	of	IN
cord-334454-cqaado3u	39	11	viral	viral	JJ
cord-334454-cqaado3u	39	12	replication	replication	NN
cord-334454-cqaado3u	39	13	and	and	CC
cord-334454-cqaado3u	39	14	decreased	decrease	VBD
cord-334454-cqaado3u	39	15	viral	viral	JJ
cord-334454-cqaado3u	39	16	integration	integration	NN
cord-334454-cqaado3u	39	17	following	follow	VBG
cord-334454-cqaado3u	39	18	anti	anti	JJ
cord-334454-cqaado3u	39	19	-	-	JJ
cord-334454-cqaado3u	39	20	retroviral	retroviral	JJ
cord-334454-cqaado3u	39	21	therapy	therapy	NN
cord-334454-cqaado3u	39	22	in	in	IN
cord-334454-cqaado3u	39	23	HIV	HIV	NNP
cord-334454-cqaado3u	39	24	individuals	individual	NNS
cord-334454-cqaado3u	39	25	[	[	-LRB-
cord-334454-cqaado3u	39	26	16	16	CD
cord-334454-cqaado3u	39	27	]	]	-RRB-
cord-334454-cqaado3u	39	28	.	.	.
cord-334454-cqaado3u	40	1	Even	even	RB
cord-334454-cqaado3u	40	2	if	if	IN
cord-334454-cqaado3u	40	3	further	further	JJ
cord-334454-cqaado3u	40	4	studies	study	NNS
cord-334454-cqaado3u	40	5	are	be	VBP
cord-334454-cqaado3u	40	6	needed	need	VBN
cord-334454-cqaado3u	40	7	to	to	TO
cord-334454-cqaado3u	40	8	investigate	investigate	VB
cord-334454-cqaado3u	40	9	the	the	DT
cord-334454-cqaado3u	40	10	therapeutic	therapeutic	JJ
cord-334454-cqaado3u	40	11	effects	effect	NNS
cord-334454-cqaado3u	40	12	of	of	IN
cord-334454-cqaado3u	40	13	IFN	IFN	NNP
cord-334454-cqaado3u	40	14	in	in	IN
cord-334454-cqaado3u	40	15	HIV	HIV	NNP
cord-334454-cqaado3u	40	16	,	,	,
cord-334454-cqaado3u	40	17	its	-PRON-	PRP$
cord-334454-cqaado3u	40	18	protective	protective	JJ
cord-334454-cqaado3u	40	19	role	role	NN
cord-334454-cqaado3u	40	20	on	on	IN
cord-334454-cqaado3u	40	21	the	the	DT
cord-334454-cqaado3u	40	22	early	early	JJ
cord-334454-cqaado3u	40	23	stages	stage	NNS
cord-334454-cqaado3u	40	24	of	of	IN
cord-334454-cqaado3u	40	25	infection	infection	NN
cord-334454-cqaado3u	40	26	aims	aim	VBZ
cord-334454-cqaado3u	40	27	to	to	TO
cord-334454-cqaado3u	40	28	consider	consider	VB
cord-334454-cqaado3u	40	29	that	that	IN
cord-334454-cqaado3u	40	30	IFN	IFN	NNP
cord-334454-cqaado3u	40	31	therapy	therapy	NN
cord-334454-cqaado3u	40	32	seems	seem	VBZ
cord-334454-cqaado3u	40	33	particularly	particularly	RB
cord-334454-cqaado3u	40	34	useful	useful	JJ
cord-334454-cqaado3u	40	35	on	on	IN
cord-334454-cqaado3u	40	36	post	post	JJ
cord-334454-cqaado3u	40	37	-	-	JJ
cord-334454-cqaado3u	40	38	exposure	exposure	JJ
cord-334454-cqaado3u	40	39	prophylaxis	prophylaxis	NN
cord-334454-cqaado3u	40	40	[	[	-LRB-
cord-334454-cqaado3u	40	41	15	15	CD
cord-334454-cqaado3u	40	42	]	]	-RRB-
cord-334454-cqaado3u	40	43	.	.	.
cord-334454-cqaado3u	41	1	Not	not	RB
cord-334454-cqaado3u	41	2	only	only	RB
cord-334454-cqaado3u	41	3	in	in	IN
cord-334454-cqaado3u	41	4	humans	human	NNS
cord-334454-cqaado3u	41	5	but	but	CC
cord-334454-cqaado3u	41	6	also	also	RB
cord-334454-cqaado3u	41	7	in	in	IN
cord-334454-cqaado3u	41	8	feline	feline	JJ
cord-334454-cqaado3u	41	9	medicine	medicine	NN
cord-334454-cqaado3u	41	10	,	,	,
cord-334454-cqaado3u	41	11	the	the	DT
cord-334454-cqaado3u	41	12	use	use	NN
cord-334454-cqaado3u	41	13	of	of	IN
cord-334454-cqaado3u	41	14	type	type	NN
cord-334454-cqaado3u	41	15	I	-PRON-	PRP
cord-334454-cqaado3u	41	16	IFNs	ifns	VBP
cord-334454-cqaado3u	41	17	as	as	IN
cord-334454-cqaado3u	41	18	immune	immune	JJ
cord-334454-cqaado3u	41	19	modulation	modulation	NN
cord-334454-cqaado3u	41	20	therapy	therapy	NN
cord-334454-cqaado3u	41	21	is	be	VBZ
cord-334454-cqaado3u	41	22	common	common	JJ
cord-334454-cqaado3u	41	23	,	,	,
cord-334454-cqaado3u	41	24	particularly	particularly	RB
cord-334454-cqaado3u	41	25	in	in	IN
cord-334454-cqaado3u	41	26	retroviral	retroviral	JJ
cord-334454-cqaado3u	41	27	infections	infection	NNS
cord-334454-cqaado3u	41	28	[	[	-LRB-
cord-334454-cqaado3u	41	29	17	17	CD
cord-334454-cqaado3u	41	30	]	]	-RRB-
cord-334454-cqaado3u	41	31	[	[	-LRB-
cord-334454-cqaado3u	41	32	18	18	CD
cord-334454-cqaado3u	41	33	]	]	-RRB-
cord-334454-cqaado3u	41	34	[	[	-LRB-
cord-334454-cqaado3u	41	35	19	19	CD
cord-334454-cqaado3u	41	36	]	]	-RRB-
cord-334454-cqaado3u	41	37	.	.	.
cord-334454-cqaado3u	42	1	Still	still	RB
cord-334454-cqaado3u	42	2	used	use	VBN
cord-334454-cqaado3u	42	3	in	in	IN
cord-334454-cqaado3u	42	4	several	several	JJ
cord-334454-cqaado3u	42	5	countries	country	NNS
cord-334454-cqaado3u	42	6	,	,	,
cord-334454-cqaado3u	42	7	HuIFN	HuIFN	NNP
cord-334454-cqaado3u	42	8	-	-	HYPH
cord-334454-cqaado3u	42	9	α	α	NNP
cord-334454-cqaado3u	42	10	was	be	VBD
cord-334454-cqaado3u	42	11	the	the	DT
cord-334454-cqaado3u	42	12	first	first	JJ
cord-334454-cqaado3u	42	13	interferon	interferon	NN
cord-334454-cqaado3u	42	14	administered	administer	VBN
cord-334454-cqaado3u	42	15	in	in	IN
cord-334454-cqaado3u	42	16	cats	cat	NNS
cord-334454-cqaado3u	42	17	,	,	,
cord-334454-cqaado3u	42	18	despite	despite	IN
cord-334454-cqaado3u	42	19	the	the	DT
cord-334454-cqaado3u	42	20	fact	fact	NN
cord-334454-cqaado3u	42	21	that	that	IN
cord-334454-cqaado3u	42	22	it	-PRON-	PRP
cord-334454-cqaado3u	42	23	is	be	VBZ
cord-334454-cqaado3u	42	24	only	only	RB
cord-334454-cqaado3u	42	25	licensed	license	VBN
cord-334454-cqaado3u	42	26	for	for	IN
cord-334454-cqaado3u	42	27	human	human	JJ
cord-334454-cqaado3u	42	28	medicine	medicine	NN
cord-334454-cqaado3u	42	29	[	[	-LRB-
cord-334454-cqaado3u	42	30	4	4	CD
cord-334454-cqaado3u	42	31	]	]	-RRB-
cord-334454-cqaado3u	42	32	.	.	.
cord-334454-cqaado3u	43	1	Among	among	IN
cord-334454-cqaado3u	43	2	their	-PRON-	PRP$
cord-334454-cqaado3u	43	3	major	major	JJ
cord-334454-cqaado3u	43	4	functions	function	NNS
cord-334454-cqaado3u	43	5	,	,	,
cord-334454-cqaado3u	43	6	it	-PRON-	PRP
cord-334454-cqaado3u	43	7	was	be	VBD
cord-334454-cqaado3u	43	8	shown	show	VBN
cord-334454-cqaado3u	43	9	that	that	IN
cord-334454-cqaado3u	43	10	HuIFN	HuIFN	NNP
cord-334454-cqaado3u	43	11	-	-	HYPH
cord-334454-cqaado3u	43	12	α	α	NNP
cord-334454-cqaado3u	43	13	inhibits	inhibit	VBZ
cord-334454-cqaado3u	43	14	oncogenic	oncogenic	JJ
cord-334454-cqaado3u	43	15	mutations	mutation	NNS
cord-334454-cqaado3u	43	16	induced	induce	VBN
cord-334454-cqaado3u	43	17	by	by	IN
cord-334454-cqaado3u	43	18	retroviruses	retrovirus	NNS
cord-334454-cqaado3u	43	19	,	,	,
cord-334454-cqaado3u	43	20	and	and	CC
cord-334454-cqaado3u	43	21	it	-PRON-	PRP
cord-334454-cqaado3u	43	22	restrains	restrain	VBZ
cord-334454-cqaado3u	43	23	viral	viral	JJ
cord-334454-cqaado3u	43	24	nucleic	nucleic	JJ
cord-334454-cqaado3u	43	25	acid	acid	NN
cord-334454-cqaado3u	43	26	synthesis	synthesis	NN
cord-334454-cqaado3u	43	27	and	and	CC
cord-334454-cqaado3u	43	28	suppress	suppress	VB
cord-334454-cqaado3u	43	29	protein	protein	NN
cord-334454-cqaado3u	43	30	production	production	NN
cord-334454-cqaado3u	43	31	.	.	.
cord-334454-cqaado3u	44	1	Due	due	IN
cord-334454-cqaado3u	44	2	to	to	IN
cord-334454-cqaado3u	44	3	these	these	DT
cord-334454-cqaado3u	44	4	anti	anti	JJ
cord-334454-cqaado3u	44	5	-	-	JJ
cord-334454-cqaado3u	44	6	viral	viral	JJ
cord-334454-cqaado3u	44	7	and	and	CC
cord-334454-cqaado3u	44	8	immune	immune	JJ
cord-334454-cqaado3u	44	9	modulation	modulation	NN
cord-334454-cqaado3u	44	10	properties	property	NNS
cord-334454-cqaado3u	44	11	,	,	,
cord-334454-cqaado3u	44	12	HuIFN	HuIFN	NNP
cord-334454-cqaado3u	44	13	-	-	HYPH
cord-334454-cqaado3u	44	14	α	α	NNP
cord-334454-cqaado3u	44	15	is	be	VBZ
cord-334454-cqaado3u	44	16	used	use	VBN
cord-334454-cqaado3u	44	17	with	with	IN
cord-334454-cqaado3u	44	18	various	various	JJ
cord-334454-cqaado3u	44	19	human	human	JJ
cord-334454-cqaado3u	44	20	diseases	disease	NNS
cord-334454-cqaado3u	44	21	such	such	JJ
cord-334454-cqaado3u	44	22	as	as	IN
cord-334454-cqaado3u	44	23	myeloid	myeloid	JJ
cord-334454-cqaado3u	44	24	leukemia	leukemia	NN
cord-334454-cqaado3u	44	25	,	,	,
cord-334454-cqaado3u	44	26	papilomatosis	papilomatosis	NNP
cord-334454-cqaado3u	44	27	,	,	,
cord-334454-cqaado3u	44	28	and	and	CC
cord-334454-cqaado3u	44	29	HIV	HIV	NNP
cord-334454-cqaado3u	44	30	[	[	-LRB-
cord-334454-cqaado3u	44	31	4	4	CD
cord-334454-cqaado3u	44	32	]	]	-RRB-
cord-334454-cqaado3u	44	33	.	.	.
cord-334454-cqaado3u	45	1	For	for	IN
cord-334454-cqaado3u	45	2	the	the	DT
cord-334454-cqaado3u	45	3	same	same	JJ
cord-334454-cqaado3u	45	4	reasons	reason	NNS
cord-334454-cqaado3u	45	5	,	,	,
cord-334454-cqaado3u	45	6	HuIFN	HuIFN	NNP
cord-334454-cqaado3u	45	7	-	-	HYPH
cord-334454-cqaado3u	45	8	α	α	NNP
cord-334454-cqaado3u	45	9	has	have	VBZ
cord-334454-cqaado3u	45	10	been	be	VBN
cord-334454-cqaado3u	45	11	also	also	RB
cord-334454-cqaado3u	45	12	used	use	VBN
cord-334454-cqaado3u	45	13	in	in	IN
cord-334454-cqaado3u	45	14	feline	feline	JJ
cord-334454-cqaado3u	45	15	medicine	medicine	NN
cord-334454-cqaado3u	45	16	,	,	,
cord-334454-cqaado3u	45	17	namely	namely	RB
cord-334454-cqaado3u	45	18	in	in	IN
cord-334454-cqaado3u	45	19	FIV	FIV	NNP
cord-334454-cqaado3u	45	20	,	,	,
cord-334454-cqaado3u	45	21	FeLV	FeLV	NNP
cord-334454-cqaado3u	45	22	,	,	,
cord-334454-cqaado3u	45	23	FHV-1	FHV-1	NNP
cord-334454-cqaado3u	45	24	,	,	,
cord-334454-cqaado3u	45	25	FCV	FCV	NNP
cord-334454-cqaado3u	45	26	,	,	,
cord-334454-cqaado3u	45	27	and	and	CC
cord-334454-cqaado3u	45	28	FCoV	fcov	JJ
cord-334454-cqaado3u	45	29	viral	viral	JJ
cord-334454-cqaado3u	45	30	infections	infection	NNS
cord-334454-cqaado3u	45	31	[	[	-LRB-
cord-334454-cqaado3u	45	32	20	20	CD
cord-334454-cqaado3u	45	33	]	]	-RRB-
cord-334454-cqaado3u	46	1	[	[	-LRB-
cord-334454-cqaado3u	46	2	21	21	CD
cord-334454-cqaado3u	46	3	]	]	-RRB-
cord-334454-cqaado3u	46	4	[	[	-LRB-
cord-334454-cqaado3u	46	5	22	22	CD
cord-334454-cqaado3u	46	6	]	]	-RRB-
cord-334454-cqaado3u	46	7	[	[	-LRB-
cord-334454-cqaado3u	46	8	23	23	CD
cord-334454-cqaado3u	46	9	]	]	-RRB-
cord-334454-cqaado3u	46	10	.	.	.
cord-334454-cqaado3u	47	1	In	in	IN
cord-334454-cqaado3u	47	2	spite	spite	NN
cord-334454-cqaado3u	47	3	of	of	IN
cord-334454-cqaado3u	47	4	its	-PRON-	PRP$
cord-334454-cqaado3u	47	5	short	short	JJ
cord-334454-cqaado3u	47	6	-	-	HYPH
cord-334454-cqaado3u	47	7	term	term	NN
cord-334454-cqaado3u	47	8	effects	effect	NNS
cord-334454-cqaado3u	47	9	,	,	,
cord-334454-cqaado3u	47	10	particularly	particularly	RB
cord-334454-cqaado3u	47	11	on	on	IN
cord-334454-cqaado3u	47	12	clinical	clinical	JJ
cord-334454-cqaado3u	47	13	improvement	improvement	NN
cord-334454-cqaado3u	47	14	and	and	CC
cord-334454-cqaado3u	47	15	the	the	DT
cord-334454-cqaado3u	47	16	increase	increase	NN
cord-334454-cqaado3u	47	17	in	in	IN
cord-334454-cqaado3u	47	18	survival	survival	NN
cord-334454-cqaado3u	47	19	time	time	NN
cord-334454-cqaado3u	47	20	,	,	,
cord-334454-cqaado3u	47	21	the	the	DT
cord-334454-cqaado3u	47	22	development	development	NN
cord-334454-cqaado3u	47	23	of	of	IN
cord-334454-cqaado3u	47	24	neutralizing	neutralize	VBG
cord-334454-cqaado3u	47	25	antibodies	antibody	NNS
cord-334454-cqaado3u	47	26	several	several	JJ
cord-334454-cqaado3u	47	27	weeks	week	NNS
cord-334454-cqaado3u	47	28	after	after	IN
cord-334454-cqaado3u	47	29	therapy	therapy	NN
cord-334454-cqaado3u	47	30	makes	make	VBZ
cord-334454-cqaado3u	47	31	HuIFN	HuIFN	NNP
cord-334454-cqaado3u	47	32	-	-	HYPH
cord-334454-cqaado3u	47	33	α	α	NN
cord-334454-cqaado3u	47	34	ineffective	ineffective	JJ
cord-334454-cqaado3u	47	35	for	for	IN
cord-334454-cqaado3u	47	36	long	long	JJ
cord-334454-cqaado3u	47	37	-	-	HYPH
cord-334454-cqaado3u	47	38	term	term	NN
cord-334454-cqaado3u	47	39	immune	immune	JJ
cord-334454-cqaado3u	47	40	modulation	modulation	NN
cord-334454-cqaado3u	47	41	therapy	therapy	NN
cord-334454-cqaado3u	47	42	in	in	IN
cord-334454-cqaado3u	47	43	cats	cat	NNS
cord-334454-cqaado3u	47	44	[	[	-LRB-
cord-334454-cqaado3u	47	45	4	4	CD
cord-334454-cqaado3u	47	46	,	,	,
cord-334454-cqaado3u	47	47	19	19	CD
cord-334454-cqaado3u	47	48	,	,	,
cord-334454-cqaado3u	47	49	21	21	CD
cord-334454-cqaado3u	47	50	]	]	-RRB-
cord-334454-cqaado3u	47	51	.	.	.
cord-334454-cqaado3u	48	1	This	this	DT
cord-334454-cqaado3u	48	2	problem	problem	NN
cord-334454-cqaado3u	48	3	was	be	VBD
cord-334454-cqaado3u	48	4	bypassed	bypass	VBN
cord-334454-cqaado3u	48	5	by	by	IN
cord-334454-cqaado3u	48	6	the	the	DT
cord-334454-cqaado3u	48	7	more	more	RBR
cord-334454-cqaado3u	48	8	recent	recent	JJ
cord-334454-cqaado3u	48	9	release	release	NN
cord-334454-cqaado3u	48	10	of	of	IN
cord-334454-cqaado3u	48	11	recombinant	recombinant	JJ
cord-334454-cqaado3u	48	12	feline	feline	JJ
cord-334454-cqaado3u	48	13	interferon	interferon	NN
cord-334454-cqaado3u	48	14	omega	omega	NN
cord-334454-cqaado3u	48	15	(	(	-LRB-
cord-334454-cqaado3u	48	16	rFeIFN	rFeIFN	NNP
cord-334454-cqaado3u	48	17	-	-	HYPH
cord-334454-cqaado3u	48	18	ω	ω	CD
cord-334454-cqaado3u	48	19	)	)	-RRB-
cord-334454-cqaado3u	48	20	.	.	.
cord-334454-cqaado3u	49	1	RFeIFN	rfeifn	NN
cord-334454-cqaado3u	49	2	-	-	NNS
cord-334454-cqaado3u	49	3	ω	ω	JJ
cord-334454-cqaado3u	49	4	is	be	VBZ
cord-334454-cqaado3u	49	5	the	the	DT
cord-334454-cqaado3u	49	6	first	first	JJ
cord-334454-cqaado3u	49	7	interferon	interferon	NN
cord-334454-cqaado3u	49	8	compound	compound	NN
cord-334454-cqaado3u	49	9	licensed	license	VBN
cord-334454-cqaado3u	49	10	for	for	IN
cord-334454-cqaado3u	49	11	use	use	NN
cord-334454-cqaado3u	49	12	in	in	IN
cord-334454-cqaado3u	49	13	veterinary	veterinary	JJ
cord-334454-cqaado3u	49	14	medicine	medicine	NN
cord-334454-cqaado3u	49	15	.	.	.
cord-334454-cqaado3u	50	1	Specifically	specifically	RB
cord-334454-cqaado3u	50	2	in	in	IN
cord-334454-cqaado3u	50	3	cats	cat	NNS
cord-334454-cqaado3u	50	4	,	,	,
cord-334454-cqaado3u	50	5	this	this	DT
cord-334454-cqaado3u	50	6	product	product	NN
cord-334454-cqaado3u	50	7	is	be	VBZ
cord-334454-cqaado3u	50	8	approved	approve	VBN
cord-334454-cqaado3u	50	9	for	for	IN
cord-334454-cqaado3u	50	10	use	use	NN
cord-334454-cqaado3u	50	11	in	in	IN
cord-334454-cqaado3u	50	12	retroviral	retroviral	JJ
cord-334454-cqaado3u	50	13	infections	infection	NNS
cord-334454-cqaado3u	50	14	,	,	,
cord-334454-cqaado3u	50	15	namely	namely	RB
cord-334454-cqaado3u	50	16	feline	feline	JJ
cord-334454-cqaado3u	50	17	immunodeficiency	immunodeficiency	NN
cord-334454-cqaado3u	50	18	virus	virus	NN
cord-334454-cqaado3u	50	19	(	(	-LRB-
cord-334454-cqaado3u	50	20	FIV	FIV	NNP
cord-334454-cqaado3u	50	21	)	)	-RRB-
cord-334454-cqaado3u	50	22	and	and	CC
cord-334454-cqaado3u	50	23	feline	feline	JJ
cord-334454-cqaado3u	50	24	leukemia	leukemia	NN
cord-334454-cqaado3u	50	25	virus	virus	NN
cord-334454-cqaado3u	50	26	(	(	-LRB-
cord-334454-cqaado3u	50	27	FeLV	FeLV	NNP
cord-334454-cqaado3u	50	28	)	)	-RRB-
cord-334454-cqaado3u	50	29	.	.	.
cord-334454-cqaado3u	51	1	According	accord	VBG
cord-334454-cqaado3u	51	2	to	to	IN
cord-334454-cqaado3u	51	3	the	the	DT
cord-334454-cqaado3u	51	4	manufacturer	manufacturer	NN
cord-334454-cqaado3u	51	5	's	's	POS
cord-334454-cqaado3u	51	6	instructions	instruction	NNS
cord-334454-cqaado3u	51	7	and	and	CC
cord-334454-cqaado3u	51	8	license	license	NN
cord-334454-cqaado3u	51	9	,	,	,
cord-334454-cqaado3u	51	10	it	-PRON-	PRP
cord-334454-cqaado3u	51	11	should	should	MD
cord-334454-cqaado3u	51	12	be	be	VB
cord-334454-cqaado3u	51	13	administered	administer	VBN
cord-334454-cqaado3u	51	14	in	in	IN
cord-334454-cqaado3u	51	15	three	three	CD
cord-334454-cqaado3u	51	16	cycles	cycle	NNS
cord-334454-cqaado3u	51	17	of	of	IN
cord-334454-cqaado3u	51	18	five	five	CD
cord-334454-cqaado3u	51	19	daily	daily	JJ
cord-334454-cqaado3u	51	20	subcutaneous	subcutaneous	JJ
cord-334454-cqaado3u	51	21	injections	injection	NNS
cord-334454-cqaado3u	51	22	of	of	IN
cord-334454-cqaado3u	51	23	1	1	CD
cord-334454-cqaado3u	51	24	MU	MU	NNP
cord-334454-cqaado3u	51	25	/	/	SYM
cord-334454-cqaado3u	51	26	kg	kg	NN
cord-334454-cqaado3u	51	27	,	,	,
cord-334454-cqaado3u	51	28	beginning	begin	VBG
cord-334454-cqaado3u	51	29	respectively	respectively	RB
cord-334454-cqaado3u	51	30	on	on	IN
cord-334454-cqaado3u	51	31	days	day	NNS
cord-334454-cqaado3u	51	32	0	0	CD
cord-334454-cqaado3u	51	33	,	,	,
cord-334454-cqaado3u	51	34	14	14	CD
cord-334454-cqaado3u	51	35	,	,	,
cord-334454-cqaado3u	51	36	and	and	CC
cord-334454-cqaado3u	51	37	60	60	CD
cord-334454-cqaado3u	51	38	.	.	.
cord-334454-cqaado3u	52	1	Despite	despite	IN
cord-334454-cqaado3u	52	2	the	the	DT
cord-334454-cqaado3u	52	3	fact	fact	NN
cord-334454-cqaado3u	52	4	that	that	IN
cord-334454-cqaado3u	52	5	it	-PRON-	PRP
cord-334454-cqaado3u	52	6	was	be	VBD
cord-334454-cqaado3u	52	7	licensed	license	VBN
cord-334454-cqaado3u	52	8	a	a	DT
cord-334454-cqaado3u	52	9	few	few	JJ
cord-334454-cqaado3u	52	10	years	year	NNS
cord-334454-cqaado3u	52	11	ago	ago	RB
cord-334454-cqaado3u	52	12	,	,	,
cord-334454-cqaado3u	52	13	only	only	RB
cord-334454-cqaado3u	52	14	a	a	DT
cord-334454-cqaado3u	52	15	few	few	JJ
cord-334454-cqaado3u	52	16	studies	study	NNS
cord-334454-cqaado3u	52	17	supported	support	VBD
cord-334454-cqaado3u	52	18	its	-PRON-	PRP$
cord-334454-cqaado3u	52	19	clinical	clinical	JJ
cord-334454-cqaado3u	52	20	benefits	benefit	NNS
cord-334454-cqaado3u	52	21	,	,	,
cord-334454-cqaado3u	52	22	particularly	particularly	RB
cord-334454-cqaado3u	52	23	in	in	IN
cord-334454-cqaado3u	52	24	retroviral	retroviral	JJ
cord-334454-cqaado3u	52	25	infections	infection	NNS
cord-334454-cqaado3u	52	26	.	.	.
cord-334454-cqaado3u	53	1	The	the	DT
cord-334454-cqaado3u	53	2	first	first	JJ
cord-334454-cqaado3u	53	3	study	study	NN
cord-334454-cqaado3u	53	4	,	,	,
cord-334454-cqaado3u	53	5	which	which	WDT
cord-334454-cqaado3u	53	6	described	describe	VBD
cord-334454-cqaado3u	53	7	its	-PRON-	PRP$
cord-334454-cqaado3u	53	8	clinical	clinical	JJ
cord-334454-cqaado3u	53	9	application	application	NN
cord-334454-cqaado3u	53	10	dates	date	NNS
cord-334454-cqaado3u	53	11	from	from	IN
cord-334454-cqaado3u	53	12	2004	2004	CD
cord-334454-cqaado3u	53	13	and	and	CC
cord-334454-cqaado3u	53	14	reported	report	VBD
cord-334454-cqaado3u	53	15	that	that	IN
cord-334454-cqaado3u	53	16	treated	treat	VBN
cord-334454-cqaado3u	53	17	feline	feline	JJ
cord-334454-cqaado3u	53	18	leukemia	leukemia	NN
cord-334454-cqaado3u	53	19	virus	virus	NN
cord-334454-cqaado3u	53	20	(	(	-LRB-
cord-334454-cqaado3u	53	21	FeLV	FeLV	NNP
cord-334454-cqaado3u	53	22	)	)	-RRB-
cord-334454-cqaado3u	53	23	and	and	CC
cord-334454-cqaado3u	53	24	FIV	FIV	NNP
cord-334454-cqaado3u	53	25	/	/	SYM
cord-334454-cqaado3u	53	26	FeLV	felv	NN
cord-334454-cqaado3u	53	27	co	co	JJ
cord-334454-cqaado3u	53	28	-	-	JJ
cord-334454-cqaado3u	53	29	infected	infected	JJ
cord-334454-cqaado3u	53	30	cats	cat	NNS
cord-334454-cqaado3u	53	31	,	,	,
cord-334454-cqaado3u	53	32	showed	show	VBD
cord-334454-cqaado3u	53	33	a	a	DT
cord-334454-cqaado3u	53	34	significant	significant	JJ
cord-334454-cqaado3u	53	35	clinical	clinical	JJ
cord-334454-cqaado3u	53	36	improvement	improvement	NN
cord-334454-cqaado3u	53	37	and	and	CC
cord-334454-cqaado3u	53	38	an	an	DT
cord-334454-cqaado3u	53	39	increased	increase	VBN
cord-334454-cqaado3u	53	40	survival	survival	NN
cord-334454-cqaado3u	53	41	time	time	NN
cord-334454-cqaado3u	53	42	[	[	-LRB-
cord-334454-cqaado3u	53	43	18	18	CD
cord-334454-cqaado3u	53	44	]	]	-RRB-
cord-334454-cqaado3u	53	45	.	.	.
cord-334454-cqaado3u	54	1	More	more	RBR
cord-334454-cqaado3u	54	2	recently	recently	RB
cord-334454-cqaado3u	54	3	,	,	,
cord-334454-cqaado3u	54	4	in	in	IN
cord-334454-cqaado3u	54	5	2011	2011	CD
cord-334454-cqaado3u	54	6	,	,	,
cord-334454-cqaado3u	54	7	another	another	DT
cord-334454-cqaado3u	54	8	research	research	NN
cord-334454-cqaado3u	54	9	group	group	NN
cord-334454-cqaado3u	54	10	reinforced	reinforce	VBD
cord-334454-cqaado3u	54	11	that	that	IN
cord-334454-cqaado3u	54	12	rFeIFN	rFeIFN	NNP
cord-334454-cqaado3u	54	13	-	-	HYPH
cord-334454-cqaado3u	54	14	ω	ω	NN
cord-334454-cqaado3u	54	15	improves	improve	VBZ
cord-334454-cqaado3u	54	16	clinical	clinical	JJ
cord-334454-cqaado3u	54	17	signs	sign	NNS
cord-334454-cqaado3u	54	18	and	and	CC
cord-334454-cqaado3u	54	19	hematologic	hematologic	JJ
cord-334454-cqaado3u	54	20	parameters	parameter	NNS
cord-334454-cqaado3u	54	21	in	in	IN
cord-334454-cqaado3u	54	22	retrovirally	retrovirally	RB
cord-334454-cqaado3u	54	23	infected	infected	JJ
cord-334454-cqaado3u	54	24	cats	cat	NNS
cord-334454-cqaado3u	54	25	.	.	.
cord-334454-cqaado3u	55	1	However	however	RB
cord-334454-cqaado3u	55	2	,	,	,
cord-334454-cqaado3u	55	3	according	accord	VBG
cord-334454-cqaado3u	55	4	to	to	IN
cord-334454-cqaado3u	55	5	this	this	DT
cord-334454-cqaado3u	55	6	study	study	NN
cord-334454-cqaado3u	55	7	,	,	,
cord-334454-cqaado3u	55	8	it	-PRON-	PRP
cord-334454-cqaado3u	55	9	does	do	VBZ
cord-334454-cqaado3u	55	10	not	not	RB
cord-334454-cqaado3u	55	11	change	change	VB
cord-334454-cqaado3u	55	12	hypergammaglobulinemia	hypergammaglobulinemia	NN
cord-334454-cqaado3u	55	13	,	,	,
cord-334454-cqaado3u	55	14	proviral	proviral	NNP
cord-334454-cqaado3u	55	15	load	load	NNP
cord-334454-cqaado3u	55	16	,	,	,
cord-334454-cqaado3u	55	17	or	or	CC
cord-334454-cqaado3u	55	18	viremia	viremia	NN
cord-334454-cqaado3u	55	19	,	,	,
cord-334454-cqaado3u	55	20	suggesting	suggest	VBG
cord-334454-cqaado3u	55	21	an	an	DT
cord-334454-cqaado3u	55	22	overall	overall	JJ
cord-334454-cqaado3u	55	23	effect	effect	NN
cord-334454-cqaado3u	55	24	mainly	mainly	RB
cord-334454-cqaado3u	55	25	on	on	IN
cord-334454-cqaado3u	55	26	the	the	DT
cord-334454-cqaado3u	55	27	innate	innate	JJ
cord-334454-cqaado3u	55	28	immune	immune	JJ
cord-334454-cqaado3u	55	29	reaction	reaction	NN
cord-334454-cqaado3u	55	30	rather	rather	RB
cord-334454-cqaado3u	55	31	than	than	IN
cord-334454-cqaado3u	55	32	on	on	IN
cord-334454-cqaado3u	55	33	the	the	DT
cord-334454-cqaado3u	55	34	acquired	acquire	VBN
cord-334454-cqaado3u	55	35	immunity	immunity	NN
cord-334454-cqaado3u	55	36	[	[	-LRB-
cord-334454-cqaado3u	55	37	17	17	CD
cord-334454-cqaado3u	55	38	]	]	-RRB-
cord-334454-cqaado3u	55	39	.	.	.
cord-334454-cqaado3u	56	1	This	this	DT
cord-334454-cqaado3u	56	2	means	mean	VBZ
cord-334454-cqaado3u	56	3	that	that	IN
cord-334454-cqaado3u	56	4	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	56	5	-	-	HYPH
cord-334454-cqaado3u	56	6	ω	ω	NN
cord-334454-cqaado3u	56	7	does	do	VBZ
cord-334454-cqaado3u	56	8	not	not	RB
cord-334454-cqaado3u	56	9	seem	seem	VB
cord-334454-cqaado3u	56	10	to	to	TO
cord-334454-cqaado3u	56	11	have	have	VB
cord-334454-cqaado3u	56	12	an	an	DT
cord-334454-cqaado3u	56	13	anti	anti	JJ
cord-334454-cqaado3u	56	14	-	-	JJ
cord-334454-cqaado3u	56	15	viral	viral	JJ
cord-334454-cqaado3u	56	16	effect	effect	NN
cord-334454-cqaado3u	56	17	in	in	IN
cord-334454-cqaado3u	56	18	vivo	vivo	NN
cord-334454-cqaado3u	56	19	,	,	,
cord-334454-cqaado3u	56	20	and	and	CC
cord-334454-cqaado3u	56	21	the	the	DT
cord-334454-cqaado3u	56	22	observed	observed	JJ
cord-334454-cqaado3u	56	23	clinical	clinical	JJ
cord-334454-cqaado3u	56	24	improvement	improvement	NN
cord-334454-cqaado3u	56	25	must	must	MD
cord-334454-cqaado3u	56	26	be	be	VB
cord-334454-cqaado3u	56	27	related	relate	VBN
cord-334454-cqaado3u	56	28	to	to	IN
cord-334454-cqaado3u	56	29	a	a	DT
cord-334454-cqaado3u	56	30	potential	potential	JJ
cord-334454-cqaado3u	56	31	immune	immune	JJ
cord-334454-cqaado3u	56	32	modulation	modulation	NN
cord-334454-cqaado3u	56	33	of	of	IN
cord-334454-cqaado3u	56	34	the	the	DT
cord-334454-cqaado3u	56	35	innate	innate	JJ
cord-334454-cqaado3u	56	36	immune	immune	JJ
cord-334454-cqaado3u	56	37	system	system	NN
cord-334454-cqaado3u	56	38	[	[	-LRB-
cord-334454-cqaado3u	56	39	17	17	CD
cord-334454-cqaado3u	56	40	]	]	-RRB-
cord-334454-cqaado3u	56	41	.	.	.
cord-334454-cqaado3u	57	1	Moreover	moreover	RB
cord-334454-cqaado3u	57	2	,	,	,
cord-334454-cqaado3u	57	3	in	in	IN
cord-334454-cqaado3u	57	4	contrast	contrast	NN
cord-334454-cqaado3u	57	5	to	to	IN
cord-334454-cqaado3u	57	6	in	in	FW
cord-334454-cqaado3u	57	7	vitro	vitro	FW
cord-334454-cqaado3u	57	8	studies	study	NNS
cord-334454-cqaado3u	57	9	[	[	-LRB-
cord-334454-cqaado3u	57	10	24	24	CD
cord-334454-cqaado3u	57	11	]	]	-RRB-
cord-334454-cqaado3u	57	12	,	,	,
cord-334454-cqaado3u	57	13	the	the	DT
cord-334454-cqaado3u	57	14	anti	anti	JJ
cord-334454-cqaado3u	57	15	-	-	JJ
cord-334454-cqaado3u	57	16	viral	viral	JJ
cord-334454-cqaado3u	57	17	in	in	IN
cord-334454-cqaado3u	57	18	vivo	vivo	NN
cord-334454-cqaado3u	57	19	action	action	NN
cord-334454-cqaado3u	57	20	of	of	IN
cord-334454-cqaado3u	57	21	the	the	DT
cord-334454-cqaado3u	57	22	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	57	23	-	-	HYPH
cord-334454-cqaado3u	57	24	ω	ω	CD
cord-334454-cqaado3u	57	25	licensed	licensed	JJ
cord-334454-cqaado3u	57	26	protocol	protocol	NN
cord-334454-cqaado3u	57	27	towards	towards	IN
cord-334454-cqaado3u	57	28	FIV	FIV	NNP
cord-334454-cqaado3u	57	29	and	and	CC
cord-334454-cqaado3u	57	30	FeLV	FeLV	NNP
cord-334454-cqaado3u	57	31	was	be	VBD
cord-334454-cqaado3u	57	32	found	find	VBN
cord-334454-cqaado3u	57	33	to	to	TO
cord-334454-cqaado3u	57	34	be	be	VB
cord-334454-cqaado3u	57	35	negligible	negligible	JJ
cord-334454-cqaado3u	57	36	according	accord	VBG
cord-334454-cqaado3u	57	37	to	to	IN
cord-334454-cqaado3u	57	38	these	these	DT
cord-334454-cqaado3u	57	39	authors	author	NNS
cord-334454-cqaado3u	57	40	[	[	-LRB-
cord-334454-cqaado3u	57	41	17	17	CD
cord-334454-cqaado3u	57	42	]	]	-RRB-
cord-334454-cqaado3u	57	43	.	.	.
cord-334454-cqaado3u	58	1	These	these	DT
cord-334454-cqaado3u	58	2	points	point	NNS
cord-334454-cqaado3u	58	3	highlight	highlight	VBP
cord-334454-cqaado3u	58	4	the	the	DT
cord-334454-cqaado3u	58	5	need	need	NN
cord-334454-cqaado3u	58	6	of	of	IN
cord-334454-cqaado3u	58	7	further	further	JJ
cord-334454-cqaado3u	58	8	studies	study	NNS
cord-334454-cqaado3u	58	9	in	in	IN
cord-334454-cqaado3u	58	10	order	order	NN
cord-334454-cqaado3u	58	11	to	to	TO
cord-334454-cqaado3u	58	12	clarify	clarify	VB
cord-334454-cqaado3u	58	13	the	the	DT
cord-334454-cqaado3u	58	14	mechanisms	mechanism	NNS
cord-334454-cqaado3u	58	15	of	of	IN
cord-334454-cqaado3u	58	16	action	action	NN
cord-334454-cqaado3u	58	17	of	of	IN
cord-334454-cqaado3u	58	18	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	58	19	-	-	HYPH
cord-334454-cqaado3u	58	20	ω	ω	NN
cord-334454-cqaado3u	58	21	.	.	.
cord-334454-cqaado3u	59	1	The	the	DT
cord-334454-cqaado3u	59	2	authors	author	NNS
cord-334454-cqaado3u	59	3	tried	try	VBD
cord-334454-cqaado3u	59	4	to	to	TO
cord-334454-cqaado3u	59	5	extend	extend	VB
cord-334454-cqaado3u	59	6	the	the	DT
cord-334454-cqaado3u	59	7	current	current	JJ
cord-334454-cqaado3u	59	8	knowledge	knowledge	NN
cord-334454-cqaado3u	59	9	about	about	IN
cord-334454-cqaado3u	59	10	this	this	DT
cord-334454-cqaado3u	59	11	compound	compound	NN
cord-334454-cqaado3u	59	12	in	in	IN
cord-334454-cqaado3u	59	13	order	order	NN
cord-334454-cqaado3u	59	14	to	to	TO
cord-334454-cqaado3u	59	15	support	support	VB
cord-334454-cqaado3u	59	16	and	and	CC
cord-334454-cqaado3u	59	17	clarify	clarify	VB
cord-334454-cqaado3u	59	18	the	the	DT
cord-334454-cqaado3u	59	19	evident	evident	JJ
cord-334454-cqaado3u	59	20	clinical	clinical	JJ
cord-334454-cqaado3u	59	21	improvement	improvement	NN
cord-334454-cqaado3u	59	22	previously	previously	RB
cord-334454-cqaado3u	59	23	described	describe	VBD
cord-334454-cqaado3u	59	24	[	[	-LRB-
cord-334454-cqaado3u	59	25	17	17	CD
cord-334454-cqaado3u	59	26	,	,	,
cord-334454-cqaado3u	59	27	18	18	CD
cord-334454-cqaado3u	59	28	]	]	-RRB-
cord-334454-cqaado3u	59	29	.	.	.
cord-334454-cqaado3u	60	1	Experimental	experimental	JJ
cord-334454-cqaado3u	60	2	work	work	NN
cord-334454-cqaado3u	60	3	relied	rely	VBD
cord-334454-cqaado3u	60	4	on	on	IN
cord-334454-cqaado3u	60	5	two	two	CD
cord-334454-cqaado3u	60	6	distinct	distinct	JJ
cord-334454-cqaado3u	60	7	clinical	clinical	JJ
cord-334454-cqaado3u	60	8	trials	trial	NNS
cord-334454-cqaado3u	60	9	[	[	-LRB-
cord-334454-cqaado3u	60	10	25	25	CD
cord-334454-cqaado3u	60	11	]	]	-RRB-
cord-334454-cqaado3u	60	12	[	[	-LRB-
cord-334454-cqaado3u	60	13	26	26	CD
cord-334454-cqaado3u	60	14	]	]	-RRB-
cord-334454-cqaado3u	60	15	[	[	-LRB-
cord-334454-cqaado3u	60	16	27	27	CD
cord-334454-cqaado3u	60	17	]	]	-RRB-
cord-334454-cqaado3u	60	18	.	.	.
cord-334454-cqaado3u	61	1	One	one	CD
cord-334454-cqaado3u	61	2	referred	refer	VBD
cord-334454-cqaado3u	61	3	to	to	IN
cord-334454-cqaado3u	61	4	16	16	CD
cord-334454-cqaado3u	61	5	retrovirally	retrovirally	NN
cord-334454-cqaado3u	61	6	infected	infected	JJ
cord-334454-cqaado3u	61	7	cats	cat	NNS
cord-334454-cqaado3u	61	8	(	(	-LRB-
cord-334454-cqaado3u	61	9	7	7	CD
cord-334454-cqaado3u	61	10	FIV	FIV	NNP
cord-334454-cqaado3u	61	11	,	,	,
cord-334454-cqaado3u	61	12	6	6	CD
cord-334454-cqaado3u	61	13	FeLV	felv	NN
cord-334454-cqaado3u	61	14	,	,	,
cord-334454-cqaado3u	61	15	and	and	CC
cord-334454-cqaado3u	61	16	3	3	CD
cord-334454-cqaado3u	61	17	co	co	JJ
cord-334454-cqaado3u	61	18	-	-	JJ
cord-334454-cqaado3u	61	19	infected	infected	JJ
cord-334454-cqaado3u	61	20	cats	cat	NNS
cord-334454-cqaado3u	61	21	)	)	-RRB-
cord-334454-cqaado3u	61	22	treated	treat	VBN
cord-334454-cqaado3u	61	23	with	with	IN
cord-334454-cqaado3u	61	24	rFeIFN	rFeIFN	NNP
cord-334454-cqaado3u	61	25	-	-	HYPH
cord-334454-cqaado3u	61	26	ω	ω	CD
cord-334454-cqaado3u	61	27	licensed	license	VBD
cord-334454-cqaado3u	61	28	subcutaneous	subcutaneous	JJ
cord-334454-cqaado3u	61	29	protocol	protocol	NN
cord-334454-cqaado3u	61	30	,	,	,
cord-334454-cqaado3u	61	31	while	while	IN
cord-334454-cqaado3u	61	32	the	the	DT
cord-334454-cqaado3u	61	33	other	other	JJ
cord-334454-cqaado3u	61	34	described	describe	VBD
cord-334454-cqaado3u	61	35	an	an	DT
cord-334454-cqaado3u	61	36	alternative	alternative	JJ
cord-334454-cqaado3u	61	37	oral	oral	JJ
cord-334454-cqaado3u	61	38	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	61	39	-	-	HYPH
cord-334454-cqaado3u	61	40	ω	ω	CD
cord-334454-cqaado3u	61	41	protocol	protocol	NN
cord-334454-cqaado3u	61	42	,	,	,
cord-334454-cqaado3u	61	43	administered	administer	VBN
cord-334454-cqaado3u	61	44	to	to	IN
cord-334454-cqaado3u	61	45	11	11	CD
cord-334454-cqaado3u	61	46	FIV	FIV	NNP
cord-334454-cqaado3u	61	47	-	-	HYPH
cord-334454-cqaado3u	61	48	infected	infect	VBN
cord-334454-cqaado3u	61	49	cats	cat	NNS
cord-334454-cqaado3u	61	50	[	[	-LRB-
cord-334454-cqaado3u	61	51	25	25	CD
cord-334454-cqaado3u	61	52	,	,	,
cord-334454-cqaado3u	61	53	26	26	CD
cord-334454-cqaado3u	61	54	]	]	-RRB-
cord-334454-cqaado3u	61	55	.	.	.
cord-334454-cqaado3u	62	1	Both	both	DT
cord-334454-cqaado3u	62	2	protocols	protocol	NNS
cord-334454-cqaado3u	62	3	were	be	VBD
cord-334454-cqaado3u	62	4	compared	compare	VBN
cord-334454-cqaado3u	62	5	in	in	IN
cord-334454-cqaado3u	62	6	an	an	DT
cord-334454-cqaado3u	62	7	immunological	immunological	JJ
cord-334454-cqaado3u	62	8	and	and	CC
cord-334454-cqaado3u	62	9	virological	virological	JJ
cord-334454-cqaado3u	62	10	perspective	perspective	NN
cord-334454-cqaado3u	62	11	[	[	-LRB-
cord-334454-cqaado3u	62	12	25	25	CD
cord-334454-cqaado3u	62	13	]	]	-RRB-
cord-334454-cqaado3u	62	14	[	[	-LRB-
cord-334454-cqaado3u	62	15	26	26	CD
cord-334454-cqaado3u	62	16	]	]	-RRB-
cord-334454-cqaado3u	62	17	[	[	-LRB-
cord-334454-cqaado3u	62	18	27	27	CD
cord-334454-cqaado3u	62	19	]	]	-RRB-
cord-334454-cqaado3u	62	20	.	.	.
cord-334454-cqaado3u	63	1	Firstly	firstly	RB
cord-334454-cqaado3u	63	2	,	,	,
cord-334454-cqaado3u	63	3	the	the	DT
cord-334454-cqaado3u	63	4	effect	effect	NN
cord-334454-cqaado3u	63	5	of	of	IN
cord-334454-cqaado3u	63	6	rFeIFN	rFeIFN	NNP
cord-334454-cqaado3u	63	7	-	-	HYPH
cord-334454-cqaado3u	63	8	ω	ω	CD
cord-334454-cqaado3u	63	9	licensed	licensed	JJ
cord-334454-cqaado3u	63	10	protocol	protocol	NN
cord-334454-cqaado3u	63	11	in	in	IN
cord-334454-cqaado3u	63	12	cats	cat	NNS
cord-334454-cqaado3u	63	13	living	live	VBG
cord-334454-cqaado3u	63	14	in	in	IN
cord-334454-cqaado3u	63	15	an	an	DT
cord-334454-cqaado3u	63	16	animal	animal	NN
cord-334454-cqaado3u	63	17	shelter	shelter	NN
cord-334454-cqaado3u	63	18	was	be	VBD
cord-334454-cqaado3u	63	19	evaluated	evaluate	VBN
cord-334454-cqaado3u	63	20	,	,	,
cord-334454-cqaado3u	63	21	assessing	assess	VBG
cord-334454-cqaado3u	63	22	clinical	clinical	JJ
cord-334454-cqaado3u	63	23	improvement	improvement	NN
cord-334454-cqaado3u	63	24	and	and	CC
cord-334454-cqaado3u	63	25	monitoring	monitor	VBG
cord-334454-cqaado3u	63	26	concurrent	concurrent	JJ
cord-334454-cqaado3u	63	27	viral	viral	JJ
cord-334454-cqaado3u	63	28	excretion	excretion	NN
cord-334454-cqaado3u	63	29	(	(	-LRB-
cord-334454-cqaado3u	63	30	namely	namely	RB
cord-334454-cqaado3u	63	31	herpesvirus	herpesvirus	NNP
cord-334454-cqaado3u	63	32	,	,	,
cord-334454-cqaado3u	63	33	calicivirus	calicivirus	NNP
cord-334454-cqaado3u	63	34	,	,	,
cord-334454-cqaado3u	63	35	and	and	CC
cord-334454-cqaado3u	63	36	coronavirus	coronavirus	NN
cord-334454-cqaado3u	63	37	)	)	-RRB-
cord-334454-cqaado3u	63	38	[	[	-LRB-
cord-334454-cqaado3u	63	39	26	26	CD
cord-334454-cqaado3u	63	40	]	]	-RRB-
cord-334454-cqaado3u	63	41	.	.	.
cord-334454-cqaado3u	64	1	A	a	DT
cord-334454-cqaado3u	64	2	previous	previous	JJ
cord-334454-cqaado3u	64	3	study	study	NN
cord-334454-cqaado3u	64	4	in	in	IN
cord-334454-cqaado3u	64	5	cats	cat	NNS
cord-334454-cqaado3u	64	6	treated	treat	VBN
cord-334454-cqaado3u	64	7	with	with	IN
cord-334454-cqaado3u	64	8	HuIFN	HuIFN	NNP
cord-334454-cqaado3u	64	9	-	-	HYPH
cord-334454-cqaado3u	64	10	α	α	NNP
cord-334454-cqaado3u	64	11	documented	document	VBD
cord-334454-cqaado3u	64	12	that	that	IN
cord-334454-cqaado3u	64	13	the	the	DT
cord-334454-cqaado3u	64	14	induced	induce	VBN
cord-334454-cqaado3u	64	15	clinical	clinical	JJ
cord-334454-cqaado3u	64	16	improvement	improvement	NN
cord-334454-cqaado3u	64	17	could	could	MD
cord-334454-cqaado3u	64	18	be	be	VB
cord-334454-cqaado3u	64	19	potentially	potentially	RB
cord-334454-cqaado3u	64	20	related	relate	VBN
cord-334454-cqaado3u	64	21	to	to	IN
cord-334454-cqaado3u	64	22	a	a	DT
cord-334454-cqaado3u	64	23	recovery	recovery	NN
cord-334454-cqaado3u	64	24	of	of	IN
cord-334454-cqaado3u	64	25	serious	serious	JJ
cord-334454-cqaado3u	64	26	opportunistic	opportunistic	JJ
cord-334454-cqaado3u	64	27	infections	infection	NNS
cord-334454-cqaado3u	64	28	[	[	-LRB-
cord-334454-cqaado3u	64	29	21	21	CD
cord-334454-cqaado3u	64	30	]	]	-RRB-
cord-334454-cqaado3u	64	31	.	.	.
cord-334454-cqaado3u	65	1	In	in	IN
cord-334454-cqaado3u	65	2	order	order	NN
cord-334454-cqaado3u	65	3	to	to	TO
cord-334454-cqaado3u	65	4	assess	assess	VB
cord-334454-cqaado3u	65	5	whether	whether	IN
cord-334454-cqaado3u	65	6	rFeIFN	rFeIFN	NNP
cord-334454-cqaado3u	65	7	-	-	HYPH
cord-334454-cqaado3u	65	8	ω	ω	NN
cord-334454-cqaado3u	65	9	had	have	VBD
cord-334454-cqaado3u	65	10	the	the	DT
cord-334454-cqaado3u	65	11	same	same	JJ
cord-334454-cqaado3u	65	12	properties	property	NNS
cord-334454-cqaado3u	65	13	,	,	,
cord-334454-cqaado3u	65	14	different	different	JJ
cord-334454-cqaado3u	65	15	hematology	hematology	NN
cord-334454-cqaado3u	65	16	and	and	CC
cord-334454-cqaado3u	65	17	biochemistry	biochemistry	NN
cord-334454-cqaado3u	65	18	parameters	parameter	NNS
cord-334454-cqaado3u	65	19	were	be	VBD
cord-334454-cqaado3u	65	20	monitored	monitor	VBN
cord-334454-cqaado3u	65	21	,	,	,
cord-334454-cqaado3u	65	22	and	and	CC
cord-334454-cqaado3u	65	23	a	a	DT
cord-334454-cqaado3u	65	24	score	score	NN
cord-334454-cqaado3u	65	25	-	-	HYPH
cord-334454-cqaado3u	65	26	scale	scale	NN
cord-334454-cqaado3u	65	27	system	system	NN
cord-334454-cqaado3u	65	28	that	that	WDT
cord-334454-cqaado3u	65	29	allowed	allow	VBD
cord-334454-cqaado3u	65	30	the	the	DT
cord-334454-cqaado3u	65	31	evaluation	evaluation	NN
cord-334454-cqaado3u	65	32	of	of	IN
cord-334454-cqaado3u	65	33	clinical	clinical	JJ
cord-334454-cqaado3u	65	34	improvement	improvement	NN
cord-334454-cqaado3u	65	35	in	in	IN
cord-334454-cqaado3u	65	36	treated	treat	VBN
cord-334454-cqaado3u	65	37	cats	cat	NNS
cord-334454-cqaado3u	65	38	was	be	VBD
cord-334454-cqaado3u	65	39	validated	validate	VBN
cord-334454-cqaado3u	65	40	.	.	.
cord-334454-cqaado3u	66	1	In	in	IN
cord-334454-cqaado3u	66	2	agreement	agreement	NN
cord-334454-cqaado3u	66	3	with	with	IN
cord-334454-cqaado3u	66	4	the	the	DT
cord-334454-cqaado3u	66	5	two	two	CD
cord-334454-cqaado3u	66	6	previous	previous	JJ
cord-334454-cqaado3u	66	7	referred	refer	VBN
cord-334454-cqaado3u	66	8	studies	study	NNS
cord-334454-cqaado3u	66	9	[	[	-LRB-
cord-334454-cqaado3u	66	10	17	17	CD
cord-334454-cqaado3u	66	11	,	,	,
cord-334454-cqaado3u	66	12	18	18	CD
cord-334454-cqaado3u	66	13	]	]	-RRB-
cord-334454-cqaado3u	66	14	,	,	,
cord-334454-cqaado3u	66	15	a	a	DT
cord-334454-cqaado3u	66	16	significant	significant	JJ
cord-334454-cqaado3u	66	17	clinical	clinical	JJ
cord-334454-cqaado3u	66	18	improvement	improvement	NN
cord-334454-cqaado3u	66	19	in	in	IN
cord-334454-cqaado3u	66	20	treated	treat	VBN
cord-334454-cqaado3u	66	21	animals	animal	NNS
cord-334454-cqaado3u	66	22	without	without	IN
cord-334454-cqaado3u	66	23	relevant	relevant	JJ
cord-334454-cqaado3u	66	24	changes	change	NNS
cord-334454-cqaado3u	66	25	on	on	IN
cord-334454-cqaado3u	66	26	hematology	hematology	NN
cord-334454-cqaado3u	66	27	and	and	CC
cord-334454-cqaado3u	66	28	biochemistry	biochemistry	NN
cord-334454-cqaado3u	66	29	profiles	profile	NNS
cord-334454-cqaado3u	66	30	was	be	VBD
cord-334454-cqaado3u	66	31	reported	report	VBN
cord-334454-cqaado3u	66	32	[	[	-LRB-
cord-334454-cqaado3u	66	33	26	26	CD
cord-334454-cqaado3u	66	34	]	]	-RRB-
cord-334454-cqaado3u	66	35	.	.	.
cord-334454-cqaado3u	67	1	Concerning	concern	VBG
cord-334454-cqaado3u	67	2	these	these	DT
cord-334454-cqaado3u	67	3	results	result	NNS
cord-334454-cqaado3u	67	4	,	,	,
cord-334454-cqaado3u	67	5	rFeIFNω	rFeIFNω	NNP
cord-334454-cqaado3u	67	6	seems	seem	VBZ
cord-334454-cqaado3u	67	7	to	to	TO
cord-334454-cqaado3u	67	8	be	be	VB
cord-334454-cqaado3u	67	9	able	able	JJ
cord-334454-cqaado3u	67	10	to	to	TO
cord-334454-cqaado3u	67	11	contribute	contribute	VB
cord-334454-cqaado3u	67	12	to	to	IN
cord-334454-cqaado3u	67	13	the	the	DT
cord-334454-cqaado3u	67	14	management	management	NN
cord-334454-cqaado3u	67	15	of	of	IN
cord-334454-cqaado3u	67	16	this	this	DT
cord-334454-cqaado3u	67	17	reality	reality	NN
cord-334454-cqaado3u	67	18	by	by	IN
cord-334454-cqaado3u	67	19	improving	improve	VBG
cord-334454-cqaado3u	67	20	clinical	clinical	JJ
cord-334454-cqaado3u	67	21	signs	sign	NNS
cord-334454-cqaado3u	67	22	and	and	CC
cord-334454-cqaado3u	67	23	decreasing	decrease	VBG
cord-334454-cqaado3u	67	24	concurrent	concurrent	JJ
cord-334454-cqaado3u	67	25	viral	viral	JJ
cord-334454-cqaado3u	67	26	excretion	excretion	NN
cord-334454-cqaado3u	67	27	.	.	.
cord-334454-cqaado3u	68	1	Therefore	therefore	RB
cord-334454-cqaado3u	68	2	,	,	,
cord-334454-cqaado3u	68	3	rFeIFNω	rFeIFNω	NNP
cord-334454-cqaado3u	68	4	must	must	MD
cord-334454-cqaado3u	68	5	be	be	VB
cord-334454-cqaado3u	68	6	considered	consider	VBN
cord-334454-cqaado3u	68	7	as	as	IN
cord-334454-cqaado3u	68	8	an	an	DT
cord-334454-cqaado3u	68	9	effective	effective	JJ
cord-334454-cqaado3u	68	10	immune	immune	JJ
cord-334454-cqaado3u	68	11	-	-	HYPH
cord-334454-cqaado3u	68	12	modulator	modulator	NN
cord-334454-cqaado3u	68	13	therapy	therapy	NN
cord-334454-cqaado3u	68	14	for	for	IN
cord-334454-cqaado3u	68	15	use	use	NN
cord-334454-cqaado3u	68	16	in	in	IN
cord-334454-cqaado3u	68	17	shelter	shelter	NN
cord-334454-cqaado3u	68	18	medicine	medicine	NN
cord-334454-cqaado3u	68	19	where	where	WRB
cord-334454-cqaado3u	68	20	the	the	DT
cord-334454-cqaado3u	68	21	prevalence	prevalence	NN
cord-334454-cqaado3u	68	22	of	of	IN
cord-334454-cqaado3u	68	23	concomitant	concomitant	JJ
cord-334454-cqaado3u	68	24	infections	infection	NNS
cord-334454-cqaado3u	68	25	is	be	VBZ
cord-334454-cqaado3u	68	26	higher	high	JJR
cord-334454-cqaado3u	68	27	.	.	.
cord-334454-cqaado3u	69	1	In	in	IN
cord-334454-cqaado3u	69	2	further	further	JJ
cord-334454-cqaado3u	69	3	studies	study	NNS
cord-334454-cqaado3u	69	4	,	,	,
cord-334454-cqaado3u	69	5	the	the	DT
cord-334454-cqaado3u	69	6	influence	influence	NN
cord-334454-cqaado3u	69	7	of	of	IN
cord-334454-cqaado3u	69	8	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	69	9	-	-	HYPH
cord-334454-cqaado3u	69	10	ω	ω	JJ
cord-334454-cqaado3u	69	11	in	in	IN
cord-334454-cqaado3u	69	12	the	the	DT
cord-334454-cqaado3u	69	13	acute	acute	JJ
cord-334454-cqaado3u	69	14	phase	phase	NN
cord-334454-cqaado3u	69	15	reaction	reaction	NN
cord-334454-cqaado3u	69	16	was	be	VBD
cord-334454-cqaado3u	69	17	investigated	investigate	VBN
cord-334454-cqaado3u	69	18	[	[	-LRB-
cord-334454-cqaado3u	69	19	28	28	CD
cord-334454-cqaado3u	69	20	]	]	-RRB-
cord-334454-cqaado3u	69	21	.	.	.
cord-334454-cqaado3u	70	1	In	in	IN
cord-334454-cqaado3u	70	2	human	human	JJ
cord-334454-cqaado3u	70	3	medicine	medicine	NN
cord-334454-cqaado3u	70	4	,	,	,
cord-334454-cqaado3u	70	5	several	several	JJ
cord-334454-cqaado3u	70	6	studies	study	NNS
cord-334454-cqaado3u	70	7	have	have	VBP
cord-334454-cqaado3u	70	8	described	describe	VBN
cord-334454-cqaado3u	70	9	its	-PRON-	PRP$
cord-334454-cqaado3u	70	10	increase	increase	NN
cord-334454-cqaado3u	70	11	in	in	IN
cord-334454-cqaado3u	70	12	HIV	HIV	NNP
cord-334454-cqaado3u	70	13	-	-	HYPH
cord-334454-cqaado3u	70	14	positive	positive	JJ
cord-334454-cqaado3u	70	15	patients	patient	NNS
cord-334454-cqaado3u	70	16	[	[	-LRB-
cord-334454-cqaado3u	70	17	29	29	CD
cord-334454-cqaado3u	70	18	,	,	,
cord-334454-cqaado3u	70	19	30	30	CD
cord-334454-cqaado3u	70	20	]	]	-RRB-
cord-334454-cqaado3u	70	21	,	,	,
cord-334454-cqaado3u	70	22	even	even	RB
cord-334454-cqaado3u	70	23	after	after	IN
cord-334454-cqaado3u	70	24	immunomodulation	immunomodulation	NN
cord-334454-cqaado3u	70	25	therapy	therapy	NN
cord-334454-cqaado3u	70	26	with	with	IN
cord-334454-cqaado3u	70	27	exogenous	exogenous	JJ
cord-334454-cqaado3u	70	28	IL-2	IL-2	NNP
cord-334454-cqaado3u	70	29	[	[	-LRB-
cord-334454-cqaado3u	70	30	31	31	CD
cord-334454-cqaado3u	70	31	]	]	-RRB-
cord-334454-cqaado3u	70	32	.	.	.
cord-334454-cqaado3u	71	1	Despite	despite	IN
cord-334454-cqaado3u	71	2	the	the	DT
cord-334454-cqaado3u	71	3	similarity	similarity	NN
cord-334454-cqaado3u	71	4	between	between	IN
cord-334454-cqaado3u	71	5	HIV	HIV	NNP
cord-334454-cqaado3u	71	6	and	and	CC
cord-334454-cqaado3u	71	7	FIV	FIV	NNP
cord-334454-cqaado3u	71	8	[	[	-LRB-
cord-334454-cqaado3u	71	9	2	2	CD
cord-334454-cqaado3u	71	10	,	,	,
cord-334454-cqaado3u	71	11	32	32	CD
cord-334454-cqaado3u	71	12	]	]	-RRB-
cord-334454-cqaado3u	71	13	,	,	,
cord-334454-cqaado3u	71	14	the	the	DT
cord-334454-cqaado3u	71	15	CRP	CRP	NNP
cord-334454-cqaado3u	71	16	behavior	behavior	NN
cord-334454-cqaado3u	71	17	in	in	IN
cord-334454-cqaado3u	71	18	FIV	fiv	NN
cord-334454-cqaado3u	71	19	-	-	HYPH
cord-334454-cqaado3u	71	20	positive	positive	JJ
cord-334454-cqaado3u	71	21	cats	cat	NNS
cord-334454-cqaado3u	71	22	undergoing	undergo	VBG
cord-334454-cqaado3u	71	23	immune	immune	JJ
cord-334454-cqaado3u	71	24	-	-	HYPH
cord-334454-cqaado3u	71	25	modulation	modulation	NN
cord-334454-cqaado3u	71	26	therapy	therapy	NN
cord-334454-cqaado3u	71	27	remains	remain	VBZ
cord-334454-cqaado3u	71	28	unknown	unknown	JJ
cord-334454-cqaado3u	71	29	.	.	.
cord-334454-cqaado3u	72	1	Following	follow	VBG
cord-334454-cqaado3u	72	2	previous	previous	JJ
cord-334454-cqaado3u	72	3	conclusions	conclusion	NNS
cord-334454-cqaado3u	72	4	suggesting	suggest	VBG
cord-334454-cqaado3u	72	5	that	that	IN
cord-334454-cqaado3u	72	6	this	this	DT
cord-334454-cqaado3u	72	7	compound	compound	NN
cord-334454-cqaado3u	72	8	acts	act	VBZ
cord-334454-cqaado3u	72	9	on	on	IN
cord-334454-cqaado3u	72	10	the	the	DT
cord-334454-cqaado3u	72	11	innate	innate	JJ
cord-334454-cqaado3u	72	12	response	response	NN
cord-334454-cqaado3u	72	13	rather	rather	RB
cord-334454-cqaado3u	72	14	than	than	IN
cord-334454-cqaado3u	72	15	on	on	IN
cord-334454-cqaado3u	72	16	the	the	DT
cord-334454-cqaado3u	72	17	acquired	acquire	VBN
cord-334454-cqaado3u	72	18	immune	immune	JJ
cord-334454-cqaado3u	72	19	system	system	NN
cord-334454-cqaado3u	72	20	,	,	,
cord-334454-cqaado3u	72	21	its	-PRON-	PRP$
cord-334454-cqaado3u	72	22	effect	effect	NN
cord-334454-cqaado3u	72	23	on	on	IN
cord-334454-cqaado3u	72	24	acute	acute	JJ
cord-334454-cqaado3u	72	25	phase	phase	NN
cord-334454-cqaado3u	72	26	proteins	protein	NNS
cord-334454-cqaado3u	72	27	(	(	-LRB-
cord-334454-cqaado3u	72	28	APPs	app	NNS
cord-334454-cqaado3u	72	29	)	)	-RRB-
cord-334454-cqaado3u	72	30	was	be	VBD
cord-334454-cqaado3u	72	31	evaluated	evaluate	VBN
cord-334454-cqaado3u	72	32	[	[	-LRB-
cord-334454-cqaado3u	72	33	17	17	CD
cord-334454-cqaado3u	72	34	]	]	-RRB-
cord-334454-cqaado3u	72	35	.	.	.
cord-334454-cqaado3u	73	1	Taking	take	VBG
cord-334454-cqaado3u	73	2	into	into	IN
cord-334454-cqaado3u	73	3	account	account	NN
cord-334454-cqaado3u	73	4	that	that	IN
cord-334454-cqaado3u	73	5	APPs	app	NNS
cord-334454-cqaado3u	73	6	are	be	VBP
cord-334454-cqaado3u	73	7	one	one	CD
cord-334454-cqaado3u	73	8	of	of	IN
cord-334454-cqaado3u	73	9	the	the	DT
cord-334454-cqaado3u	73	10	key	key	JJ
cord-334454-cqaado3u	73	11	components	component	NNS
cord-334454-cqaado3u	73	12	of	of	IN
cord-334454-cqaado3u	73	13	the	the	DT
cord-334454-cqaado3u	73	14	innate	innate	JJ
cord-334454-cqaado3u	73	15	immune	immune	JJ
cord-334454-cqaado3u	73	16	system	system	NN
cord-334454-cqaado3u	73	17	,	,	,
cord-334454-cqaado3u	73	18	they	-PRON-	PRP
cord-334454-cqaado3u	73	19	seemed	seem	VBD
cord-334454-cqaado3u	73	20	reasonable	reasonable	JJ
cord-334454-cqaado3u	73	21	predictors	predictor	NNS
cord-334454-cqaado3u	73	22	of	of	IN
cord-334454-cqaado3u	73	23	an	an	DT
cord-334454-cqaado3u	73	24	innate	innate	JJ
cord-334454-cqaado3u	73	25	immune	immune	JJ
cord-334454-cqaado3u	73	26	-	-	HYPH
cord-334454-cqaado3u	73	27	stimulation	stimulation	NN
cord-334454-cqaado3u	73	28	[	[	-LRB-
cord-334454-cqaado3u	73	29	33	33	CD
cord-334454-cqaado3u	73	30	]	]	-RRB-
cord-334454-cqaado3u	73	31	.	.	.
cord-334454-cqaado3u	74	1	Authors	author	NNS
cord-334454-cqaado3u	74	2	showed	show	VBD
cord-334454-cqaado3u	74	3	that	that	IN
cord-334454-cqaado3u	74	4	APPs	app	NNS
cord-334454-cqaado3u	74	5	significantly	significantly	RB
cord-334454-cqaado3u	74	6	increased	increase	VBD
cord-334454-cqaado3u	74	7	in	in	IN
cord-334454-cqaado3u	74	8	cats	cat	NNS
cord-334454-cqaado3u	74	9	treated	treat	VBN
cord-334454-cqaado3u	74	10	with	with	IN
cord-334454-cqaado3u	74	11	the	the	DT
cord-334454-cqaado3u	74	12	licensed	license	VBN
cord-334454-cqaado3u	74	13	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	74	14	-	-	HYPH
cord-334454-cqaado3u	74	15	ω	ω	CD
cord-334454-cqaado3u	74	16	protocol	protocol	NN
cord-334454-cqaado3u	74	17	[	[	-LRB-
cord-334454-cqaado3u	74	18	28	28	CD
cord-334454-cqaado3u	74	19	]	]	-RRB-
cord-334454-cqaado3u	74	20	.	.	.
cord-334454-cqaado3u	75	1	Despite	despite	IN
cord-334454-cqaado3u	75	2	the	the	DT
cord-334454-cqaado3u	75	3	fact	fact	NN
cord-334454-cqaado3u	75	4	that	that	IN
cord-334454-cqaado3u	75	5	APPs	app	NNS
cord-334454-cqaado3u	75	6	usually	usually	RB
cord-334454-cqaado3u	75	7	increase	increase	VBP
cord-334454-cqaado3u	75	8	in	in	IN
cord-334454-cqaado3u	75	9	different	different	JJ
cord-334454-cqaado3u	75	10	situations	situation	NNS
cord-334454-cqaado3u	75	11	such	such	JJ
cord-334454-cqaado3u	75	12	as	as	IN
cord-334454-cqaado3u	75	13	chronic	chronic	JJ
cord-334454-cqaado3u	75	14	infection	infection	NN
cord-334454-cqaado3u	75	15	and	and	CC
cord-334454-cqaado3u	75	16	severe	severe	JJ
cord-334454-cqaado3u	75	17	inflammation	inflammation	NN
cord-334454-cqaado3u	75	18	[	[	-LRB-
cord-334454-cqaado3u	75	19	33	33	CD
cord-334454-cqaado3u	75	20	,	,	,
cord-334454-cqaado3u	75	21	34	34	CD
cord-334454-cqaado3u	75	22	]	]	-RRB-
cord-334454-cqaado3u	75	23	,	,	,
cord-334454-cqaado3u	75	24	in	in	IN
cord-334454-cqaado3u	75	25	this	this	DT
cord-334454-cqaado3u	75	26	study	study	NN
cord-334454-cqaado3u	75	27	,	,	,
cord-334454-cqaado3u	75	28	their	-PRON-	PRP$
cord-334454-cqaado3u	75	29	increment	increment	NN
cord-334454-cqaado3u	75	30	was	be	VBD
cord-334454-cqaado3u	75	31	concomitant	concomitant	JJ
cord-334454-cqaado3u	75	32	with	with	IN
cord-334454-cqaado3u	75	33	the	the	DT
cord-334454-cqaado3u	75	34	described	describe	VBN
cord-334454-cqaado3u	75	35	clinical	clinical	JJ
cord-334454-cqaado3u	75	36	improvement	improvement	NN
cord-334454-cqaado3u	75	37	and	and	CC
cord-334454-cqaado3u	75	38	reduction	reduction	NN
cord-334454-cqaado3u	75	39	in	in	IN
cord-334454-cqaado3u	75	40	opportunistic	opportunistic	JJ
cord-334454-cqaado3u	75	41	infections	infection	NNS
cord-334454-cqaado3u	75	42	.	.	.
cord-334454-cqaado3u	76	1	This	this	DT
cord-334454-cqaado3u	76	2	work	work	NN
cord-334454-cqaado3u	76	3	showed	show	VBD
cord-334454-cqaado3u	76	4	that	that	IN
cord-334454-cqaado3u	76	5	the	the	DT
cord-334454-cqaado3u	76	6	APP	app	NN
cord-334454-cqaado3u	76	7	increment	increment	NN
cord-334454-cqaado3u	76	8	might	may	MD
cord-334454-cqaado3u	76	9	be	be	VB
cord-334454-cqaado3u	76	10	beneficial	beneficial	JJ
cord-334454-cqaado3u	76	11	in	in	IN
cord-334454-cqaado3u	76	12	retrovirally	retrovirally	NN
cord-334454-cqaado3u	76	13	infected	infected	JJ
cord-334454-cqaado3u	76	14	cats	cat	NNS
cord-334454-cqaado3u	76	15	,	,	,
cord-334454-cqaado3u	76	16	confirming	confirm	VBG
cord-334454-cqaado3u	76	17	that	that	IN
cord-334454-cqaado3u	76	18	they	-PRON-	PRP
cord-334454-cqaado3u	76	19	can	can	MD
cord-334454-cqaado3u	76	20	be	be	VB
cord-334454-cqaado3u	76	21	a	a	DT
cord-334454-cqaado3u	76	22	reasonable	reasonable	JJ
cord-334454-cqaado3u	76	23	indicator	indicator	NN
cord-334454-cqaado3u	76	24	of	of	IN
cord-334454-cqaado3u	76	25	a	a	DT
cord-334454-cqaado3u	76	26	potentiated	potentiate	VBN
cord-334454-cqaado3u	76	27	innate	innate	JJ
cord-334454-cqaado3u	76	28	immune	immune	JJ
cord-334454-cqaado3u	76	29	response	response	NN
cord-334454-cqaado3u	76	30	.	.	.
cord-334454-cqaado3u	77	1	Being	be	VBG
cord-334454-cqaado3u	77	2	the	the	DT
cord-334454-cqaado3u	77	3	first	first	JJ
cord-334454-cqaado3u	77	4	work	work	NN
cord-334454-cqaado3u	77	5	documenting	document	VBG
cord-334454-cqaado3u	77	6	the	the	DT
cord-334454-cqaado3u	77	7	effect	effect	NN
cord-334454-cqaado3u	77	8	of	of	IN
cord-334454-cqaado3u	77	9	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	77	10	-	-	HYPH
cord-334454-cqaado3u	77	11	ω	ω	NN
cord-334454-cqaado3u	77	12	on	on	IN
cord-334454-cqaado3u	77	13	APP	app	NN
cord-334454-cqaado3u	77	14	profiles	profile	NNS
cord-334454-cqaado3u	77	15	,	,	,
cord-334454-cqaado3u	77	16	this	this	DT
cord-334454-cqaado3u	77	17	study	study	NN
cord-334454-cqaado3u	77	18	reinforces	reinforce	VBZ
cord-334454-cqaado3u	77	19	the	the	DT
cord-334454-cqaado3u	77	20	action	action	NN
cord-334454-cqaado3u	77	21	of	of	IN
cord-334454-cqaado3u	77	22	this	this	DT
cord-334454-cqaado3u	77	23	compound	compound	NN
cord-334454-cqaado3u	77	24	on	on	IN
cord-334454-cqaado3u	77	25	the	the	DT
cord-334454-cqaado3u	77	26	innate	innate	JJ
cord-334454-cqaado3u	77	27	immune	immune	JJ
cord-334454-cqaado3u	77	28	system	system	NN
cord-334454-cqaado3u	77	29	,	,	,
cord-334454-cqaado3u	77	30	helping	help	VBG
cord-334454-cqaado3u	77	31	to	to	TO
cord-334454-cqaado3u	77	32	clarify	clarify	VB
cord-334454-cqaado3u	77	33	the	the	DT
cord-334454-cqaado3u	77	34	mechanisms	mechanism	NNS
cord-334454-cqaado3u	77	35	of	of	IN
cord-334454-cqaado3u	77	36	action	action	NN
cord-334454-cqaado3u	77	37	of	of	IN
cord-334454-cqaado3u	77	38	the	the	DT
cord-334454-cqaado3u	77	39	licensed	licensed	JJ
cord-334454-cqaado3u	77	40	protocol	protocol	NN
cord-334454-cqaado3u	77	41	[	[	-LRB-
cord-334454-cqaado3u	77	42	28	28	CD
cord-334454-cqaado3u	77	43	]	]	-RRB-
cord-334454-cqaado3u	77	44	.	.	.
cord-334454-cqaado3u	78	1	In	in	IN
cord-334454-cqaado3u	78	2	order	order	NN
cord-334454-cqaado3u	78	3	to	to	TO
cord-334454-cqaado3u	78	4	explore	explore	VB
cord-334454-cqaado3u	78	5	in	in	IN
cord-334454-cqaado3u	78	6	greater	great	JJR
cord-334454-cqaado3u	78	7	detail	detail	NN
cord-334454-cqaado3u	78	8	these	these	DT
cord-334454-cqaado3u	78	9	conclusions	conclusion	NNS
cord-334454-cqaado3u	78	10	,	,	,
cord-334454-cqaado3u	78	11	the	the	DT
cord-334454-cqaado3u	78	12	evaluation	evaluation	NN
cord-334454-cqaado3u	78	13	of	of	IN
cord-334454-cqaado3u	78	14	other	other	JJ
cord-334454-cqaado3u	78	15	innate	innate	JJ
cord-334454-cqaado3u	78	16	immunity	immunity	NN
cord-334454-cqaado3u	78	17	biomarkers	biomarker	NNS
cord-334454-cqaado3u	78	18	(	(	-LRB-
cord-334454-cqaado3u	78	19	namely	namely	RB
cord-334454-cqaado3u	78	20	Mx	Mx	NNP
cord-334454-cqaado3u	78	21	protein	protein	NN
cord-334454-cqaado3u	78	22	)	)	-RRB-
cord-334454-cqaado3u	78	23	would	would	MD
cord-334454-cqaado3u	78	24	be	be	VB
cord-334454-cqaado3u	78	25	useful	useful	JJ
cord-334454-cqaado3u	78	26	.	.	.
cord-334454-cqaado3u	79	1	Although	although	IN
cord-334454-cqaado3u	79	2	its	-PRON-	PRP$
cord-334454-cqaado3u	79	3	use	use	NN
cord-334454-cqaado3u	79	4	in	in	IN
cord-334454-cqaado3u	79	5	feline	feline	JJ
cord-334454-cqaado3u	79	6	medicine	medicine	NN
cord-334454-cqaado3u	79	7	is	be	VBZ
cord-334454-cqaado3u	79	8	scarce	scarce	JJ
cord-334454-cqaado3u	79	9	,	,	,
cord-334454-cqaado3u	79	10	Mx	Mx	NNP
cord-334454-cqaado3u	79	11	protein	protein	NN
cord-334454-cqaado3u	79	12	is	be	VBZ
cord-334454-cqaado3u	79	13	a	a	DT
cord-334454-cqaado3u	79	14	specific	specific	JJ
cord-334454-cqaado3u	79	15	type	type	NN
cord-334454-cqaado3u	80	1	I	-PRON-	PRP
cord-334454-cqaado3u	80	2	IFN	IFN	NNP
cord-334454-cqaado3u	80	3	biomarker	biomarker	NN
cord-334454-cqaado3u	80	4	[	[	-LRB-
cord-334454-cqaado3u	80	5	8	8	CD
cord-334454-cqaado3u	80	6	,	,	,
cord-334454-cqaado3u	80	7	35	35	CD
cord-334454-cqaado3u	80	8	]	]	-RRB-
cord-334454-cqaado3u	80	9	;	;	:
cord-334454-cqaado3u	81	1	hence	hence	RB
cord-334454-cqaado3u	81	2	,	,	,
cord-334454-cqaado3u	81	3	its	-PRON-	PRP$
cord-334454-cqaado3u	81	4	production	production	NN
cord-334454-cqaado3u	81	5	is	be	VBZ
cord-334454-cqaado3u	81	6	directly	directly	RB
cord-334454-cqaado3u	81	7	related	relate	VBN
cord-334454-cqaado3u	81	8	with	with	IN
cord-334454-cqaado3u	81	9	the	the	DT
cord-334454-cqaado3u	81	10	activation	activation	NN
cord-334454-cqaado3u	81	11	of	of	IN
cord-334454-cqaado3u	81	12	a	a	DT
cord-334454-cqaado3u	81	13	type	type	NN
cord-334454-cqaado3u	81	14	I	-PRON-	PRP
cord-334454-cqaado3u	81	15	IFN	IFN	NNP
cord-334454-cqaado3u	81	16	signal	signal	NN
cord-334454-cqaado3u	81	17	transduction	transduction	NN
cord-334454-cqaado3u	81	18	pathway	pathway	NN
cord-334454-cqaado3u	81	19	.	.	.
cord-334454-cqaado3u	82	1	In	in	IN
cord-334454-cqaado3u	82	2	this	this	DT
cord-334454-cqaado3u	82	3	sense	sense	NN
cord-334454-cqaado3u	82	4	,	,	,
cord-334454-cqaado3u	82	5	from	from	IN
cord-334454-cqaado3u	82	6	the	the	DT
cord-334454-cqaado3u	82	7	authors	author	NNS
cord-334454-cqaado3u	82	8	'	'	POS
cord-334454-cqaado3u	82	9	point	point	NN
cord-334454-cqaado3u	82	10	of	of	IN
cord-334454-cqaado3u	82	11	view	view	NN
cord-334454-cqaado3u	82	12	,	,	,
cord-334454-cqaado3u	82	13	further	further	JJ
cord-334454-cqaado3u	82	14	studies	study	NNS
cord-334454-cqaado3u	82	15	are	be	VBP
cord-334454-cqaado3u	82	16	needed	need	VBN
cord-334454-cqaado3u	82	17	to	to	TO
cord-334454-cqaado3u	82	18	strengthen	strengthen	VB
cord-334454-cqaado3u	82	19	these	these	DT
cord-334454-cqaado3u	82	20	conclusions	conclusion	NNS
cord-334454-cqaado3u	82	21	and	and	CC
cord-334454-cqaado3u	82	22	to	to	TO
cord-334454-cqaado3u	82	23	assess	assess	VB
cord-334454-cqaado3u	82	24	whether	whether	IN
cord-334454-cqaado3u	82	25	Mx	Mx	NNP
cord-334454-cqaado3u	82	26	protein	protein	NN
cord-334454-cqaado3u	82	27	can	can	MD
cord-334454-cqaado3u	82	28	be	be	VB
cord-334454-cqaado3u	82	29	a	a	DT
cord-334454-cqaado3u	82	30	reasonable	reasonable	JJ
cord-334454-cqaado3u	82	31	biomarker	biomarker	NN
cord-334454-cqaado3u	82	32	of	of	IN
cord-334454-cqaado3u	82	33	innate	innate	JJ
cord-334454-cqaado3u	82	34	immunity	immunity	NN
cord-334454-cqaado3u	82	35	in	in	IN
cord-334454-cqaado3u	82	36	cats	cat	NNS
cord-334454-cqaado3u	82	37	under	under	IN
cord-334454-cqaado3u	82	38	rFeIFN	rFeIFN	NNP
cord-334454-cqaado3u	82	39	-	-	HYPH
cord-334454-cqaado3u	82	40	ω	ω	VBG
cord-334454-cqaado3u	82	41	therapy	therapy	NN
cord-334454-cqaado3u	82	42	.	.	.
cord-334454-cqaado3u	83	1	Recognizing	recognize	VBG
cord-334454-cqaado3u	83	2	that	that	IN
cord-334454-cqaado3u	83	3	,	,	,
cord-334454-cqaado3u	83	4	in	in	IN
cord-334454-cqaado3u	83	5	clinical	clinical	JJ
cord-334454-cqaado3u	83	6	practice	practice	NN
cord-334454-cqaado3u	83	7	,	,	,
cord-334454-cqaado3u	83	8	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	83	9	-	-	HYPH
cord-334454-cqaado3u	83	10	ω	ω	NN
cord-334454-cqaado3u	83	11	is	be	VBZ
cord-334454-cqaado3u	83	12	very	very	RB
cord-334454-cqaado3u	83	13	often	often	RB
cord-334454-cqaado3u	83	14	a	a	DT
cord-334454-cqaado3u	83	15	cost	cost	NN
cord-334454-cqaado3u	83	16	-	-	HYPH
cord-334454-cqaado3u	83	17	limiting	limit	VBG
cord-334454-cqaado3u	83	18	therapy	therapy	NN
cord-334454-cqaado3u	83	19	,	,	,
cord-334454-cqaado3u	83	20	the	the	DT
cord-334454-cqaado3u	83	21	use	use	NN
cord-334454-cqaado3u	83	22	of	of	IN
cord-334454-cqaado3u	83	23	an	an	DT
cord-334454-cqaado3u	83	24	alternative	alternative	JJ
cord-334454-cqaado3u	83	25	oral	oral	JJ
cord-334454-cqaado3u	83	26	protocol	protocol	NN
cord-334454-cqaado3u	83	27	in	in	IN
cord-334454-cqaado3u	83	28	FIV	FIV	NNP
cord-334454-cqaado3u	83	29	-	-	HYPH
cord-334454-cqaado3u	83	30	infected	infect	VBN
cord-334454-cqaado3u	83	31	cats	cat	NNS
cord-334454-cqaado3u	83	32	has	have	VBZ
cord-334454-cqaado3u	83	33	also	also	RB
cord-334454-cqaado3u	83	34	been	be	VBN
cord-334454-cqaado3u	83	35	documented	document	VBN
cord-334454-cqaado3u	83	36	[	[	-LRB-
cord-334454-cqaado3u	83	37	25	25	CD
cord-334454-cqaado3u	83	38	]	]	-RRB-
cord-334454-cqaado3u	83	39	.	.	.
cord-334454-cqaado3u	84	1	In	in	IN
cord-334454-cqaado3u	84	2	fact	fact	NN
cord-334454-cqaado3u	84	3	,	,	,
cord-334454-cqaado3u	84	4	different	different	JJ
cord-334454-cqaado3u	84	5	authors	author	NNS
cord-334454-cqaado3u	84	6	reported	report	VBD
cord-334454-cqaado3u	84	7	the	the	DT
cord-334454-cqaado3u	84	8	clinical	clinical	JJ
cord-334454-cqaado3u	84	9	benefits	benefit	NNS
cord-334454-cqaado3u	84	10	of	of	IN
cord-334454-cqaado3u	84	11	oral	oral	JJ
cord-334454-cqaado3u	84	12	low	low	JJ
cord-334454-cqaado3u	84	13	dose	dose	NN
cord-334454-cqaado3u	84	14	HuIFN	HuIFN	NNP
cord-334454-cqaado3u	84	15	-	-	HYPH
cord-334454-cqaado3u	84	16	α	α	NN
cord-334454-cqaado3u	84	17	protocols	protocol	NNS
cord-334454-cqaado3u	84	18	in	in	IN
cord-334454-cqaado3u	84	19	viral	viral	JJ
cord-334454-cqaado3u	84	20	infections	infection	NNS
cord-334454-cqaado3u	84	21	such	such	JJ
cord-334454-cqaado3u	84	22	as	as	IN
cord-334454-cqaado3u	84	23	FIV	FIV	NNP
cord-334454-cqaado3u	84	24	[	[	-LRB-
cord-334454-cqaado3u	84	25	19	19	CD
cord-334454-cqaado3u	84	26	,	,	,
cord-334454-cqaado3u	84	27	21	21	CD
cord-334454-cqaado3u	84	28	]	]	-RRB-
cord-334454-cqaado3u	84	29	.	.	.
cord-334454-cqaado3u	85	1	After	after	IN
cord-334454-cqaado3u	85	2	the	the	DT
cord-334454-cqaado3u	85	3	release	release	NN
cord-334454-cqaado3u	85	4	of	of	IN
cord-334454-cqaado3u	85	5	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	85	6	-	-	HYPH
cord-334454-cqaado3u	85	7	ω	ω	JJS
cord-334454-cqaado3u	85	8	,	,	,
cord-334454-cqaado3u	85	9	several	several	JJ
cord-334454-cqaado3u	85	10	clinical	clinical	JJ
cord-334454-cqaado3u	85	11	trials	trial	NNS
cord-334454-cqaado3u	85	12	had	have	VBD
cord-334454-cqaado3u	85	13	also	also	RB
cord-334454-cqaado3u	85	14	been	be	VBN
cord-334454-cqaado3u	85	15	conducted	conduct	VBN
cord-334454-cqaado3u	85	16	in	in	IN
cord-334454-cqaado3u	85	17	specific	specific	JJ
cord-334454-cqaado3u	85	18	-	-	HYPH
cord-334454-cqaado3u	85	19	pathogen	pathogen	NN
cord-334454-cqaado3u	85	20	free	free	JJ
cord-334454-cqaado3u	85	21	cats	cat	NNS
cord-334454-cqaado3u	85	22	and	and	CC
cord-334454-cqaado3u	85	23	calicivirus	calicivirus	JJ
cord-334454-cqaado3u	85	24	-	-	HYPH
cord-334454-cqaado3u	85	25	positive	positive	JJ
cord-334454-cqaado3u	85	26	cats	cat	NNS
cord-334454-cqaado3u	85	27	in	in	IN
cord-334454-cqaado3u	85	28	order	order	NN
cord-334454-cqaado3u	85	29	to	to	TO
cord-334454-cqaado3u	85	30	study	study	VB
cord-334454-cqaado3u	85	31	the	the	DT
cord-334454-cqaado3u	85	32	immune	immune	JJ
cord-334454-cqaado3u	85	33	-	-	HYPH
cord-334454-cqaado3u	85	34	modulation	modulation	NN
cord-334454-cqaado3u	85	35	properties	property	NNS
cord-334454-cqaado3u	85	36	of	of	IN
cord-334454-cqaado3u	85	37	oral	oral	JJ
cord-334454-cqaado3u	85	38	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	85	39	-	-	HYPH
cord-334454-cqaado3u	85	40	ω	ω	VBG
cord-334454-cqaado3u	85	41	[	[	-LRB-
cord-334454-cqaado3u	85	42	8	8	CD
cord-334454-cqaado3u	85	43	,	,	,
cord-334454-cqaado3u	85	44	36	36	CD
cord-334454-cqaado3u	85	45	]	]	-RRB-
cord-334454-cqaado3u	85	46	.	.	.
cord-334454-cqaado3u	86	1	However	however	RB
cord-334454-cqaado3u	86	2	,	,	,
cord-334454-cqaado3u	86	3	no	no	DT
cord-334454-cqaado3u	86	4	studies	study	NNS
cord-334454-cqaado3u	86	5	have	have	VBP
cord-334454-cqaado3u	86	6	documented	document	VBN
cord-334454-cqaado3u	86	7	its	-PRON-	PRP$
cord-334454-cqaado3u	86	8	use	use	NN
cord-334454-cqaado3u	86	9	in	in	IN
cord-334454-cqaado3u	86	10	retrovirally	retrovirally	NN
cord-334454-cqaado3u	86	11	infected	infected	JJ
cord-334454-cqaado3u	86	12	cats	cat	NNS
cord-334454-cqaado3u	86	13	,	,	,
cord-334454-cqaado3u	86	14	particularly	particularly	RB
cord-334454-cqaado3u	86	15	in	in	IN
cord-334454-cqaado3u	86	16	FIV	fiv	NN
cord-334454-cqaado3u	86	17	-	-	HYPH
cord-334454-cqaado3u	86	18	infected	infect	VBN
cord-334454-cqaado3u	86	19	ones	one	NNS
cord-334454-cqaado3u	86	20	.	.	.
cord-334454-cqaado3u	87	1	In	in	IN
cord-334454-cqaado3u	87	2	this	this	DT
cord-334454-cqaado3u	87	3	sense	sense	NN
cord-334454-cqaado3u	87	4	,	,	,
cord-334454-cqaado3u	87	5	an	an	DT
cord-334454-cqaado3u	87	6	oral	oral	JJ
cord-334454-cqaado3u	87	7	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	87	8	-	-	HYPH
cord-334454-cqaado3u	87	9	ω	ω	CD
cord-334454-cqaado3u	87	10	protocol	protocol	NN
cord-334454-cqaado3u	87	11	was	be	VBD
cord-334454-cqaado3u	87	12	developed	develop	VBN
cord-334454-cqaado3u	87	13	and	and	CC
cord-334454-cqaado3u	87	14	administered	administer	VBN
cord-334454-cqaado3u	87	15	to	to	IN
cord-334454-cqaado3u	87	16	11	11	CD
cord-334454-cqaado3u	87	17	client	client	NN
cord-334454-cqaado3u	87	18	-	-	HYPH
cord-334454-cqaado3u	87	19	owned	own	VBN
cord-334454-cqaado3u	87	20	FIV	FIV	NNP
cord-334454-cqaado3u	87	21	-	-	HYPH
cord-334454-cqaado3u	87	22	infected	infect	VBN
cord-334454-cqaado3u	87	23	cats	cat	NNS
cord-334454-cqaado3u	87	24	[	[	-LRB-
cord-334454-cqaado3u	87	25	25	25	CD
cord-334454-cqaado3u	87	26	]	]	-RRB-
cord-334454-cqaado3u	87	27	.	.	.
cord-334454-cqaado3u	88	1	The	the	DT
cord-334454-cqaado3u	88	2	oral	oral	JJ
cord-334454-cqaado3u	88	3	dose	dose	NN
cord-334454-cqaado3u	88	4	was	be	VBD
cord-334454-cqaado3u	88	5	based	base	VBN
cord-334454-cqaado3u	88	6	on	on	IN
cord-334454-cqaado3u	88	7	the	the	DT
cord-334454-cqaado3u	88	8	referred	refer	VBN
cord-334454-cqaado3u	88	9	previous	previous	JJ
cord-334454-cqaado3u	88	10	studies	study	NNS
cord-334454-cqaado3u	88	11	and	and	CC
cord-334454-cqaado3u	88	12	was	be	VBD
cord-334454-cqaado3u	88	13	decided	decide	VBN
cord-334454-cqaado3u	88	14	according	accord	VBG
cord-334454-cqaado3u	88	15	to	to	IN
cord-334454-cqaado3u	88	16	the	the	DT
cord-334454-cqaado3u	88	17	manufacturer	manufacturer	NN
cord-334454-cqaado3u	88	18	's	's	POS
cord-334454-cqaado3u	88	19	previous	previous	JJ
cord-334454-cqaado3u	88	20	trials	trial	NNS
cord-334454-cqaado3u	88	21	[	[	-LRB-
cord-334454-cqaado3u	88	22	8	8	CD
cord-334454-cqaado3u	88	23	,	,	,
cord-334454-cqaado3u	88	24	36	36	CD
cord-334454-cqaado3u	88	25	]	]	-RRB-
cord-334454-cqaado3u	88	26	.	.	.
cord-334454-cqaado3u	89	1	The	the	DT
cord-334454-cqaado3u	89	2	oral	oral	JJ
cord-334454-cqaado3u	89	3	protocol	protocol	NN
cord-334454-cqaado3u	89	4	was	be	VBD
cord-334454-cqaado3u	89	5	10-fold	10-fold	JJ
cord-334454-cqaado3u	89	6	lower	low	JJR
cord-334454-cqaado3u	89	7	that	that	IN
cord-334454-cqaado3u	89	8	the	the	DT
cord-334454-cqaado3u	89	9	licensed	licensed	JJ
cord-334454-cqaado3u	89	10	subcutaneous	subcutaneous	JJ
cord-334454-cqaado3u	89	11	protocol	protocol	NN
cord-334454-cqaado3u	89	12	,	,	,
cord-334454-cqaado3u	89	13	and	and	CC
cord-334454-cqaado3u	89	14	it	-PRON-	PRP
cord-334454-cqaado3u	89	15	was	be	VBD
cord-334454-cqaado3u	89	16	given	give	VBN
cord-334454-cqaado3u	89	17	orally	orally	RB
cord-334454-cqaado3u	89	18	instead	instead	RB
cord-334454-cqaado3u	89	19	of	of	IN
cord-334454-cqaado3u	89	20	subcutaneously	subcutaneously	RB
cord-334454-cqaado3u	89	21	and	and	CC
cord-334454-cqaado3u	89	22	for	for	IN
cord-334454-cqaado3u	89	23	a	a	DT
cord-334454-cqaado3u	89	24	longer	long	JJR
cord-334454-cqaado3u	89	25	period	period	NN
cord-334454-cqaado3u	89	26	of	of	IN
cord-334454-cqaado3u	89	27	time	time	NN
cord-334454-cqaado3u	89	28	(	(	-LRB-
cord-334454-cqaado3u	89	29	90	90	CD
cord-334454-cqaado3u	89	30	continuous	continuous	JJ
cord-334454-cqaado3u	89	31	days	day	NNS
cord-334454-cqaado3u	89	32	)	)	-RRB-
cord-334454-cqaado3u	89	33	.	.	.
cord-334454-cqaado3u	90	1	Following	follow	VBG
cord-334454-cqaado3u	90	2	the	the	DT
cord-334454-cqaado3u	90	3	same	same	JJ
cord-334454-cqaado3u	90	4	methodology	methodology	NN
cord-334454-cqaado3u	90	5	of	of	IN
cord-334454-cqaado3u	90	6	previous	previous	JJ
cord-334454-cqaado3u	90	7	studies	study	NNS
cord-334454-cqaado3u	90	8	,	,	,
cord-334454-cqaado3u	90	9	the	the	DT
cord-334454-cqaado3u	90	10	clinical	clinical	JJ
cord-334454-cqaado3u	90	11	improvement	improvement	NN
cord-334454-cqaado3u	90	12	,	,	,
cord-334454-cqaado3u	90	13	concurrent	concurrent	JJ
cord-334454-cqaado3u	90	14	viral	viral	JJ
cord-334454-cqaado3u	90	15	excretion	excretion	NN
cord-334454-cqaado3u	90	16	,	,	,
cord-334454-cqaado3u	90	17	APP	app	NN
cord-334454-cqaado3u	90	18	profiles	profile	NNS
cord-334454-cqaado3u	90	19	,	,	,
cord-334454-cqaado3u	90	20	and	and	CC
cord-334454-cqaado3u	90	21	different	different	JJ
cord-334454-cqaado3u	90	22	hematology	hematology	NN
cord-334454-cqaado3u	90	23	and	and	CC
cord-334454-cqaado3u	90	24	biochemistry	biochemistry	NN
cord-334454-cqaado3u	90	25	parameters	parameter	NNS
cord-334454-cqaado3u	90	26	in	in	IN
cord-334454-cqaado3u	90	27	FIV	fiv	NN
cord-334454-cqaado3u	90	28	-	-	HYPH
cord-334454-cqaado3u	90	29	infected	infect	VBN
cord-334454-cqaado3u	90	30	cats	cat	NNS
cord-334454-cqaado3u	90	31	treated	treat	VBN
cord-334454-cqaado3u	90	32	with	with	IN
cord-334454-cqaado3u	90	33	the	the	DT
cord-334454-cqaado3u	90	34	oral	oral	JJ
cord-334454-cqaado3u	90	35	protocol	protocol	NN
cord-334454-cqaado3u	90	36	were	be	VBD
cord-334454-cqaado3u	90	37	assessed	assess	VBN
cord-334454-cqaado3u	90	38	.	.	.
cord-334454-cqaado3u	91	1	Similarly	similarly	RB
cord-334454-cqaado3u	91	2	to	to	IN
cord-334454-cqaado3u	91	3	what	what	WP
cord-334454-cqaado3u	91	4	was	be	VBD
cord-334454-cqaado3u	91	5	observed	observe	VBN
cord-334454-cqaado3u	91	6	for	for	IN
cord-334454-cqaado3u	91	7	the	the	DT
cord-334454-cqaado3u	91	8	licensed	licensed	JJ
cord-334454-cqaado3u	91	9	protocol	protocol	NN
cord-334454-cqaado3u	91	10	,	,	,
cord-334454-cqaado3u	91	11	cats	cat	NNS
cord-334454-cqaado3u	91	12	treated	treat	VBN
cord-334454-cqaado3u	91	13	with	with	IN
cord-334454-cqaado3u	91	14	oral	oral	JJ
cord-334454-cqaado3u	91	15	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	91	16	-	-	HYPH
cord-334454-cqaado3u	91	17	ω	ω	JJ
cord-334454-cqaado3u	92	1	showed	show	VBD
cord-334454-cqaado3u	92	2	a	a	DT
cord-334454-cqaado3u	92	3	significant	significant	JJ
cord-334454-cqaado3u	92	4	clinical	clinical	JJ
cord-334454-cqaado3u	92	5	improvement	improvement	NN
cord-334454-cqaado3u	92	6	without	without	IN
cord-334454-cqaado3u	92	7	remarkable	remarkable	JJ
cord-334454-cqaado3u	92	8	changes	change	NNS
cord-334454-cqaado3u	92	9	in	in	IN
cord-334454-cqaado3u	92	10	hematology	hematology	NN
cord-334454-cqaado3u	92	11	and	and	CC
cord-334454-cqaado3u	92	12	biochemistry	biochemistry	NN
cord-334454-cqaado3u	92	13	profiles	profile	NNS
cord-334454-cqaado3u	92	14	,	,	,
cord-334454-cqaado3u	92	15	which	which	WDT
cord-334454-cqaado3u	92	16	were	be	VBD
cord-334454-cqaado3u	92	17	within	within	IN
cord-334454-cqaado3u	92	18	the	the	DT
cord-334454-cqaado3u	92	19	reference	reference	NN
cord-334454-cqaado3u	92	20	range	range	NN
cord-334454-cqaado3u	92	21	in	in	IN
cord-334454-cqaado3u	92	22	the	the	DT
cord-334454-cqaado3u	92	23	majority	majority	NN
cord-334454-cqaado3u	92	24	of	of	IN
cord-334454-cqaado3u	92	25	the	the	DT
cord-334454-cqaado3u	92	26	treated	treat	VBN
cord-334454-cqaado3u	92	27	cats	cat	NNS
cord-334454-cqaado3u	92	28	[	[	-LRB-
cord-334454-cqaado3u	92	29	25	25	CD
cord-334454-cqaado3u	92	30	]	]	-RRB-
cord-334454-cqaado3u	92	31	.	.	.
cord-334454-cqaado3u	93	1	Conversely	conversely	RB
cord-334454-cqaado3u	93	2	,	,	,
cord-334454-cqaado3u	93	3	mainly	mainly	RB
cord-334454-cqaado3u	93	4	due	due	IN
cord-334454-cqaado3u	93	5	to	to	IN
cord-334454-cqaado3u	93	6	the	the	DT
cord-334454-cqaado3u	93	7	fact	fact	NN
cord-334454-cqaado3u	93	8	that	that	IN
cord-334454-cqaado3u	93	9	client	client	NN
cord-334454-cqaado3u	93	10	-	-	HYPH
cord-334454-cqaado3u	93	11	owned	own	VBN
cord-334454-cqaado3u	93	12	cats	cat	NNS
cord-334454-cqaado3u	93	13	were	be	VBD
cord-334454-cqaado3u	93	14	less	less	RBR
cord-334454-cqaado3u	93	15	prone	prone	JJ
cord-334454-cqaado3u	93	16	to	to	IN
cord-334454-cqaado3u	93	17	opportunistic	opportunistic	JJ
cord-334454-cqaado3u	93	18	infections	infection	NNS
cord-334454-cqaado3u	93	19	,	,	,
cord-334454-cqaado3u	93	20	concurrent	concurrent	JJ
cord-334454-cqaado3u	93	21	viral	viral	JJ
cord-334454-cqaado3u	93	22	excretion	excretion	NN
cord-334454-cqaado3u	93	23	was	be	VBD
cord-334454-cqaado3u	93	24	very	very	RB
cord-334454-cqaado3u	93	25	low	low	JJ
cord-334454-cqaado3u	93	26	and	and	CC
cord-334454-cqaado3u	93	27	did	do	VBD
cord-334454-cqaado3u	93	28	not	not	RB
cord-334454-cqaado3u	93	29	change	change	VB
cord-334454-cqaado3u	93	30	with	with	IN
cord-334454-cqaado3u	93	31	the	the	DT
cord-334454-cqaado3u	93	32	applied	apply	VBN
cord-334454-cqaado3u	93	33	protocol	protocol	NN
cord-334454-cqaado3u	93	34	.	.	.
cord-334454-cqaado3u	94	1	Additionally	additionally	RB
cord-334454-cqaado3u	94	2	,	,	,
cord-334454-cqaado3u	94	3	APP	app	NN
cord-334454-cqaado3u	94	4	profiles	profile	NNS
cord-334454-cqaado3u	94	5	did	do	VBD
cord-334454-cqaado3u	94	6	not	not	RB
cord-334454-cqaado3u	94	7	change	change	VB
cord-334454-cqaado3u	94	8	in	in	IN
cord-334454-cqaado3u	94	9	cats	cat	NNS
cord-334454-cqaado3u	94	10	treated	treat	VBN
cord-334454-cqaado3u	94	11	with	with	IN
cord-334454-cqaado3u	94	12	oral	oral	JJ
cord-334454-cqaado3u	94	13	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	94	14	-	-	HYPH
cord-334454-cqaado3u	94	15	ω	ω	JJS
cord-334454-cqaado3u	94	16	,	,	,
cord-334454-cqaado3u	94	17	meaning	mean	VBG
cord-334454-cqaado3u	94	18	that	that	IN
cord-334454-cqaado3u	94	19	the	the	DT
cord-334454-cqaado3u	94	20	two	two	CD
cord-334454-cqaado3u	94	21	distinct	distinct	JJ
cord-334454-cqaado3u	94	22	protocols	protocol	NNS
cord-334454-cqaado3u	94	23	seem	seem	VBP
cord-334454-cqaado3u	94	24	to	to	TO
cord-334454-cqaado3u	94	25	act	act	VB
cord-334454-cqaado3u	94	26	differently	differently	RB
cord-334454-cqaado3u	94	27	.	.	.
cord-334454-cqaado3u	95	1	Taking	take	VBG
cord-334454-cqaado3u	95	2	APPs	app	NNS
cord-334454-cqaado3u	95	3	as	as	IN
cord-334454-cqaado3u	95	4	biomarkers	biomarker	NNS
cord-334454-cqaado3u	95	5	of	of	IN
cord-334454-cqaado3u	95	6	the	the	DT
cord-334454-cqaado3u	95	7	innate	innate	JJ
cord-334454-cqaado3u	95	8	immune	immune	JJ
cord-334454-cqaado3u	95	9	response	response	NN
cord-334454-cqaado3u	95	10	,	,	,
cord-334454-cqaado3u	95	11	it	-PRON-	PRP
cord-334454-cqaado3u	95	12	seems	seem	VBZ
cord-334454-cqaado3u	95	13	reasonable	reasonable	JJ
cord-334454-cqaado3u	95	14	to	to	TO
cord-334454-cqaado3u	95	15	say	say	VB
cord-334454-cqaado3u	95	16	that	that	IN
cord-334454-cqaado3u	95	17	innate	innate	JJ
cord-334454-cqaado3u	95	18	immune	immune	JJ
cord-334454-cqaado3u	95	19	reaction	reaction	NN
cord-334454-cqaado3u	95	20	does	do	VBZ
cord-334454-cqaado3u	95	21	not	not	RB
cord-334454-cqaado3u	95	22	seem	seem	VB
cord-334454-cqaado3u	95	23	to	to	TO
cord-334454-cqaado3u	95	24	be	be	VB
cord-334454-cqaado3u	95	25	potentiated	potentiate	VBN
cord-334454-cqaado3u	95	26	in	in	IN
cord-334454-cqaado3u	95	27	the	the	DT
cord-334454-cqaado3u	95	28	same	same	JJ
cord-334454-cqaado3u	95	29	way	way	NN
cord-334454-cqaado3u	95	30	as	as	IN
cord-334454-cqaado3u	95	31	observed	observe	VBN
cord-334454-cqaado3u	95	32	in	in	IN
cord-334454-cqaado3u	95	33	the	the	DT
cord-334454-cqaado3u	95	34	licensed	licensed	JJ
cord-334454-cqaado3u	95	35	protocol	protocol	NN
cord-334454-cqaado3u	95	36	.	.	.
cord-334454-cqaado3u	96	1	However	however	RB
cord-334454-cqaado3u	96	2	,	,	,
cord-334454-cqaado3u	96	3	as	as	IN
cord-334454-cqaado3u	96	4	interferons	interferon	NNS
cord-334454-cqaado3u	96	5	have	have	VBP
cord-334454-cqaado3u	96	6	pleotropic	pleotropic	JJ
cord-334454-cqaado3u	96	7	effects	effect	NNS
cord-334454-cqaado3u	96	8	and	and	CC
cord-334454-cqaado3u	96	9	APPs	app	NNS
cord-334454-cqaado3u	96	10	are	be	VBP
cord-334454-cqaado3u	96	11	only	only	RB
cord-334454-cqaado3u	96	12	a	a	DT
cord-334454-cqaado3u	96	13	part	part	NN
cord-334454-cqaado3u	96	14	of	of	IN
cord-334454-cqaado3u	96	15	the	the	DT
cord-334454-cqaado3u	96	16	innate	innate	JJ
cord-334454-cqaado3u	96	17	immune	immune	JJ
cord-334454-cqaado3u	96	18	response	response	NN
cord-334454-cqaado3u	96	19	,	,	,
cord-334454-cqaado3u	96	20	it	-PRON-	PRP
cord-334454-cqaado3u	96	21	is	be	VBZ
cord-334454-cqaado3u	96	22	overspeculative	overspeculative	VBN
cord-334454-cqaado3u	96	23	to	to	TO
cord-334454-cqaado3u	96	24	assume	assume	VB
cord-334454-cqaado3u	96	25	that	that	IN
cord-334454-cqaado3u	96	26	oral	oral	JJ
cord-334454-cqaado3u	96	27	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	96	28	-	-	HYPH
cord-334454-cqaado3u	96	29	ω	ω	NN
cord-334454-cqaado3u	96	30	does	do	VBZ
cord-334454-cqaado3u	96	31	not	not	RB
cord-334454-cqaado3u	96	32	interfere	interfere	VB
cord-334454-cqaado3u	96	33	with	with	IN
cord-334454-cqaado3u	96	34	innate	innate	JJ
cord-334454-cqaado3u	96	35	immunity	immunity	NN
cord-334454-cqaado3u	96	36	.	.	.
cord-334454-cqaado3u	97	1	Even	even	RB
cord-334454-cqaado3u	97	2	if	if	IN
cord-334454-cqaado3u	97	3	APPs	app	NNS
cord-334454-cqaado3u	97	4	did	do	VBD
cord-334454-cqaado3u	97	5	not	not	RB
cord-334454-cqaado3u	97	6	change	change	VB
cord-334454-cqaado3u	97	7	,	,	,
cord-334454-cqaado3u	97	8	overall	overall	JJ
cord-334454-cqaado3u	97	9	results	result	NNS
cord-334454-cqaado3u	97	10	showed	show	VBD
cord-334454-cqaado3u	97	11	an	an	DT
cord-334454-cqaado3u	97	12	important	important	JJ
cord-334454-cqaado3u	97	13	clinical	clinical	JJ
cord-334454-cqaado3u	97	14	improvement	improvement	NN
cord-334454-cqaado3u	97	15	and	and	CC
cord-334454-cqaado3u	97	16	reinforced	reinforce	VBD
cord-334454-cqaado3u	97	17	the	the	DT
cord-334454-cqaado3u	97	18	potential	potential	JJ
cord-334454-cqaado3u	97	19	extra	extra	JJ
cord-334454-cqaado3u	97	20	-	-	JJ
cord-334454-cqaado3u	97	21	label	label	JJ
cord-334454-cqaado3u	97	22	use	use	NN
cord-334454-cqaado3u	97	23	of	of	IN
cord-334454-cqaado3u	97	24	rFeIFN	rFeIFN	NNP
cord-334454-cqaado3u	97	25	-	-	HYPH
cord-334454-cqaado3u	97	26	ω	ω	JJ
cord-334454-cqaado3u	97	27	in	in	IN
cord-334454-cqaado3u	97	28	an	an	DT
cord-334454-cqaado3u	97	29	oral	oral	JJ
cord-334454-cqaado3u	97	30	continuous	continuous	JJ
cord-334454-cqaado3u	97	31	low	low	JJ
cord-334454-cqaado3u	97	32	-	-	HYPH
cord-334454-cqaado3u	97	33	dose	dose	NN
cord-334454-cqaado3u	97	34	protocol	protocol	NN
cord-334454-cqaado3u	97	35	.	.	.
cord-334454-cqaado3u	98	1	For	for	IN
cord-334454-cqaado3u	98	2	a	a	DT
cord-334454-cqaado3u	98	3	second	second	JJ
cord-334454-cqaado3u	98	4	time	time	NN
cord-334454-cqaado3u	98	5	,	,	,
cord-334454-cqaado3u	98	6	the	the	DT
cord-334454-cqaado3u	98	7	effect	effect	NN
cord-334454-cqaado3u	98	8	of	of	IN
cord-334454-cqaado3u	98	9	both	both	DT
cord-334454-cqaado3u	98	10	protocols	protocol	NNS
cord-334454-cqaado3u	98	11	of	of	IN
cord-334454-cqaado3u	98	12	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	98	13	-	-	HYPH
cord-334454-cqaado3u	98	14	ω	ω	JJ
cord-334454-cqaado3u	98	15	on	on	IN
cord-334454-cqaado3u	98	16	cytokine	cytokine	NN
cord-334454-cqaado3u	98	17	profile	profile	NN
cord-334454-cqaado3u	98	18	,	,	,
cord-334454-cqaado3u	98	19	viremia	viremia	NN
cord-334454-cqaado3u	98	20	,	,	,
cord-334454-cqaado3u	98	21	and	and	CC
cord-334454-cqaado3u	98	22	proviral	proviral	NNP
cord-334454-cqaado3u	98	23	load	load	NNP
cord-334454-cqaado3u	98	24	was	be	VBD
cord-334454-cqaado3u	98	25	evaluated	evaluate	VBN
cord-334454-cqaado3u	98	26	[	[	-LRB-
cord-334454-cqaado3u	98	27	27	27	CD
cord-334454-cqaado3u	98	28	]	]	-RRB-
cord-334454-cqaado3u	98	29	.	.	.
cord-334454-cqaado3u	99	1	Only	only	RB
cord-334454-cqaado3u	99	2	one	one	CD
cord-334454-cqaado3u	99	3	study	study	NN
cord-334454-cqaado3u	99	4	had	have	VBD
cord-334454-cqaado3u	99	5	previously	previously	RB
cord-334454-cqaado3u	99	6	reported	report	VBN
cord-334454-cqaado3u	99	7	that	that	IN
cord-334454-cqaado3u	99	8	the	the	DT
cord-334454-cqaado3u	99	9	licensed	licensed	JJ
cord-334454-cqaado3u	99	10	protocol	protocol	NN
cord-334454-cqaado3u	99	11	does	do	VBZ
cord-334454-cqaado3u	99	12	not	not	RB
cord-334454-cqaado3u	99	13	change	change	VB
cord-334454-cqaado3u	99	14	viremia	viremia	NN
cord-334454-cqaado3u	99	15	or	or	CC
cord-334454-cqaado3u	99	16	proviral	proviral	JJ
cord-334454-cqaado3u	99	17	load	load	NN
cord-334454-cqaado3u	99	18	in	in	IN
cord-334454-cqaado3u	99	19	treated	treat	VBN
cord-334454-cqaado3u	99	20	FIV	fiv	NN
cord-334454-cqaado3u	99	21	-	-	HYPH
cord-334454-cqaado3u	99	22	infected	infect	VBN
cord-334454-cqaado3u	99	23	cats	cat	NNS
cord-334454-cqaado3u	99	24	,	,	,
cord-334454-cqaado3u	99	25	suggesting	suggest	VBG
cord-334454-cqaado3u	99	26	that	that	IN
cord-334454-cqaado3u	99	27	this	this	DT
cord-334454-cqaado3u	99	28	compound	compound	NN
cord-334454-cqaado3u	99	29	may	may	MD
cord-334454-cqaado3u	99	30	not	not	RB
cord-334454-cqaado3u	99	31	act	act	VB
cord-334454-cqaado3u	99	32	on	on	IN
cord-334454-cqaado3u	99	33	acquired	acquire	VBN
cord-334454-cqaado3u	99	34	immunity	immunity	NN
cord-334454-cqaado3u	99	35	[	[	-LRB-
cord-334454-cqaado3u	99	36	17	17	CD
cord-334454-cqaado3u	99	37	]	]	-RRB-
cord-334454-cqaado3u	99	38	.	.	.
cord-334454-cqaado3u	100	1	In	in	IN
cord-334454-cqaado3u	100	2	agreement	agreement	NN
cord-334454-cqaado3u	100	3	with	with	IN
cord-334454-cqaado3u	100	4	these	these	DT
cord-334454-cqaado3u	100	5	results	result	NNS
cord-334454-cqaado3u	100	6	,	,	,
cord-334454-cqaado3u	100	7	authors	author	NNS
cord-334454-cqaado3u	100	8	concluded	conclude	VBD
cord-334454-cqaado3u	100	9	that	that	IN
cord-334454-cqaado3u	100	10	viremia	viremia	NN
cord-334454-cqaado3u	100	11	did	do	VBD
cord-334454-cqaado3u	100	12	not	not	RB
cord-334454-cqaado3u	100	13	change	change	VB
cord-334454-cqaado3u	100	14	in	in	IN
cord-334454-cqaado3u	100	15	the	the	DT
cord-334454-cqaado3u	100	16	group	group	NN
cord-334454-cqaado3u	100	17	of	of	IN
cord-334454-cqaado3u	100	18	FIV	FIV	NNP
cord-334454-cqaado3u	100	19	-	-	HYPH
cord-334454-cqaado3u	100	20	infected	infect	VBN
cord-334454-cqaado3u	100	21	cats	cat	NNS
cord-334454-cqaado3u	100	22	treated	treat	VBN
cord-334454-cqaado3u	100	23	with	with	IN
cord-334454-cqaado3u	100	24	the	the	DT
cord-334454-cqaado3u	100	25	licensed	licensed	JJ
cord-334454-cqaado3u	100	26	protocol	protocol	NN
cord-334454-cqaado3u	100	27	[	[	-LRB-
cord-334454-cqaado3u	100	28	27	27	CD
cord-334454-cqaado3u	100	29	]	]	-RRB-
cord-334454-cqaado3u	100	30	.	.	.
cord-334454-cqaado3u	101	1	However	however	RB
cord-334454-cqaado3u	101	2	,	,	,
cord-334454-cqaado3u	101	3	in	in	IN
cord-334454-cqaado3u	101	4	opposition	opposition	NN
cord-334454-cqaado3u	101	5	to	to	IN
cord-334454-cqaado3u	101	6	what	what	WP
cord-334454-cqaado3u	101	7	was	be	VBD
cord-334454-cqaado3u	101	8	previously	previously	RB
cord-334454-cqaado3u	101	9	reported	report	VBN
cord-334454-cqaado3u	101	10	,	,	,
cord-334454-cqaado3u	101	11	a	a	DT
cord-334454-cqaado3u	101	12	significant	significant	JJ
cord-334454-cqaado3u	101	13	increase	increase	NN
cord-334454-cqaado3u	101	14	on	on	IN
cord-334454-cqaado3u	101	15	proviral	proviral	JJ
cord-334454-cqaado3u	101	16	load	load	NN
cord-334454-cqaado3u	101	17	was	be	VBD
cord-334454-cqaado3u	101	18	reported	report	VBN
cord-334454-cqaado3u	101	19	and	and	CC
cord-334454-cqaado3u	101	20	correlated	correlate	VBN
cord-334454-cqaado3u	101	21	to	to	IN
cord-334454-cqaado3u	101	22	a	a	DT
cord-334454-cqaado3u	101	23	relative	relative	JJ
cord-334454-cqaado3u	101	24	increase	increase	NN
cord-334454-cqaado3u	101	25	of	of	IN
cord-334454-cqaado3u	101	26	lymphocytes	lymphocyte	NNS
cord-334454-cqaado3u	101	27	cell	cell	NN
cord-334454-cqaado3u	101	28	count	count	NN
cord-334454-cqaado3u	101	29	(	(	-LRB-
cord-334454-cqaado3u	101	30	even	even	RB
cord-334454-cqaado3u	101	31	within	within	IN
cord-334454-cqaado3u	101	32	the	the	DT
cord-334454-cqaado3u	101	33	normal	normal	JJ
cord-334454-cqaado3u	101	34	range	range	NN
cord-334454-cqaado3u	101	35	)	)	-RRB-
cord-334454-cqaado3u	102	1	[	[	-LRB-
cord-334454-cqaado3u	102	2	27	27	CD
cord-334454-cqaado3u	102	3	]	]	-RRB-
cord-334454-cqaado3u	102	4	.	.	.
cord-334454-cqaado3u	103	1	In	in	IN
cord-334454-cqaado3u	103	2	this	this	DT
cord-334454-cqaado3u	103	3	study	study	NN
cord-334454-cqaado3u	103	4	,	,	,
cord-334454-cqaado3u	103	5	viremia	viremia	NNP
cord-334454-cqaado3u	103	6	and	and	CC
cord-334454-cqaado3u	103	7	proviral	proviral	JJ
cord-334454-cqaado3u	103	8	load	load	NN
cord-334454-cqaado3u	103	9	changes	change	NNS
cord-334454-cqaado3u	103	10	in	in	IN
cord-334454-cqaado3u	103	11	FIV	FIV	NNP
cord-334454-cqaado3u	103	12	-	-	HYPH
cord-334454-cqaado3u	103	13	infected	infect	VBN
cord-334454-cqaado3u	103	14	cats	cat	NNS
cord-334454-cqaado3u	103	15	treated	treat	VBN
cord-334454-cqaado3u	103	16	with	with	IN
cord-334454-cqaado3u	103	17	oral	oral	JJ
cord-334454-cqaado3u	103	18	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	103	19	-	-	HYPH
cord-334454-cqaado3u	103	20	ω	ω	NN
cord-334454-cqaado3u	103	21	were	be	VBD
cord-334454-cqaado3u	103	22	also	also	RB
cord-334454-cqaado3u	103	23	evaluated	evaluate	VBN
cord-334454-cqaado3u	103	24	.	.	.
cord-334454-cqaado3u	104	1	As	as	IN
cord-334454-cqaado3u	104	2	expected	expect	VBN
cord-334454-cqaado3u	104	3	,	,	,
cord-334454-cqaado3u	104	4	no	no	DT
cord-334454-cqaado3u	104	5	changes	change	NNS
cord-334454-cqaado3u	104	6	were	be	VBD
cord-334454-cqaado3u	104	7	obtained	obtain	VBN
cord-334454-cqaado3u	104	8	in	in	IN
cord-334454-cqaado3u	104	9	either	either	DT
cord-334454-cqaado3u	104	10	parameter	parameter	NN
cord-334454-cqaado3u	104	11	,	,	,
cord-334454-cqaado3u	104	12	which	which	WDT
cord-334454-cqaado3u	104	13	reinforced	reinforce	VBD
cord-334454-cqaado3u	104	14	the	the	DT
cord-334454-cqaado3u	104	15	previous	previous	JJ
cord-334454-cqaado3u	104	16	suggestion	suggestion	NN
cord-334454-cqaado3u	104	17	that	that	IN
cord-334454-cqaado3u	104	18	,	,	,
cord-334454-cqaado3u	104	19	independently	independently	RB
cord-334454-cqaado3u	104	20	of	of	IN
cord-334454-cqaado3u	104	21	the	the	DT
cord-334454-cqaado3u	104	22	administered	administer	VBN
cord-334454-cqaado3u	104	23	protocol	protocol	NN
cord-334454-cqaado3u	104	24	,	,	,
cord-334454-cqaado3u	104	25	the	the	DT
cord-334454-cqaado3u	104	26	rFeIFN	rFeIFN	NNP
cord-334454-cqaado3u	104	27	-	-	HYPH
cord-334454-cqaado3u	104	28	ω	ω	NNP
cord-334454-cqaado3u	104	29	's	's	POS
cord-334454-cqaado3u	104	30	anti	anti	JJ
cord-334454-cqaado3u	104	31	-	-	JJ
cord-334454-cqaado3u	104	32	viral	viral	JJ
cord-334454-cqaado3u	104	33	effect	effect	NN
cord-334454-cqaado3u	104	34	in	in	IN
cord-334454-cqaado3u	104	35	vivo	vivo	NN
cord-334454-cqaado3u	104	36	is	be	VBZ
cord-334454-cqaado3u	104	37	negligible	negligible	JJ
cord-334454-cqaado3u	104	38	.	.	.
cord-334454-cqaado3u	105	1	At	at	IN
cord-334454-cqaado3u	105	2	this	this	DT
cord-334454-cqaado3u	105	3	point	point	NN
cord-334454-cqaado3u	105	4	,	,	,
cord-334454-cqaado3u	105	5	it	-PRON-	PRP
cord-334454-cqaado3u	105	6	was	be	VBD
cord-334454-cqaado3u	105	7	concluded	conclude	VBN
cord-334454-cqaado3u	105	8	that	that	IN
cord-334454-cqaado3u	105	9	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	105	10	-	-	HYPH
cord-334454-cqaado3u	105	11	ω	ω	CD
cord-334454-cqaado3u	105	12	licensed	licensed	JJ
cord-334454-cqaado3u	105	13	protocol	protocol	NN
cord-334454-cqaado3u	105	14	induced	induce	VBD
cord-334454-cqaado3u	105	15	a	a	DT
cord-334454-cqaado3u	105	16	decrease	decrease	NN
cord-334454-cqaado3u	105	17	in	in	IN
cord-334454-cqaado3u	105	18	concurrent	concurrent	JJ
cord-334454-cqaado3u	105	19	viral	viral	JJ
cord-334454-cqaado3u	105	20	infections	infection	NNS
cord-334454-cqaado3u	105	21	,	,	,
cord-334454-cqaado3u	105	22	even	even	RB
cord-334454-cqaado3u	105	23	if	if	IN
cord-334454-cqaado3u	105	24	there	there	EX
cord-334454-cqaado3u	105	25	were	be	VBD
cord-334454-cqaado3u	105	26	no	no	DT
cord-334454-cqaado3u	105	27	true	true	JJ
cord-334454-cqaado3u	105	28	changes	change	NNS
cord-334454-cqaado3u	105	29	in	in	IN
cord-334454-cqaado3u	105	30	FIV	FIV	NNP
cord-334454-cqaado3u	105	31	viral	viral	JJ
cord-334454-cqaado3u	105	32	load	load	NN
cord-334454-cqaado3u	105	33	.	.	.
cord-334454-cqaado3u	106	1	On	on	IN
cord-334454-cqaado3u	106	2	the	the	DT
cord-334454-cqaado3u	106	3	other	other	JJ
cord-334454-cqaado3u	106	4	hand	hand	NN
cord-334454-cqaado3u	106	5	,	,	,
cord-334454-cqaado3u	106	6	in	in	IN
cord-334454-cqaado3u	106	7	the	the	DT
cord-334454-cqaado3u	106	8	oral	oral	JJ
cord-334454-cqaado3u	106	9	protocol	protocol	NN
cord-334454-cqaado3u	106	10	,	,	,
cord-334454-cqaado3u	106	11	albeit	albeit	IN
cord-334454-cqaado3u	106	12	no	no	DT
cord-334454-cqaado3u	106	13	changes	change	NNS
cord-334454-cqaado3u	106	14	on	on	IN
cord-334454-cqaado3u	106	15	the	the	DT
cord-334454-cqaado3u	106	16	viral	viral	JJ
cord-334454-cqaado3u	106	17	load	load	NN
cord-334454-cqaado3u	106	18	and	and	CC
cord-334454-cqaado3u	106	19	concurrent	concurrent	JJ
cord-334454-cqaado3u	106	20	viral	viral	JJ
cord-334454-cqaado3u	106	21	infections	infection	NNS
cord-334454-cqaado3u	106	22	,	,	,
cord-334454-cqaado3u	106	23	there	there	EX
cord-334454-cqaado3u	106	24	was	be	VBD
cord-334454-cqaado3u	106	25	a	a	DT
cord-334454-cqaado3u	106	26	significant	significant	JJ
cord-334454-cqaado3u	106	27	clinical	clinical	JJ
cord-334454-cqaado3u	106	28	improvement	improvement	NN
cord-334454-cqaado3u	106	29	in	in	IN
cord-334454-cqaado3u	106	30	treated	treat	VBN
cord-334454-cqaado3u	106	31	cats	cat	NNS
cord-334454-cqaado3u	106	32	.	.	.
cord-334454-cqaado3u	107	1	Therefore	therefore	RB
cord-334454-cqaado3u	107	2	,	,	,
cord-334454-cqaado3u	107	3	even	even	RB
cord-334454-cqaado3u	107	4	if	if	IN
cord-334454-cqaado3u	107	5	the	the	DT
cord-334454-cqaado3u	107	6	antiviral	antiviral	JJ
cord-334454-cqaado3u	107	7	properties	property	NNS
cord-334454-cqaado3u	107	8	against	against	IN
cord-334454-cqaado3u	107	9	FIV	FIV	NNP
cord-334454-cqaado3u	107	10	seem	seem	VBP
cord-334454-cqaado3u	107	11	negligible	negligible	JJ
cord-334454-cqaado3u	107	12	in	in	IN
cord-334454-cqaado3u	107	13	both	both	DT
cord-334454-cqaado3u	107	14	protocols	protocol	NNS
cord-334454-cqaado3u	107	15	,	,	,
cord-334454-cqaado3u	107	16	the	the	DT
cord-334454-cqaado3u	107	17	fact	fact	NN
cord-334454-cqaado3u	107	18	that	that	IN
cord-334454-cqaado3u	107	19	there	there	EX
cord-334454-cqaado3u	107	20	was	be	VBD
cord-334454-cqaado3u	107	21	a	a	DT
cord-334454-cqaado3u	107	22	decrease	decrease	NN
cord-334454-cqaado3u	107	23	in	in	IN
cord-334454-cqaado3u	107	24	concurrent	concurrent	JJ
cord-334454-cqaado3u	107	25	viral	viral	JJ
cord-334454-cqaado3u	107	26	infections	infection	NNS
cord-334454-cqaado3u	107	27	in	in	IN
cord-334454-cqaado3u	107	28	cats	cat	NNS
cord-334454-cqaado3u	107	29	treated	treat	VBN
cord-334454-cqaado3u	107	30	with	with	IN
cord-334454-cqaado3u	107	31	the	the	DT
cord-334454-cqaado3u	107	32	licensed	licensed	JJ
cord-334454-cqaado3u	107	33	protocol	protocol	NN
cord-334454-cqaado3u	107	34	raises	raise	VBZ
cord-334454-cqaado3u	107	35	the	the	DT
cord-334454-cqaado3u	107	36	question	question	NN
cord-334454-cqaado3u	107	37	of	of	IN
cord-334454-cqaado3u	107	38	whether	whether	IN
cord-334454-cqaado3u	107	39	there	there	EX
cord-334454-cqaado3u	107	40	is	be	VBZ
cord-334454-cqaado3u	107	41	a	a	DT
cord-334454-cqaado3u	107	42	true	true	JJ
cord-334454-cqaado3u	107	43	antiviral	antiviral	JJ
cord-334454-cqaado3u	107	44	effect	effect	NN
cord-334454-cqaado3u	107	45	towards	towards	IN
cord-334454-cqaado3u	107	46	other	other	JJ
cord-334454-cqaado3u	107	47	viruses	virus	NNS
cord-334454-cqaado3u	107	48	or	or	CC
cord-334454-cqaado3u	107	49	whether	whether	IN
cord-334454-cqaado3u	107	50	this	this	DT
cord-334454-cqaado3u	107	51	is	be	VBZ
cord-334454-cqaado3u	107	52	the	the	DT
cord-334454-cqaado3u	107	53	result	result	NN
cord-334454-cqaado3u	107	54	of	of	IN
cord-334454-cqaado3u	107	55	an	an	DT
cord-334454-cqaado3u	107	56	overall	overall	JJ
cord-334454-cqaado3u	107	57	stimulation	stimulation	NN
cord-334454-cqaado3u	107	58	of	of	IN
cord-334454-cqaado3u	107	59	the	the	DT
cord-334454-cqaado3u	107	60	innate	innate	JJ
cord-334454-cqaado3u	107	61	and	and	CC
cord-334454-cqaado3u	107	62	acquired	acquire	VBN
cord-334454-cqaado3u	107	63	immune	immune	JJ
cord-334454-cqaado3u	107	64	system	system	NN
cord-334454-cqaado3u	107	65	.	.	.
cord-334454-cqaado3u	108	1	From	from	IN
cord-334454-cqaado3u	108	2	the	the	DT
cord-334454-cqaado3u	108	3	authors	author	NNS
cord-334454-cqaado3u	108	4	'	'	POS
cord-334454-cqaado3u	108	5	point	point	NN
cord-334454-cqaado3u	108	6	of	of	IN
cord-334454-cqaado3u	108	7	view	view	NN
cord-334454-cqaado3u	108	8	,	,	,
cord-334454-cqaado3u	108	9	it	-PRON-	PRP
cord-334454-cqaado3u	108	10	is	be	VBZ
cord-334454-cqaado3u	108	11	overspeculative	overspeculative	VBN
cord-334454-cqaado3u	108	12	to	to	IN
cord-334454-cqaado3u	108	13	state	state	NN
cord-334454-cqaado3u	108	14	that	that	IN
cord-334454-cqaado3u	108	15	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	108	16	-	-	HYPH
cord-334454-cqaado3u	108	17	ω	ω	NN
cord-334454-cqaado3u	108	18	does	do	VBZ
cord-334454-cqaado3u	108	19	not	not	RB
cord-334454-cqaado3u	108	20	act	act	VB
cord-334454-cqaado3u	108	21	on	on	IN
cord-334454-cqaado3u	108	22	the	the	DT
cord-334454-cqaado3u	108	23	acquired	acquire	VBN
cord-334454-cqaado3u	108	24	immune	immune	JJ
cord-334454-cqaado3u	108	25	system	system	NN
cord-334454-cqaado3u	108	26	only	only	RB
cord-334454-cqaado3u	108	27	based	base	VBN
cord-334454-cqaado3u	108	28	on	on	IN
cord-334454-cqaado3u	108	29	viremia	viremia	NN
cord-334454-cqaado3u	108	30	and	and	CC
cord-334454-cqaado3u	108	31	proviral	proviral	NNP
cord-334454-cqaado3u	108	32	load	load	NNP
cord-334454-cqaado3u	108	33	.	.	.
cord-334454-cqaado3u	109	1	Therefore	therefore	RB
cord-334454-cqaado3u	109	2	,	,	,
cord-334454-cqaado3u	109	3	an	an	DT
cord-334454-cqaado3u	109	4	evaluation	evaluation	NN
cord-334454-cqaado3u	109	5	of	of	IN
cord-334454-cqaado3u	109	6	cytokine	cytokine	NN
cord-334454-cqaado3u	109	7	profiles	profile	NNS
cord-334454-cqaado3u	109	8	in	in	IN
cord-334454-cqaado3u	109	9	these	these	DT
cord-334454-cqaado3u	109	10	animals	animal	NNS
cord-334454-cqaado3u	109	11	seemed	seem	VBD
cord-334454-cqaado3u	109	12	essential	essential	JJ
cord-334454-cqaado3u	109	13	to	to	TO
cord-334454-cqaado3u	109	14	fully	fully	RB
cord-334454-cqaado3u	109	15	understand	understand	VB
cord-334454-cqaado3u	109	16	the	the	DT
cord-334454-cqaado3u	109	17	actions	action	NNS
cord-334454-cqaado3u	109	18	of	of	IN
cord-334454-cqaado3u	109	19	rFeIFN	rFeIFN	NNP
cord-334454-cqaado3u	109	20	-	-	HYPH
cord-334454-cqaado3u	109	21	ω	ω	NN
cord-334454-cqaado3u	109	22	.	.	.
cord-334454-cqaado3u	110	1	In	in	IN
cord-334454-cqaado3u	110	2	order	order	NN
cord-334454-cqaado3u	110	3	to	to	TO
cord-334454-cqaado3u	110	4	reinforce	reinforce	VB
cord-334454-cqaado3u	110	5	the	the	DT
cord-334454-cqaado3u	110	6	previous	previous	JJ
cord-334454-cqaado3u	110	7	suggestions	suggestion	NNS
cord-334454-cqaado3u	110	8	that	that	IN
cord-334454-cqaado3u	110	9	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	110	10	-	-	HYPH
cord-334454-cqaado3u	110	11	ω	ω	NN
cord-334454-cqaado3u	110	12	does	do	VBZ
cord-334454-cqaado3u	110	13	not	not	RB
cord-334454-cqaado3u	110	14	affect	affect	VB
cord-334454-cqaado3u	110	15	the	the	DT
cord-334454-cqaado3u	110	16	acquired	acquire	VBN
cord-334454-cqaado3u	110	17	immune	immune	JJ
cord-334454-cqaado3u	110	18	system	system	NN
cord-334454-cqaado3u	110	19	of	of	IN
cord-334454-cqaado3u	110	20	FIV	fiv	NN
cord-334454-cqaado3u	110	21	-	-	HYPH
cord-334454-cqaado3u	110	22	infected	infect	VBN
cord-334454-cqaado3u	110	23	cats	cat	NNS
cord-334454-cqaado3u	110	24	,	,	,
cord-334454-cqaado3u	110	25	mRNA	mrna	NN
cord-334454-cqaado3u	110	26	expression	expression	NN
cord-334454-cqaado3u	110	27	and	and	CC
cord-334454-cqaado3u	110	28	concurrent	concurrent	JJ
cord-334454-cqaado3u	110	29	plasma	plasma	NN
cord-334454-cqaado3u	110	30	levels	level	NNS
cord-334454-cqaado3u	110	31	of	of	IN
cord-334454-cqaado3u	110	32	various	various	JJ
cord-334454-cqaado3u	110	33	cytokines	cytokine	NNS
cord-334454-cqaado3u	110	34	were	be	VBD
cord-334454-cqaado3u	110	35	monitored	monitor	VBN
cord-334454-cqaado3u	110	36	using	use	VBG
cord-334454-cqaado3u	110	37	biological	biological	JJ
cord-334454-cqaado3u	110	38	samples	sample	NNS
cord-334454-cqaado3u	110	39	from	from	IN
cord-334454-cqaado3u	110	40	the	the	DT
cord-334454-cqaado3u	110	41	two	two	CD
cord-334454-cqaado3u	110	42	groups	group	NNS
cord-334454-cqaado3u	110	43	of	of	IN
cord-334454-cqaado3u	110	44	FIV	fiv	NN
cord-334454-cqaado3u	110	45	-	-	HYPH
cord-334454-cqaado3u	110	46	infected	infect	VBN
cord-334454-cqaado3u	110	47	cats	cat	NNS
cord-334454-cqaado3u	110	48	treated	treat	VBN
cord-334454-cqaado3u	110	49	with	with	IN
cord-334454-cqaado3u	110	50	either	either	CC
cord-334454-cqaado3u	110	51	subcutaneous	subcutaneous	JJ
cord-334454-cqaado3u	110	52	or	or	CC
cord-334454-cqaado3u	110	53	oral	oral	JJ
cord-334454-cqaado3u	110	54	rFEIFN	rfeifn	NN
cord-334454-cqaado3u	110	55	-	-	HYPH
cord-334454-cqaado3u	110	56	ω	ω	JJS
cord-334454-cqaado3u	110	57	protocols	protocol	NNS
cord-334454-cqaado3u	110	58	[	[	-LRB-
cord-334454-cqaado3u	110	59	27	27	CD
cord-334454-cqaado3u	110	60	]	]	-RRB-
cord-334454-cqaado3u	110	61	.	.	.
cord-334454-cqaado3u	111	1	Despite	despite	IN
cord-334454-cqaado3u	111	2	its	-PRON-	PRP$
cord-334454-cqaado3u	111	3	pleiotropic	pleiotropic	JJ
cord-334454-cqaado3u	111	4	effect	effect	NN
cord-334454-cqaado3u	111	5	,	,	,
cord-334454-cqaado3u	111	6	variations	variation	NNS
cord-334454-cqaado3u	111	7	of	of	IN
cord-334454-cqaado3u	111	8	Th-1	Th-1	NNP
cord-334454-cqaado3u	111	9	and	and	CC
cord-334454-cqaado3u	111	10	Th-2	Th-2	NNP
cord-334454-cqaado3u	111	11	responses	response	NNS
cord-334454-cqaado3u	111	12	were	be	VBD
cord-334454-cqaado3u	111	13	assessed	assess	VBN
cord-334454-cqaado3u	111	14	based	base	VBN
cord-334454-cqaado3u	111	15	on	on	IN
cord-334454-cqaado3u	111	16	different	different	JJ
cord-334454-cqaado3u	111	17	measured	measure	VBN
cord-334454-cqaado3u	111	18	cytokines	cytokine	NNS
cord-334454-cqaado3u	111	19	.	.	.
cord-334454-cqaado3u	112	1	Results	result	NNS
cord-334454-cqaado3u	112	2	showed	show	VBD
cord-334454-cqaado3u	112	3	that	that	IN
cord-334454-cqaado3u	112	4	Th-1	Th-1	NNP
cord-334454-cqaado3u	112	5	and	and	CC
cord-334454-cqaado3u	112	6	Th-2	Th-2	NNP
cord-334454-cqaado3u	112	7	responses	response	NNS
cord-334454-cqaado3u	112	8	did	do	VBD
cord-334454-cqaado3u	112	9	not	not	RB
cord-334454-cqaado3u	112	10	significantly	significantly	RB
cord-334454-cqaado3u	112	11	change	change	VB
cord-334454-cqaado3u	112	12	in	in	IN
cord-334454-cqaado3u	112	13	either	either	DT
cord-334454-cqaado3u	112	14	protocol	protocol	NN
cord-334454-cqaado3u	112	15	,	,	,
cord-334454-cqaado3u	112	16	which	which	WDT
cord-334454-cqaado3u	112	17	supported	support	VBD
cord-334454-cqaado3u	112	18	the	the	DT
cord-334454-cqaado3u	112	19	previous	previous	JJ
cord-334454-cqaado3u	112	20	suggestions	suggestion	NNS
cord-334454-cqaado3u	112	21	that	that	IN
cord-334454-cqaado3u	112	22	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	112	23	-	-	HYPH
cord-334454-cqaado3u	112	24	ω	ω	NN
cord-334454-cqaado3u	112	25	does	do	VBZ
cord-334454-cqaado3u	112	26	not	not	RB
cord-334454-cqaado3u	112	27	strongly	strongly	RB
cord-334454-cqaado3u	112	28	affect	affect	VB
cord-334454-cqaado3u	112	29	the	the	DT
cord-334454-cqaado3u	112	30	acquired	acquire	VBN
cord-334454-cqaado3u	112	31	immune	immune	JJ
cord-334454-cqaado3u	112	32	system	system	NN
cord-334454-cqaado3u	112	33	.	.	.
cord-334454-cqaado3u	113	1	Among	among	IN
cord-334454-cqaado3u	113	2	the	the	DT
cord-334454-cqaado3u	113	3	measured	measure	VBN
cord-334454-cqaado3u	113	4	cytokines	cytokine	NNS
cord-334454-cqaado3u	113	5	,	,	,
cord-334454-cqaado3u	113	6	only	only	RB
cord-334454-cqaado3u	113	7	IL-6	IL-6	NNP
cord-334454-cqaado3u	113	8	(	(	-LRB-
cord-334454-cqaado3u	113	9	a	a	DT
cord-334454-cqaado3u	113	10	pro	pro	JJ
cord-334454-cqaado3u	113	11	-	-	JJ
cord-334454-cqaado3u	113	12	inflammatory	inflammatory	JJ
cord-334454-cqaado3u	113	13	cytokine	cytokine	NN
cord-334454-cqaado3u	113	14	involved	involve	VBN
cord-334454-cqaado3u	113	15	in	in	IN
cord-334454-cqaado3u	113	16	different	different	JJ
cord-334454-cqaado3u	113	17	immune	immune	JJ
cord-334454-cqaado3u	113	18	pathways	pathway	NNS
cord-334454-cqaado3u	113	19	and	and	CC
cord-334454-cqaado3u	113	20	particularly	particularly	RB
cord-334454-cqaado3u	113	21	in	in	IN
cord-334454-cqaado3u	113	22	the	the	DT
cord-334454-cqaado3u	113	23	innate	innate	JJ
cord-334454-cqaado3u	113	24	immune	immune	JJ
cord-334454-cqaado3u	113	25	response	response	NN
cord-334454-cqaado3u	113	26	)	)	-RRB-
cord-334454-cqaado3u	113	27	significantly	significantly	RB
cord-334454-cqaado3u	113	28	changed	change	VBD
cord-334454-cqaado3u	113	29	in	in	IN
cord-334454-cqaado3u	113	30	both	both	DT
cord-334454-cqaado3u	113	31	groups	group	NNS
cord-334454-cqaado3u	113	32	.	.	.
cord-334454-cqaado3u	114	1	In	in	IN
cord-334454-cqaado3u	114	2	fact	fact	NN
cord-334454-cqaado3u	114	3	,	,	,
cord-334454-cqaado3u	114	4	in	in	IN
cord-334454-cqaado3u	114	5	cats	cat	NNS
cord-334454-cqaado3u	114	6	treated	treat	VBN
cord-334454-cqaado3u	114	7	with	with	IN
cord-334454-cqaado3u	114	8	the	the	DT
cord-334454-cqaado3u	114	9	licensed	licensed	JJ
cord-334454-cqaado3u	114	10	protocol	protocol	NN
cord-334454-cqaado3u	114	11	,	,	,
cord-334454-cqaado3u	114	12	IL-6	IL-6	NNP
cord-334454-cqaado3u	114	13	plasma	plasma	NN
cord-334454-cqaado3u	114	14	levels	level	NNS
cord-334454-cqaado3u	114	15	were	be	VBD
cord-334454-cqaado3u	114	16	significantly	significantly	RB
cord-334454-cqaado3u	114	17	reduced	reduce	VBN
cord-334454-cqaado3u	114	18	,	,	,
cord-334454-cqaado3u	114	19	whilst	whilst	IN
cord-334454-cqaado3u	114	20	its	-PRON-	PRP$
cord-334454-cqaado3u	114	21	respective	respective	JJ
cord-334454-cqaado3u	114	22	mRNA	mRNA	NNP
cord-334454-cqaado3u	114	23	expression	expression	NN
cord-334454-cqaado3u	114	24	showed	show	VBD
cord-334454-cqaado3u	114	25	a	a	DT
cord-334454-cqaado3u	114	26	decreasing	decrease	VBG
cord-334454-cqaado3u	114	27	tendency	tendency	NN
cord-334454-cqaado3u	114	28	that	that	WDT
cord-334454-cqaado3u	114	29	was	be	VBD
cord-334454-cqaado3u	114	30	not	not	RB
cord-334454-cqaado3u	114	31	statistically	statistically	RB
cord-334454-cqaado3u	114	32	significant	significant	JJ
cord-334454-cqaado3u	114	33	.	.	.
cord-334454-cqaado3u	115	1	On	on	IN
cord-334454-cqaado3u	115	2	the	the	DT
cord-334454-cqaado3u	115	3	other	other	JJ
cord-334454-cqaado3u	115	4	hand	hand	NN
cord-334454-cqaado3u	115	5	,	,	,
cord-334454-cqaado3u	115	6	in	in	IN
cord-334454-cqaado3u	115	7	cats	cat	NNS
cord-334454-cqaado3u	115	8	treated	treat	VBN
cord-334454-cqaado3u	115	9	with	with	IN
cord-334454-cqaado3u	115	10	oral	oral	JJ
cord-334454-cqaado3u	115	11	rFEIFN	rfeifn	NN
cord-334454-cqaado3u	115	12	-	-	HYPH
cord-334454-cqaado3u	115	13	ω	ω	JJ
cord-334454-cqaado3u	115	14	,	,	,
cord-334454-cqaado3u	115	15	IL-6	IL-6	NNP
cord-334454-cqaado3u	115	16	plasma	plasma	NN
cord-334454-cqaado3u	115	17	levels	level	NNS
cord-334454-cqaado3u	115	18	did	do	VBD
cord-334454-cqaado3u	115	19	not	not	RB
cord-334454-cqaado3u	115	20	change	change	VB
cord-334454-cqaado3u	115	21	,	,	,
cord-334454-cqaado3u	115	22	but	but	CC
cord-334454-cqaado3u	115	23	the	the	DT
cord-334454-cqaado3u	115	24	concurrent	concurrent	JJ
cord-334454-cqaado3u	115	25	mRNA	mRNA	NNP
cord-334454-cqaado3u	115	26	expression	expression	NN
cord-334454-cqaado3u	115	27	significantly	significantly	RB
cord-334454-cqaado3u	115	28	decreased	decrease	VBD
cord-334454-cqaado3u	115	29	.	.	.
cord-334454-cqaado3u	116	1	All	all	DT
cord-334454-cqaado3u	116	2	in	in	RB
cord-334454-cqaado3u	116	3	all	all	DT
cord-334454-cqaado3u	116	4	,	,	,
cord-334454-cqaado3u	116	5	it	-PRON-	PRP
cord-334454-cqaado3u	116	6	was	be	VBD
cord-334454-cqaado3u	116	7	documented	document	VBN
cord-334454-cqaado3u	116	8	that	that	IN
cord-334454-cqaado3u	116	9	IL-6	IL-6	NNP
cord-334454-cqaado3u	116	10	production	production	NN
cord-334454-cqaado3u	116	11	is	be	VBZ
cord-334454-cqaado3u	116	12	affected	affect	VBN
cord-334454-cqaado3u	116	13	in	in	IN
cord-334454-cqaado3u	116	14	both	both	DT
cord-334454-cqaado3u	116	15	protocols	protocol	NNS
cord-334454-cqaado3u	116	16	,	,	,
cord-334454-cqaado3u	116	17	meaning	mean	VBG
cord-334454-cqaado3u	116	18	that	that	IN
cord-334454-cqaado3u	116	19	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	116	20	-	-	HYPH
cord-334454-cqaado3u	116	21	ω	ω	NN
cord-334454-cqaado3u	116	22	has	have	VBZ
cord-334454-cqaado3u	116	23	anti	anti	JJ
cord-334454-cqaado3u	116	24	-	-	JJ
cord-334454-cqaado3u	116	25	inflammatory	inflammatory	JJ
cord-334454-cqaado3u	116	26	properties	property	NNS
cord-334454-cqaado3u	116	27	.	.	.
cord-334454-cqaado3u	117	1	Moreover	moreover	RB
cord-334454-cqaado3u	117	2	,	,	,
cord-334454-cqaado3u	117	3	considering	consider	VBG
cord-334454-cqaado3u	117	4	that	that	IN
cord-334454-cqaado3u	117	5	plasma	plasma	NN
cord-334454-cqaado3u	117	6	changes	change	NNS
cord-334454-cqaado3u	117	7	were	be	VBD
cord-334454-cqaado3u	117	8	only	only	RB
cord-334454-cqaado3u	117	9	significant	significant	JJ
cord-334454-cqaado3u	117	10	in	in	IN
cord-334454-cqaado3u	117	11	cats	cat	NNS
cord-334454-cqaado3u	117	12	treated	treat	VBN
cord-334454-cqaado3u	117	13	with	with	IN
cord-334454-cqaado3u	117	14	the	the	DT
cord-334454-cqaado3u	117	15	licensed	licensed	JJ
cord-334454-cqaado3u	117	16	protocol	protocol	NN
cord-334454-cqaado3u	117	17	,	,	,
cord-334454-cqaado3u	117	18	it	-PRON-	PRP
cord-334454-cqaado3u	117	19	seems	seem	VBZ
cord-334454-cqaado3u	117	20	reasonable	reasonable	JJ
cord-334454-cqaado3u	117	21	to	to	IN
cord-334454-cqaado3u	117	22	state	state	VB
cord-334454-cqaado3u	117	23	that	that	IN
cord-334454-cqaado3u	117	24	this	this	DT
cord-334454-cqaado3u	117	25	higher	high	JJR
cord-334454-cqaado3u	117	26	pulsate	pulsate	VBP
cord-334454-cqaado3u	117	27	therapeutic	therapeutic	JJ
cord-334454-cqaado3u	117	28	scheme	scheme	NN
cord-334454-cqaado3u	117	29	is	be	VBZ
cord-334454-cqaado3u	117	30	more	more	RBR
cord-334454-cqaado3u	117	31	efficient	efficient	JJ
cord-334454-cqaado3u	117	32	in	in	IN
cord-334454-cqaado3u	117	33	reducing	reduce	VBG
cord-334454-cqaado3u	117	34	the	the	DT
cord-334454-cqaado3u	117	35	pro	pro	JJ
cord-334454-cqaado3u	117	36	-	-	JJ
cord-334454-cqaado3u	117	37	inflammatory	inflammatory	JJ
cord-334454-cqaado3u	117	38	stimuli	stimulus	NNS
cord-334454-cqaado3u	117	39	than	than	IN
cord-334454-cqaado3u	117	40	the	the	DT
cord-334454-cqaado3u	117	41	continuous	continuous	JJ
cord-334454-cqaado3u	117	42	low	low	JJ
cord-334454-cqaado3u	117	43	dose	dose	NN
cord-334454-cqaado3u	117	44	therapy	therapy	NN
cord-334454-cqaado3u	117	45	.	.	.
cord-334454-cqaado3u	118	1	These	these	DT
cord-334454-cqaado3u	118	2	were	be	VBD
cord-334454-cqaado3u	118	3	the	the	DT
cord-334454-cqaado3u	118	4	first	first	JJ
cord-334454-cqaado3u	118	5	studies	study	NNS
cord-334454-cqaado3u	118	6	exploring	explore	VBG
cord-334454-cqaado3u	118	7	the	the	DT
cord-334454-cqaado3u	118	8	effect	effect	NN
cord-334454-cqaado3u	118	9	of	of	IN
cord-334454-cqaado3u	118	10	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	118	11	-	-	HYPH
cord-334454-cqaado3u	118	12	ω	ω	JJ
cord-334454-cqaado3u	118	13	in	in	IN
cord-334454-cqaado3u	118	14	different	different	JJ
cord-334454-cqaado3u	118	15	biomarkers	biomarker	NNS
cord-334454-cqaado3u	118	16	of	of	IN
cord-334454-cqaado3u	118	17	the	the	DT
cord-334454-cqaado3u	118	18	immune	immune	JJ
cord-334454-cqaado3u	118	19	system	system	NN
cord-334454-cqaado3u	118	20	.	.	.
cord-334454-cqaado3u	119	1	However	however	RB
cord-334454-cqaado3u	119	2	,	,	,
cord-334454-cqaado3u	119	3	there	there	EX
cord-334454-cqaado3u	119	4	are	be	VBP
cord-334454-cqaado3u	119	5	still	still	RB
cord-334454-cqaado3u	119	6	many	many	JJ
cord-334454-cqaado3u	119	7	points	point	NNS
cord-334454-cqaado3u	119	8	to	to	TO
cord-334454-cqaado3u	119	9	investigate	investigate	VB
cord-334454-cqaado3u	119	10	in	in	IN
cord-334454-cqaado3u	119	11	order	order	NN
cord-334454-cqaado3u	119	12	to	to	TO
cord-334454-cqaado3u	119	13	explore	explore	VB
cord-334454-cqaado3u	119	14	the	the	DT
cord-334454-cqaado3u	119	15	whole	whole	JJ
cord-334454-cqaado3u	119	16	potential	potential	NN
cord-334454-cqaado3u	119	17	of	of	IN
cord-334454-cqaado3u	119	18	this	this	DT
cord-334454-cqaado3u	119	19	compound	compound	NN
cord-334454-cqaado3u	119	20	in	in	IN
cord-334454-cqaado3u	119	21	retroviral	retroviral	JJ
cord-334454-cqaado3u	119	22	infections	infection	NNS
cord-334454-cqaado3u	119	23	.	.	.
cord-334454-cqaado3u	120	1	In	in	IN
cord-334454-cqaado3u	120	2	FIV	FIV	NNP
cord-334454-cqaado3u	120	3	-	-	HYPH
cord-334454-cqaado3u	120	4	infected	infect	VBN
cord-334454-cqaado3u	120	5	cats	cat	NNS
cord-334454-cqaado3u	120	6	,	,	,
cord-334454-cqaado3u	120	7	only	only	RB
cord-334454-cqaado3u	120	8	two	two	CD
cord-334454-cqaado3u	120	9	protocols	protocol	NNS
cord-334454-cqaado3u	120	10	were	be	VBD
cord-334454-cqaado3u	120	11	assessed	assess	VBN
cord-334454-cqaado3u	120	12	.	.	.
cord-334454-cqaado3u	121	1	Following	follow	VBG
cord-334454-cqaado3u	121	2	the	the	DT
cord-334454-cqaado3u	121	3	same	same	JJ
cord-334454-cqaado3u	121	4	research	research	NN
cord-334454-cqaado3u	121	5	line	line	NN
cord-334454-cqaado3u	121	6	,	,	,
cord-334454-cqaado3u	121	7	it	-PRON-	PRP
cord-334454-cqaado3u	121	8	would	would	MD
cord-334454-cqaado3u	121	9	be	be	VB
cord-334454-cqaado3u	121	10	interesting	interesting	JJ
cord-334454-cqaado3u	121	11	to	to	TO
cord-334454-cqaado3u	121	12	reinforce	reinforce	VB
cord-334454-cqaado3u	121	13	these	these	DT
cord-334454-cqaado3u	121	14	conclusions	conclusion	NNS
cord-334454-cqaado3u	121	15	with	with	IN
cord-334454-cqaado3u	121	16	pharmacokinetic	pharmacokinetic	JJ
cord-334454-cqaado3u	121	17	and	and	CC
cord-334454-cqaado3u	121	18	pharmacodynamic	pharmacodynamic	JJ
cord-334454-cqaado3u	121	19	studies	study	NNS
cord-334454-cqaado3u	121	20	.	.	.
cord-334454-cqaado3u	122	1	In	in	IN
cord-334454-cqaado3u	122	2	the	the	DT
cord-334454-cqaado3u	122	3	subcutaneous	subcutaneous	JJ
cord-334454-cqaado3u	122	4	protocol	protocol	NN
cord-334454-cqaado3u	122	5	,	,	,
cord-334454-cqaado3u	122	6	it	-PRON-	PRP
cord-334454-cqaado3u	122	7	would	would	MD
cord-334454-cqaado3u	122	8	be	be	VB
cord-334454-cqaado3u	122	9	useful	useful	JJ
cord-334454-cqaado3u	122	10	to	to	TO
cord-334454-cqaado3u	122	11	document	document	VB
cord-334454-cqaado3u	122	12	the	the	DT
cord-334454-cqaado3u	122	13	effect	effect	NN
cord-334454-cqaado3u	122	14	of	of	IN
cord-334454-cqaado3u	122	15	lower	low	JJR
cord-334454-cqaado3u	122	16	doses	dose	NNS
cord-334454-cqaado3u	122	17	but	but	CC
cord-334454-cqaado3u	123	1	in	in	IN
cord-334454-cqaado3u	123	2	longer	long	JJR
cord-334454-cqaado3u	123	3	therapy	therapy	NN
cord-334454-cqaado3u	123	4	cycles	cycle	NNS
cord-334454-cqaado3u	123	5	and	and	CC
cord-334454-cqaado3u	123	6	vice	vice	NN
cord-334454-cqaado3u	123	7	-	-	HYPH
cord-334454-cqaado3u	123	8	versa	versa	RB
cord-334454-cqaado3u	123	9	,	,	,
cord-334454-cqaado3u	123	10	in	in	IN
cord-334454-cqaado3u	123	11	order	order	NN
cord-334454-cqaado3u	123	12	to	to	TO
cord-334454-cqaado3u	123	13	correlate	correlate	VB
cord-334454-cqaado3u	123	14	the	the	DT
cord-334454-cqaado3u	123	15	therapy	therapy	NN
cord-334454-cqaado3u	123	16	requirements	requirement	NNS
cord-334454-cqaado3u	123	17	with	with	IN
cord-334454-cqaado3u	123	18	clinical	clinical	JJ
cord-334454-cqaado3u	123	19	and	and	CC
cord-334454-cqaado3u	123	20	virological	virological	JJ
cord-334454-cqaado3u	123	21	conditions	condition	NNS
cord-334454-cqaado3u	123	22	.	.	.
cord-334454-cqaado3u	124	1	For	for	IN
cord-334454-cqaado3u	124	2	the	the	DT
cord-334454-cqaado3u	124	3	oral	oral	JJ
cord-334454-cqaado3u	124	4	group	group	NN
cord-334454-cqaado3u	124	5	,	,	,
cord-334454-cqaado3u	124	6	it	-PRON-	PRP
cord-334454-cqaado3u	124	7	would	would	MD
cord-334454-cqaado3u	124	8	also	also	RB
cord-334454-cqaado3u	124	9	be	be	VB
cord-334454-cqaado3u	124	10	interesting	interesting	JJ
cord-334454-cqaado3u	124	11	to	to	TO
cord-334454-cqaado3u	124	12	assess	assess	VB
cord-334454-cqaado3u	124	13	the	the	DT
cord-334454-cqaado3u	124	14	effect	effect	NN
cord-334454-cqaado3u	124	15	of	of	IN
cord-334454-cqaado3u	124	16	intermediate	intermediate	JJ
cord-334454-cqaado3u	124	17	higher	high	JJR
cord-334454-cqaado3u	124	18	doses	dose	NNS
cord-334454-cqaado3u	124	19	for	for	IN
cord-334454-cqaado3u	124	20	shorter	short	JJR
cord-334454-cqaado3u	124	21	periods	period	NNS
cord-334454-cqaado3u	124	22	and	and	CC
cord-334454-cqaado3u	124	23	also	also	RB
cord-334454-cqaado3u	124	24	to	to	TO
cord-334454-cqaado3u	124	25	extend	extend	VB
cord-334454-cqaado3u	124	26	the	the	DT
cord-334454-cqaado3u	124	27	protocol	protocol	NN
cord-334454-cqaado3u	124	28	to	to	IN
cord-334454-cqaado3u	124	29	FeLV	FeLV	NNP
cord-334454-cqaado3u	124	30	-	-	HYPH
cord-334454-cqaado3u	124	31	infected	infect	VBN
cord-334454-cqaado3u	124	32	cats	cat	NNS
cord-334454-cqaado3u	124	33	.	.	.
cord-334454-cqaado3u	125	1	In	in	IN
cord-334454-cqaado3u	125	2	spite	spite	NN
cord-334454-cqaado3u	125	3	of	of	IN
cord-334454-cqaado3u	125	4	the	the	DT
cord-334454-cqaado3u	125	5	different	different	JJ
cord-334454-cqaado3u	125	6	physiopathology	physiopathology	NN
cord-334454-cqaado3u	125	7	and	and	CC
cord-334454-cqaado3u	125	8	the	the	DT
cord-334454-cqaado3u	125	9	aggressive	aggressive	JJ
cord-334454-cqaado3u	125	10	clinical	clinical	JJ
cord-334454-cqaado3u	125	11	portrait	portrait	NN
cord-334454-cqaado3u	125	12	,	,	,
cord-334454-cqaado3u	125	13	it	-PRON-	PRP
cord-334454-cqaado3u	125	14	would	would	MD
cord-334454-cqaado3u	125	15	be	be	VB
cord-334454-cqaado3u	125	16	interesting	interesting	JJ
cord-334454-cqaado3u	125	17	to	to	TO
cord-334454-cqaado3u	125	18	assess	assess	VB
cord-334454-cqaado3u	125	19	the	the	DT
cord-334454-cqaado3u	125	20	effect	effect	NN
cord-334454-cqaado3u	125	21	of	of	IN
cord-334454-cqaado3u	125	22	the	the	DT
cord-334454-cqaado3u	125	23	suggested	suggest	VBN
cord-334454-cqaado3u	125	24	oral	oral	JJ
cord-334454-cqaado3u	125	25	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	125	26	-	-	HYPH
cord-334454-cqaado3u	125	27	ω	ω	JJ
cord-334454-cqaado3u	125	28	in	in	IN
cord-334454-cqaado3u	125	29	these	these	DT
cord-334454-cqaado3u	125	30	animals	animal	NNS
cord-334454-cqaado3u	125	31	.	.	.
cord-334454-cqaado3u	126	1	According	accord	VBG
cord-334454-cqaado3u	126	2	to	to	IN
cord-334454-cqaado3u	126	3	the	the	DT
cord-334454-cqaado3u	126	4	authors	author	NNS
cord-334454-cqaado3u	126	5	'	'	POS
cord-334454-cqaado3u	126	6	point	point	NN
cord-334454-cqaado3u	126	7	of	of	IN
cord-334454-cqaado3u	126	8	view	view	NN
cord-334454-cqaado3u	126	9	,	,	,
cord-334454-cqaado3u	126	10	it	-PRON-	PRP
cord-334454-cqaado3u	126	11	is	be	VBZ
cord-334454-cqaado3u	126	12	unlikely	unlikely	JJ
cord-334454-cqaado3u	126	13	that	that	IN
cord-334454-cqaado3u	126	14	such	such	PDT
cord-334454-cqaado3u	126	15	a	a	DT
cord-334454-cqaado3u	126	16	lower	low	JJR
cord-334454-cqaado3u	126	17	oral	oral	JJ
cord-334454-cqaado3u	126	18	dose	dose	NN
cord-334454-cqaado3u	126	19	will	will	MD
cord-334454-cqaado3u	126	20	have	have	VB
cord-334454-cqaado3u	126	21	the	the	DT
cord-334454-cqaado3u	126	22	same	same	JJ
cord-334454-cqaado3u	126	23	effect	effect	NN
cord-334454-cqaado3u	126	24	on	on	IN
cord-334454-cqaado3u	126	25	clinical	clinical	JJ
cord-334454-cqaado3u	126	26	improvement	improvement	NN
cord-334454-cqaado3u	126	27	of	of	IN
cord-334454-cqaado3u	126	28	FeLV	FeLV	NNP
cord-334454-cqaado3u	126	29	-	-	HYPH
cord-334454-cqaado3u	126	30	infected	infect	VBN
cord-334454-cqaado3u	126	31	cats	cat	NNS
cord-334454-cqaado3u	126	32	since	since	IN
cord-334454-cqaado3u	126	33	these	these	DT
cord-334454-cqaado3u	126	34	animals	animal	NNS
cord-334454-cqaado3u	126	35	are	be	VBP
cord-334454-cqaado3u	126	36	usually	usually	RB
cord-334454-cqaado3u	126	37	more	more	RBR
cord-334454-cqaado3u	126	38	symptomatic	symptomatic	JJ
cord-334454-cqaado3u	126	39	and	and	CC
cord-334454-cqaado3u	126	40	in	in	IN
cord-334454-cqaado3u	126	41	worse	bad	JJR
cord-334454-cqaado3u	126	42	overall	overall	JJ
cord-334454-cqaado3u	126	43	clinical	clinical	JJ
cord-334454-cqaado3u	126	44	condition	condition	NN
cord-334454-cqaado3u	126	45	than	than	IN
cord-334454-cqaado3u	126	46	FIV	fiv	NN
cord-334454-cqaado3u	126	47	-	-	HYPH
cord-334454-cqaado3u	126	48	infected	infect	VBN
cord-334454-cqaado3u	126	49	animals	animal	NNS
cord-334454-cqaado3u	126	50	.	.	.
cord-334454-cqaado3u	127	1	Consequently	consequently	RB
cord-334454-cqaado3u	127	2	,	,	,
cord-334454-cqaado3u	127	3	the	the	DT
cord-334454-cqaado3u	127	4	higher	high	JJR
cord-334454-cqaado3u	127	5	subcutaneous	subcutaneous	JJ
cord-334454-cqaado3u	127	6	protocol	protocol	NN
cord-334454-cqaado3u	127	7	will	will	MD
cord-334454-cqaado3u	127	8	always	always	RB
cord-334454-cqaado3u	127	9	be	be	VB
cord-334454-cqaado3u	127	10	preferable	preferable	JJ
cord-334454-cqaado3u	127	11	in	in	IN
cord-334454-cqaado3u	127	12	these	these	DT
cord-334454-cqaado3u	127	13	cats	cat	NNS
cord-334454-cqaado3u	127	14	.	.	.
cord-334454-cqaado3u	128	1	As	as	IN
cord-334454-cqaado3u	128	2	previously	previously	RB
cord-334454-cqaado3u	128	3	stated	state	VBN
cord-334454-cqaado3u	128	4	,	,	,
cord-334454-cqaado3u	128	5	several	several	JJ
cord-334454-cqaado3u	128	6	studies	study	NNS
cord-334454-cqaado3u	128	7	have	have	VBP
cord-334454-cqaado3u	128	8	shown	show	VBN
cord-334454-cqaado3u	128	9	that	that	IN
cord-334454-cqaado3u	128	10	IFNs	ifn	NNS
cord-334454-cqaado3u	128	11	can	can	MD
cord-334454-cqaado3u	128	12	be	be	VB
cord-334454-cqaado3u	128	13	beneficial	beneficial	JJ
cord-334454-cqaado3u	128	14	in	in	IN
cord-334454-cqaado3u	128	15	the	the	DT
cord-334454-cqaado3u	128	16	early	early	JJ
cord-334454-cqaado3u	128	17	stages	stage	NNS
cord-334454-cqaado3u	128	18	of	of	IN
cord-334454-cqaado3u	128	19	HIV	HIV	NNP
cord-334454-cqaado3u	128	20	infection	infection	NN
cord-334454-cqaado3u	128	21	[	[	-LRB-
cord-334454-cqaado3u	128	22	15	15	CD
cord-334454-cqaado3u	128	23	]	]	-RRB-
cord-334454-cqaado3u	128	24	.	.	.
cord-334454-cqaado3u	129	1	Recognizing	recognize	VBG
cord-334454-cqaado3u	129	2	that	that	IN
cord-334454-cqaado3u	129	3	these	these	DT
cord-334454-cqaado3u	129	4	results	result	NNS
cord-334454-cqaado3u	129	5	concern	concern	NN
cord-334454-cqaado3u	129	6	naturally	naturally	RB
cord-334454-cqaado3u	129	7	infected	infect	VBN
cord-334454-cqaado3u	129	8	cats	cat	NNS
cord-334454-cqaado3u	129	9	in	in	IN
cord-334454-cqaado3u	129	10	which	which	WDT
cord-334454-cqaado3u	129	11	the	the	DT
cord-334454-cqaado3u	129	12	time	time	NN
cord-334454-cqaado3u	129	13	of	of	IN
cord-334454-cqaado3u	129	14	infection	infection	NN
cord-334454-cqaado3u	129	15	is	be	VBZ
cord-334454-cqaado3u	129	16	unknown	unknown	JJ
cord-334454-cqaado3u	129	17	,	,	,
cord-334454-cqaado3u	129	18	these	these	DT
cord-334454-cqaado3u	129	19	findings	finding	NNS
cord-334454-cqaado3u	129	20	are	be	VBP
cord-334454-cqaado3u	129	21	in	in	IN
cord-334454-cqaado3u	129	22	some	some	DT
cord-334454-cqaado3u	129	23	way	way	NN
cord-334454-cqaado3u	129	24	in	in	IN
cord-334454-cqaado3u	129	25	agreement	agreement	NN
cord-334454-cqaado3u	129	26	with	with	IN
cord-334454-cqaado3u	129	27	these	these	DT
cord-334454-cqaado3u	129	28	HIV	HIV	NNP
cord-334454-cqaado3u	129	29	studies	study	NNS
cord-334454-cqaado3u	129	30	as	as	IN
cord-334454-cqaado3u	129	31	they	-PRON-	PRP
cord-334454-cqaado3u	129	32	indirectly	indirectly	RB
cord-334454-cqaado3u	129	33	reflect	reflect	VBP
cord-334454-cqaado3u	129	34	an	an	DT
cord-334454-cqaado3u	129	35	innate	innate	JJ
cord-334454-cqaado3u	129	36	immune	immune	JJ
cord-334454-cqaado3u	129	37	-	-	HYPH
cord-334454-cqaado3u	129	38	modulation	modulation	NN
cord-334454-cqaado3u	129	39	and	and	CC
cord-334454-cqaado3u	129	40	decrease	decrease	NN
cord-334454-cqaado3u	129	41	in	in	IN
cord-334454-cqaado3u	129	42	clinical	clinical	JJ
cord-334454-cqaado3u	129	43	signs	sign	NNS
cord-334454-cqaado3u	129	44	and	and	CC
cord-334454-cqaado3u	129	45	co	co	NNS
cord-334454-cqaado3u	129	46	-	-	NNS
cord-334454-cqaado3u	129	47	infections	infection	NNS
cord-334454-cqaado3u	129	48	.	.	.
cord-334454-cqaado3u	130	1	Compared	compare	VBN
cord-334454-cqaado3u	130	2	with	with	IN
cord-334454-cqaado3u	130	3	exploring	explore	VBG
cord-334454-cqaado3u	130	4	the	the	DT
cord-334454-cqaado3u	130	5	full	full	JJ
cord-334454-cqaado3u	130	6	potential	potential	NN
cord-334454-cqaado3u	130	7	of	of	IN
cord-334454-cqaado3u	130	8	each	each	DT
cord-334454-cqaado3u	130	9	route	route	NN
cord-334454-cqaado3u	130	10	and	and	CC
cord-334454-cqaado3u	130	11	dose	dose	NN
cord-334454-cqaado3u	130	12	,	,	,
cord-334454-cqaado3u	130	13	it	-PRON-	PRP
cord-334454-cqaado3u	130	14	would	would	MD
cord-334454-cqaado3u	130	15	be	be	VB
cord-334454-cqaado3u	130	16	interesting	interesting	JJ
cord-334454-cqaado3u	130	17	to	to	TO
cord-334454-cqaado3u	130	18	study	study	VB
cord-334454-cqaado3u	130	19	a	a	DT
cord-334454-cqaado3u	130	20	combination	combination	NN
cord-334454-cqaado3u	130	21	of	of	IN
cord-334454-cqaado3u	130	22	protocols	protocol	NNS
cord-334454-cqaado3u	130	23	to	to	TO
cord-334454-cqaado3u	130	24	be	be	VB
cord-334454-cqaado3u	130	25	used	use	VBN
cord-334454-cqaado3u	130	26	according	accord	VBG
cord-334454-cqaado3u	130	27	to	to	IN
cord-334454-cqaado3u	130	28	different	different	JJ
cord-334454-cqaado3u	130	29	clinical	clinical	JJ
cord-334454-cqaado3u	130	30	presentations	presentation	NNS
cord-334454-cqaado3u	130	31	.	.	.
cord-334454-cqaado3u	131	1	Although	although	IN
cord-334454-cqaado3u	131	2	there	there	EX
cord-334454-cqaado3u	131	3	are	be	VBP
cord-334454-cqaado3u	131	4	no	no	DT
cord-334454-cqaado3u	131	5	studies	study	NNS
cord-334454-cqaado3u	131	6	assessing	assess	VBG
cord-334454-cqaado3u	131	7	a	a	DT
cord-334454-cqaado3u	131	8	possible	possible	JJ
cord-334454-cqaado3u	131	9	combination	combination	NN
cord-334454-cqaado3u	131	10	of	of	IN
cord-334454-cqaado3u	131	11	both	both	DT
cord-334454-cqaado3u	131	12	protocols	protocol	NNS
cord-334454-cqaado3u	131	13	,	,	,
cord-334454-cqaado3u	131	14	we	-PRON-	PRP
cord-334454-cqaado3u	131	15	think	think	VBP
cord-334454-cqaado3u	131	16	that	that	IN
cord-334454-cqaado3u	131	17	they	-PRON-	PRP
cord-334454-cqaado3u	131	18	can	can	MD
cord-334454-cqaado3u	131	19	be	be	VB
cord-334454-cqaado3u	131	20	reasonably	reasonably	RB
cord-334454-cqaado3u	131	21	associated	associate	VBN
cord-334454-cqaado3u	131	22	,	,	,
cord-334454-cqaado3u	131	23	as	as	IN
cord-334454-cqaado3u	131	24	both	both	DT
cord-334454-cqaado3u	131	25	therapies	therapy	NNS
cord-334454-cqaado3u	131	26	are	be	VBP
cord-334454-cqaado3u	131	27	well	well	RB
cord-334454-cqaado3u	131	28	documented	documented	JJ
cord-334454-cqaado3u	131	29	and	and	CC
cord-334454-cqaado3u	131	30	do	do	VBP
cord-334454-cqaado3u	131	31	not	not	RB
cord-334454-cqaado3u	131	32	show	show	VB
cord-334454-cqaado3u	131	33	important	important	JJ
cord-334454-cqaado3u	131	34	adverse	adverse	JJ
cord-334454-cqaado3u	131	35	effects	effect	NNS
cord-334454-cqaado3u	131	36	.	.	.
cord-334454-cqaado3u	132	1	For	for	IN
cord-334454-cqaado3u	132	2	instance	instance	NN
cord-334454-cqaado3u	132	3	,	,	,
cord-334454-cqaado3u	132	4	in	in	IN
cord-334454-cqaado3u	132	5	symptomatic	symptomatic	JJ
cord-334454-cqaado3u	132	6	animals	animal	NNS
cord-334454-cqaado3u	132	7	,	,	,
cord-334454-cqaado3u	132	8	an	an	DT
cord-334454-cqaado3u	132	9	initial	initial	JJ
cord-334454-cqaado3u	132	10	subcutaneous	subcutaneous	JJ
cord-334454-cqaado3u	132	11	protocol	protocol	NN
cord-334454-cqaado3u	132	12	followed	follow	VBN
cord-334454-cqaado3u	132	13	by	by	IN
cord-334454-cqaado3u	132	14	an	an	DT
cord-334454-cqaado3u	132	15	oral	oral	JJ
cord-334454-cqaado3u	132	16	continuous	continuous	JJ
cord-334454-cqaado3u	132	17	lower	low	JJR
cord-334454-cqaado3u	132	18	-	-	HYPH
cord-334454-cqaado3u	132	19	dose	dose	NN
cord-334454-cqaado3u	132	20	therapy	therapy	NN
cord-334454-cqaado3u	132	21	can	can	MD
cord-334454-cqaado3u	132	22	now	now	RB
cord-334454-cqaado3u	132	23	be	be	VB
cord-334454-cqaado3u	132	24	recommended	recommend	VBN
cord-334454-cqaado3u	132	25	.	.	.
cord-334454-cqaado3u	133	1	From	from	IN
cord-334454-cqaado3u	133	2	the	the	DT
cord-334454-cqaado3u	133	3	authors	author	NNS
cord-334454-cqaado3u	133	4	'	'	POS
cord-334454-cqaado3u	133	5	point	point	NN
cord-334454-cqaado3u	133	6	of	of	IN
cord-334454-cqaado3u	133	7	view	view	NN
cord-334454-cqaado3u	133	8	,	,	,
cord-334454-cqaado3u	133	9	this	this	DT
cord-334454-cqaado3u	133	10	seems	seem	VBZ
cord-334454-cqaado3u	133	11	a	a	DT
cord-334454-cqaado3u	133	12	reasonable	reasonable	JJ
cord-334454-cqaado3u	133	13	approach	approach	NN
cord-334454-cqaado3u	133	14	that	that	IN
cord-334454-cqaado3u	133	15	sooner	soon	RBR
cord-334454-cqaado3u	133	16	or	or	CC
cord-334454-cqaado3u	133	17	later	later	RB
cord-334454-cqaado3u	133	18	can	can	MD
cord-334454-cqaado3u	133	19	be	be	VB
cord-334454-cqaado3u	133	20	considered	consider	VBN
cord-334454-cqaado3u	133	21	in	in	IN
cord-334454-cqaado3u	133	22	routine	routine	JJ
cord-334454-cqaado3u	133	23	clinical	clinical	JJ
cord-334454-cqaado3u	133	24	practice	practice	NN
cord-334454-cqaado3u	133	25	.	.	.
cord-334454-cqaado3u	134	1	Also	also	RB
cord-334454-cqaado3u	134	2	regarding	regard	VBG
cord-334454-cqaado3u	134	3	the	the	DT
cord-334454-cqaado3u	134	4	follow	follow	NN
cord-334454-cqaado3u	134	5	-	-	HYPH
cord-334454-cqaado3u	134	6	up	up	NN
cord-334454-cqaado3u	134	7	and	and	CC
cord-334454-cqaado3u	134	8	life	life	NN
cord-334454-cqaado3u	134	9	span	span	NN
cord-334454-cqaado3u	134	10	,	,	,
cord-334454-cqaado3u	134	11	studies	study	NNS
cord-334454-cqaado3u	134	12	are	be	VBP
cord-334454-cqaado3u	134	13	warranted	warrant	VBN
cord-334454-cqaado3u	134	14	.	.	.
cord-334454-cqaado3u	135	1	In	in	IN
cord-334454-cqaado3u	135	2	fact	fact	NN
cord-334454-cqaado3u	135	3	,	,	,
cord-334454-cqaado3u	135	4	some	some	DT
cord-334454-cqaado3u	135	5	authors	author	NNS
cord-334454-cqaado3u	135	6	have	have	VBP
cord-334454-cqaado3u	135	7	tried	try	VBN
cord-334454-cqaado3u	135	8	to	to	TO
cord-334454-cqaado3u	135	9	perform	perform	VB
cord-334454-cqaado3u	135	10	monthly	monthly	RB
cord-334454-cqaado3u	135	11	to	to	IN
cord-334454-cqaado3u	135	12	trimester	trimester	NN
cord-334454-cqaado3u	135	13	follow	follow	NN
cord-334454-cqaado3u	135	14	-	-	HYPH
cord-334454-cqaado3u	135	15	ups	up	NNS
cord-334454-cqaado3u	135	16	after	after	IN
cord-334454-cqaado3u	135	17	the	the	DT
cord-334454-cqaado3u	135	18	end	end	NN
cord-334454-cqaado3u	135	19	of	of	IN
cord-334454-cqaado3u	135	20	therapy	therapy	NN
cord-334454-cqaado3u	135	21	.	.	.
cord-334454-cqaado3u	136	1	In	in	IN
cord-334454-cqaado3u	136	2	both	both	DT
cord-334454-cqaado3u	136	3	groups	group	NNS
cord-334454-cqaado3u	136	4	,	,	,
cord-334454-cqaado3u	136	5	it	-PRON-	PRP
cord-334454-cqaado3u	136	6	was	be	VBD
cord-334454-cqaado3u	136	7	unsuccessful	unsuccessful	JJ
cord-334454-cqaado3u	136	8	.	.	.
cord-334454-cqaado3u	137	1	In	in	IN
cord-334454-cqaado3u	137	2	the	the	DT
cord-334454-cqaado3u	137	3	animal	animal	NN
cord-334454-cqaado3u	137	4	shelter	shelter	NN
cord-334454-cqaado3u	137	5	,	,	,
cord-334454-cqaado3u	137	6	clinical	clinical	JJ
cord-334454-cqaado3u	137	7	evaluations	evaluation	NNS
cord-334454-cqaado3u	137	8	after	after	IN
cord-334454-cqaado3u	137	9	therapy	therapy	NN
cord-334454-cqaado3u	137	10	were	be	VBD
cord-334454-cqaado3u	137	11	unreasonable	unreasonable	JJ
cord-334454-cqaado3u	137	12	once	once	IN
cord-334454-cqaado3u	137	13	the	the	DT
cord-334454-cqaado3u	137	14	income	income	NN
cord-334454-cqaado3u	137	15	and	and	CC
cord-334454-cqaado3u	137	16	outcome	outcome	NN
cord-334454-cqaado3u	137	17	of	of	IN
cord-334454-cqaado3u	137	18	cats	cat	NNS
cord-334454-cqaado3u	137	19	impaired	impair	VBD
cord-334454-cqaado3u	137	20	correct	correct	JJ
cord-334454-cqaado3u	137	21	conclusions	conclusion	NNS
cord-334454-cqaado3u	137	22	.	.	.
cord-334454-cqaado3u	138	1	Regarding	regard	VBG
cord-334454-cqaado3u	138	2	client	client	NN
cord-334454-cqaado3u	138	3	-	-	HYPH
cord-334454-cqaado3u	138	4	owned	own	VBN
cord-334454-cqaado3u	138	5	cats	cat	NNS
cord-334454-cqaado3u	138	6	,	,	,
cord-334454-cqaado3u	138	7	it	-PRON-	PRP
cord-334454-cqaado3u	138	8	was	be	VBD
cord-334454-cqaado3u	138	9	only	only	RB
cord-334454-cqaado3u	138	10	correctly	correctly	RB
cord-334454-cqaado3u	138	11	achieved	achieve	VBN
cord-334454-cqaado3u	138	12	in	in	IN
cord-334454-cqaado3u	138	13	a	a	DT
cord-334454-cqaado3u	138	14	small	small	JJ
cord-334454-cqaado3u	138	15	number	number	NN
cord-334454-cqaado3u	138	16	of	of	IN
cord-334454-cqaado3u	138	17	treated	treat	VBN
cord-334454-cqaado3u	138	18	animals	animal	NNS
cord-334454-cqaado3u	138	19	(	(	-LRB-
cord-334454-cqaado3u	138	20	unpublished	unpublished	JJ
cord-334454-cqaado3u	138	21	data	datum	NNS
cord-334454-cqaado3u	138	22	)	)	-RRB-
cord-334454-cqaado3u	138	23	.	.	.
cord-334454-cqaado3u	139	1	In	in	IN
cord-334454-cqaado3u	139	2	fact	fact	NN
cord-334454-cqaado3u	139	3	,	,	,
cord-334454-cqaado3u	139	4	the	the	DT
cord-334454-cqaado3u	139	5	individual	individual	JJ
cord-334454-cqaado3u	139	6	oral	oral	JJ
cord-334454-cqaado3u	139	7	therapy	therapy	NN
cord-334454-cqaado3u	139	8	for	for	IN
cord-334454-cqaado3u	139	9	each	each	DT
cord-334454-cqaado3u	139	10	cat	cat	NN
cord-334454-cqaado3u	139	11	was	be	VBD
cord-334454-cqaado3u	139	12	free	free	JJ
cord-334454-cqaado3u	139	13	of	of	IN
cord-334454-cqaado3u	139	14	charge	charge	NN
cord-334454-cqaado3u	139	15	and	and	CC
cord-334454-cqaado3u	139	16	comprised	comprise	VBD
cord-334454-cqaado3u	139	17	a	a	DT
cord-334454-cqaado3u	139	18	total	total	NN
cord-334454-cqaado3u	139	19	of	of	IN
cord-334454-cqaado3u	139	20	90	90	CD
cord-334454-cqaado3u	139	21	daily	daily	JJ
cord-334454-cqaado3u	139	22	doses	dose	NNS
cord-334454-cqaado3u	139	23	that	that	WDT
cord-334454-cqaado3u	139	24	were	be	VBD
cord-334454-cqaado3u	139	25	partially	partially	RB
cord-334454-cqaado3u	139	26	given	give	VBN
cord-334454-cqaado3u	139	27	to	to	IN
cord-334454-cqaado3u	139	28	the	the	DT
cord-334454-cqaado3u	139	29	owners	owner	NNS
cord-334454-cqaado3u	139	30	at	at	IN
cord-334454-cqaado3u	139	31	each	each	DT
cord-334454-cqaado3u	139	32	evaluation	evaluation	NN
cord-334454-cqaado3u	139	33	time	time	NN
cord-334454-cqaado3u	139	34	point	point	NN
cord-334454-cqaado3u	139	35	.	.	.
cord-334454-cqaado3u	140	1	After	after	IN
cord-334454-cqaado3u	140	2	the	the	DT
cord-334454-cqaado3u	140	3	end	end	NN
cord-334454-cqaado3u	140	4	of	of	IN
cord-334454-cqaado3u	140	5	the	the	DT
cord-334454-cqaado3u	140	6	therapy	therapy	NN
cord-334454-cqaado3u	140	7	,	,	,
cord-334454-cqaado3u	140	8	the	the	DT
cord-334454-cqaado3u	140	9	monitoring	monitoring	NN
cord-334454-cqaado3u	140	10	was	be	VBD
cord-334454-cqaado3u	140	11	unpractical	unpractical	JJ
cord-334454-cqaado3u	140	12	once	once	IN
cord-334454-cqaado3u	140	13	the	the	DT
cord-334454-cqaado3u	140	14	majority	majority	NN
cord-334454-cqaado3u	140	15	of	of	IN
cord-334454-cqaado3u	140	16	owners	owner	NNS
cord-334454-cqaado3u	140	17	were	be	VBD
cord-334454-cqaado3u	140	18	unavailable	unavailable	JJ
cord-334454-cqaado3u	140	19	to	to	IN
cord-334454-cqaado3u	140	20	pursuit	pursuit	NN
cord-334454-cqaado3u	140	21	with	with	IN
cord-334454-cqaado3u	140	22	monthly	monthly	JJ
cord-334454-cqaado3u	140	23	follow	follow	NN
cord-334454-cqaado3u	140	24	-	-	HYPH
cord-334454-cqaado3u	140	25	ups	up	NNS
cord-334454-cqaado3u	140	26	.	.	.
cord-334454-cqaado3u	141	1	Consequently	consequently	RB
cord-334454-cqaado3u	141	2	,	,	,
cord-334454-cqaado3u	141	3	a	a	DT
cord-334454-cqaado3u	141	4	structured	structured	JJ
cord-334454-cqaado3u	141	5	prospective	prospective	JJ
cord-334454-cqaado3u	141	6	study	study	NN
cord-334454-cqaado3u	141	7	would	would	MD
cord-334454-cqaado3u	141	8	be	be	VB
cord-334454-cqaado3u	141	9	interesting	interesting	JJ
cord-334454-cqaado3u	141	10	in	in	IN
cord-334454-cqaado3u	141	11	order	order	NN
cord-334454-cqaado3u	141	12	to	to	TO
cord-334454-cqaado3u	141	13	evaluate	evaluate	VB
cord-334454-cqaado3u	141	14	not	not	RB
cord-334454-cqaado3u	141	15	only	only	RB
cord-334454-cqaado3u	141	16	the	the	DT
cord-334454-cqaado3u	141	17	long	long	JJ
cord-334454-cqaado3u	141	18	-	-	HYPH
cord-334454-cqaado3u	141	19	term	term	NN
cord-334454-cqaado3u	141	20	benefits	benefit	NNS
cord-334454-cqaado3u	141	21	of	of	IN
cord-334454-cqaado3u	141	22	therapy	therapy	NN
cord-334454-cqaado3u	141	23	but	but	CC
cord-334454-cqaado3u	141	24	also	also	RB
cord-334454-cqaado3u	141	25	any	any	DT
cord-334454-cqaado3u	141	26	effect	effect	NN
cord-334454-cqaado3u	141	27	on	on	IN
cord-334454-cqaado3u	141	28	the	the	DT
cord-334454-cqaado3u	141	29	mean	mean	JJ
cord-334454-cqaado3u	141	30	life	life	NN
cord-334454-cqaado3u	141	31	span	span	NN
cord-334454-cqaado3u	141	32	of	of	IN
cord-334454-cqaado3u	141	33	FIV	fiv	NN
cord-334454-cqaado3u	141	34	-	-	HYPH
cord-334454-cqaado3u	141	35	infected	infect	VBN
cord-334454-cqaado3u	141	36	cats	cat	NNS
cord-334454-cqaado3u	141	37	.	.	.
cord-334454-cqaado3u	142	1	These	these	DT
cord-334454-cqaado3u	142	2	studies	study	NNS
cord-334454-cqaado3u	142	3	innovated	innovate	VBD
cord-334454-cqaado3u	142	4	in	in	IN
cord-334454-cqaado3u	142	5	the	the	DT
cord-334454-cqaado3u	142	6	extension	extension	NN
cord-334454-cqaado3u	142	7	of	of	IN
cord-334454-cqaado3u	142	8	the	the	DT
cord-334454-cqaado3u	142	9	main	main	JJ
cord-334454-cqaado3u	142	10	therapeutic	therapeutic	JJ
cord-334454-cqaado3u	142	11	properties	property	NNS
cord-334454-cqaado3u	142	12	of	of	IN
cord-334454-cqaado3u	142	13	the	the	DT
cord-334454-cqaado3u	142	14	licensed	licensed	JJ
cord-334454-cqaado3u	142	15	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	142	16	-	-	HYPH
cord-334454-cqaado3u	142	17	ω	ω	CD
cord-334454-cqaado3u	142	18	protocol	protocol	NN
cord-334454-cqaado3u	142	19	in	in	IN
cord-334454-cqaado3u	142	20	naturally	naturally	RB
cord-334454-cqaado3u	142	21	retrovirally	retrovirally	NN
cord-334454-cqaado3u	142	22	infected	infected	JJ
cord-334454-cqaado3u	142	23	cats	cat	NNS
cord-334454-cqaado3u	142	24	.	.	.
cord-334454-cqaado3u	143	1	It	-PRON-	PRP
cord-334454-cqaado3u	143	2	is	be	VBZ
cord-334454-cqaado3u	143	3	now	now	RB
cord-334454-cqaado3u	143	4	documented	document	VBN
cord-334454-cqaado3u	143	5	that	that	IN
cord-334454-cqaado3u	143	6	it	-PRON-	PRP
cord-334454-cqaado3u	143	7	must	must	MD
cord-334454-cqaado3u	143	8	be	be	VB
cord-334454-cqaado3u	143	9	used	use	VBN
cord-334454-cqaado3u	143	10	not	not	RB
cord-334454-cqaado3u	143	11	only	only	RB
cord-334454-cqaado3u	143	12	in	in	IN
cord-334454-cqaado3u	143	13	client	client	NN
cord-334454-cqaado3u	143	14	-	-	HYPH
cord-334454-cqaado3u	143	15	owned	own	VBN
cord-334454-cqaado3u	143	16	symptomatic	symptomatic	JJ
cord-334454-cqaado3u	143	17	cats	cat	NNS
cord-334454-cqaado3u	143	18	but	but	CC
cord-334454-cqaado3u	143	19	also	also	RB
cord-334454-cqaado3u	143	20	in	in	IN
cord-334454-cqaado3u	143	21	animals	animal	NNS
cord-334454-cqaado3u	143	22	living	live	VBG
cord-334454-cqaado3u	143	23	in	in	IN
cord-334454-cqaado3u	143	24	catteries	catterie	NNS
cord-334454-cqaado3u	143	25	or	or	CC
cord-334454-cqaado3u	143	26	shelters	shelter	NNS
cord-334454-cqaado3u	143	27	where	where	WRB
cord-334454-cqaado3u	143	28	opportunistic	opportunistic	JJ
cord-334454-cqaado3u	143	29	infections	infection	NNS
cord-334454-cqaado3u	143	30	are	be	VBP
cord-334454-cqaado3u	143	31	problematic	problematic	JJ
cord-334454-cqaado3u	143	32	.	.	.
cord-334454-cqaado3u	144	1	Although	although	IN
cord-334454-cqaado3u	144	2	without	without	IN
cord-334454-cqaado3u	144	3	a	a	DT
cord-334454-cqaado3u	144	4	truly	truly	RB
cord-334454-cqaado3u	144	5	effect	effect	NN
cord-334454-cqaado3u	144	6	on	on	IN
cord-334454-cqaado3u	144	7	the	the	DT
cord-334454-cqaado3u	144	8	cytokine	cytokine	NN
cord-334454-cqaado3u	144	9	profile	profile	NN
cord-334454-cqaado3u	144	10	,	,	,
cord-334454-cqaado3u	144	11	this	this	DT
cord-334454-cqaado3u	144	12	compound	compound	NN
cord-334454-cqaado3u	144	13	induces	induce	VBZ
cord-334454-cqaado3u	144	14	a	a	DT
cord-334454-cqaado3u	144	15	significant	significant	JJ
cord-334454-cqaado3u	144	16	clinical	clinical	JJ
cord-334454-cqaado3u	144	17	improvement	improvement	NN
cord-334454-cqaado3u	144	18	and	and	CC
cord-334454-cqaado3u	144	19	seems	seem	VBZ
cord-334454-cqaado3u	144	20	to	to	TO
cord-334454-cqaado3u	144	21	reduce	reduce	VB
cord-334454-cqaado3u	144	22	the	the	DT
cord-334454-cqaado3u	144	23	pro	pro	JJ
cord-334454-cqaado3u	144	24	-	-	JJ
cord-334454-cqaado3u	144	25	inflammatory	inflammatory	JJ
cord-334454-cqaado3u	144	26	stimuli	stimulus	NNS
cord-334454-cqaado3u	144	27	.	.	.
cord-334454-cqaado3u	145	1	Particularly	particularly	RB
cord-334454-cqaado3u	145	2	,	,	,
cord-334454-cqaado3u	145	3	for	for	IN
cord-334454-cqaado3u	145	4	FIV	fiv	NN
cord-334454-cqaado3u	145	5	-	-	HYPH
cord-334454-cqaado3u	145	6	infected	infect	VBN
cord-334454-cqaado3u	145	7	cats	cat	NNS
cord-334454-cqaado3u	145	8	,	,	,
cord-334454-cqaado3u	145	9	this	this	DT
cord-334454-cqaado3u	145	10	work	work	NN
cord-334454-cqaado3u	145	11	presents	present	VBZ
cord-334454-cqaado3u	145	12	a	a	DT
cord-334454-cqaado3u	145	13	new	new	JJ
cord-334454-cqaado3u	145	14	oral	oral	JJ
cord-334454-cqaado3u	145	15	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	145	16	-	-	HYPH
cord-334454-cqaado3u	145	17	ω	ω	CD
cord-334454-cqaado3u	145	18	protocol	protocol	NN
cord-334454-cqaado3u	145	19	,	,	,
cord-334454-cqaado3u	145	20	which	which	WDT
cord-334454-cqaado3u	145	21	was	be	VBD
cord-334454-cqaado3u	145	22	successfully	successfully	RB
cord-334454-cqaado3u	145	23	tested	test	VBN
cord-334454-cqaado3u	145	24	and	and	CC
cord-334454-cqaado3u	145	25	validated	validate	VBN
cord-334454-cqaado3u	145	26	.	.	.
cord-334454-cqaado3u	146	1	Although	although	IN
cord-334454-cqaado3u	146	2	it	-PRON-	PRP
cord-334454-cqaado3u	146	3	induces	induce	VBZ
cord-334454-cqaado3u	146	4	a	a	DT
cord-334454-cqaado3u	146	5	significant	significant	JJ
cord-334454-cqaado3u	146	6	clinical	clinical	JJ
cord-334454-cqaado3u	146	7	improvement	improvement	NN
cord-334454-cqaado3u	146	8	,	,	,
cord-334454-cqaado3u	146	9	its	-PRON-	PRP$
cord-334454-cqaado3u	146	10	overall	overall	JJ
cord-334454-cqaado3u	146	11	action	action	NN
cord-334454-cqaado3u	146	12	as	as	IN
cord-334454-cqaado3u	146	13	an	an	DT
cord-334454-cqaado3u	146	14	immune	immune	JJ
cord-334454-cqaado3u	146	15	modulator	modulator	NN
cord-334454-cqaado3u	146	16	is	be	VBZ
cord-334454-cqaado3u	146	17	less	less	JJR
cord-334454-cqaado3u	146	18	than	than	IN
cord-334454-cqaado3u	146	19	the	the	DT
cord-334454-cqaado3u	146	20	subcutaneous	subcutaneous	JJ
cord-334454-cqaado3u	146	21	protocol	protocol	NN
cord-334454-cqaado3u	146	22	.	.	.
cord-334454-cqaado3u	147	1	In	in	IN
cord-334454-cqaado3u	147	2	fact	fact	NN
cord-334454-cqaado3u	147	3	,	,	,
cord-334454-cqaado3u	147	4	it	-PRON-	PRP
cord-334454-cqaado3u	147	5	slightly	slightly	RB
cord-334454-cqaado3u	147	6	decreases	decrease	VBZ
cord-334454-cqaado3u	147	7	the	the	DT
cord-334454-cqaado3u	147	8	pro	pro	JJ
cord-334454-cqaado3u	147	9	-	-	JJ
cord-334454-cqaado3u	147	10	inflammatory	inflammatory	JJ
cord-334454-cqaado3u	147	11	stimuli	stimulus	NNS
cord-334454-cqaado3u	147	12	without	without	IN
cord-334454-cqaado3u	147	13	affecting	affect	VBG
cord-334454-cqaado3u	147	14	the	the	DT
cord-334454-cqaado3u	147	15	acquired	acquire	VBN
cord-334454-cqaado3u	147	16	immunity	immunity	NN
cord-334454-cqaado3u	147	17	,	,	,
cord-334454-cqaado3u	147	18	or	or	CC
cord-334454-cqaado3u	147	19	even	even	RB
cord-334454-cqaado3u	147	20	other	other	JJ
cord-334454-cqaado3u	147	21	parameters	parameter	NNS
cord-334454-cqaado3u	147	22	of	of	IN
cord-334454-cqaado3u	147	23	the	the	DT
cord-334454-cqaado3u	147	24	innate	innate	JJ
cord-334454-cqaado3u	147	25	response	response	NN
cord-334454-cqaado3u	147	26	such	such	JJ
cord-334454-cqaado3u	147	27	as	as	IN
cord-334454-cqaado3u	147	28	acute	acute	JJ
cord-334454-cqaado3u	147	29	phase	phase	NN
cord-334454-cqaado3u	147	30	proteins	protein	NNS
cord-334454-cqaado3u	147	31	.	.	.
cord-334454-cqaado3u	148	1	Therefore	therefore	RB
cord-334454-cqaado3u	148	2	,	,	,
cord-334454-cqaado3u	148	3	whilst	whilst	IN
cord-334454-cqaado3u	148	4	the	the	DT
cord-334454-cqaado3u	148	5	high	high	JJ
cord-334454-cqaado3u	148	6	pulsate	pulsate	VBP
cord-334454-cqaado3u	148	7	subcutaneous	subcutaneous	JJ
cord-334454-cqaado3u	148	8	protocol	protocol	NN
cord-334454-cqaado3u	148	9	is	be	VBZ
cord-334454-cqaado3u	148	10	strongly	strongly	RB
cord-334454-cqaado3u	148	11	recommended	recommend	VBN
cord-334454-cqaado3u	148	12	for	for	IN
cord-334454-cqaado3u	148	13	symptomatic	symptomatic	JJ
cord-334454-cqaado3u	148	14	FIV	fiv	NN
cord-334454-cqaado3u	148	15	-	-	HYPH
cord-334454-cqaado3u	148	16	infected	infect	VBN
cord-334454-cqaado3u	148	17	cats	cat	NNS
cord-334454-cqaado3u	148	18	,	,	,
cord-334454-cqaado3u	148	19	this	this	DT
cord-334454-cqaado3u	148	20	lower	lower	RBR
cord-334454-cqaado3u	148	21	continuous	continuous	JJ
cord-334454-cqaado3u	148	22	oral	oral	JJ
cord-334454-cqaado3u	148	23	protocol	protocol	NN
cord-334454-cqaado3u	148	24	is	be	VBZ
cord-334454-cqaado3u	148	25	a	a	DT
cord-334454-cqaado3u	148	26	good	good	JJ
cord-334454-cqaado3u	148	27	alternative	alternative	NN
cord-334454-cqaado3u	148	28	for	for	IN
cord-334454-cqaado3u	148	29	cats	cat	NNS
cord-334454-cqaado3u	148	30	presenting	present	VBG
cord-334454-cqaado3u	148	31	mild	mild	JJ
cord-334454-cqaado3u	148	32	clinical	clinical	JJ
cord-334454-cqaado3u	148	33	signs	sign	NNS
cord-334454-cqaado3u	148	34	,	,	,
cord-334454-cqaado3u	148	35	for	for	IN
cord-334454-cqaado3u	148	36	cases	case	NNS
cord-334454-cqaado3u	148	37	where	where	WRB
cord-334454-cqaado3u	148	38	cost	cost	NN
cord-334454-cqaado3u	148	39	limits	limit	NNS
cord-334454-cqaado3u	148	40	the	the	DT
cord-334454-cqaado3u	148	41	use	use	NN
cord-334454-cqaado3u	148	42	of	of	IN
cord-334454-cqaado3u	148	43	licensed	licensed	JJ
cord-334454-cqaado3u	148	44	protocol	protocol	NN
cord-334454-cqaado3u	148	45	or	or	CC
cord-334454-cqaado3u	148	46	even	even	RB
cord-334454-cqaado3u	148	47	for	for	IN
cord-334454-cqaado3u	148	48	cats	cat	NNS
cord-334454-cqaado3u	148	49	,	,	,
cord-334454-cqaado3u	148	50	which	which	WDT
cord-334454-cqaado3u	148	51	previously	previously	RB
cord-334454-cqaado3u	148	52	received	receive	VBD
cord-334454-cqaado3u	148	53	subcutaneous	subcutaneous	JJ
cord-334454-cqaado3u	148	54	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	148	55	-	-	HYPH
cord-334454-cqaado3u	148	56	ω	ω	JJS
cord-334454-cqaado3u	148	57	and	and	CC
cord-334454-cqaado3u	148	58	require	require	VB
cord-334454-cqaado3u	148	59	continuous	continuous	JJ
cord-334454-cqaado3u	148	60	immune	immune	JJ
cord-334454-cqaado3u	148	61	modulation	modulation	NN
cord-334454-cqaado3u	148	62	therapy	therapy	NN
cord-334454-cqaado3u	148	63	.	.	.
cord-334454-cqaado3u	149	1	These	these	DT
cord-334454-cqaado3u	149	2	studies	study	NNS
cord-334454-cqaado3u	149	3	did	do	VBD
cord-334454-cqaado3u	149	4	not	not	RB
cord-334454-cqaado3u	149	5	contribute	contribute	VB
cord-334454-cqaado3u	149	6	to	to	IN
cord-334454-cqaado3u	149	7	a	a	DT
cord-334454-cqaado3u	149	8	better	well	JJR
cord-334454-cqaado3u	149	9	understanding	understanding	NN
cord-334454-cqaado3u	149	10	of	of	IN
cord-334454-cqaado3u	149	11	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	149	12	-	-	HYPH
cord-334454-cqaado3u	149	13	ω	ω	JJ
cord-334454-cqaado3u	149	14	as	as	RB
cord-334454-cqaado3u	149	15	much	much	RB
cord-334454-cqaado3u	149	16	as	as	IN
cord-334454-cqaado3u	149	17	they	-PRON-	PRP
cord-334454-cqaado3u	149	18	explored	explore	VBD
cord-334454-cqaado3u	149	19	its	-PRON-	PRP$
cord-334454-cqaado3u	149	20	immune	immune	JJ
cord-334454-cqaado3u	149	21	modulation	modulation	NN
cord-334454-cqaado3u	149	22	properties	property	NNS
cord-334454-cqaado3u	149	23	and	and	CC
cord-334454-cqaado3u	149	24	validated	validate	VBD
cord-334454-cqaado3u	149	25	a	a	DT
cord-334454-cqaado3u	149	26	new	new	JJ
cord-334454-cqaado3u	149	27	oral	oral	JJ
cord-334454-cqaado3u	149	28	protocol	protocol	NN
cord-334454-cqaado3u	149	29	,	,	,
cord-334454-cqaado3u	149	30	which	which	WDT
cord-334454-cqaado3u	149	31	can	can	MD
cord-334454-cqaado3u	149	32	be	be	VB
cord-334454-cqaado3u	149	33	included	include	VBN
cord-334454-cqaado3u	149	34	in	in	IN
cord-334454-cqaado3u	149	35	future	future	JJ
cord-334454-cqaado3u	149	36	FIV	fiv	NN
cord-334454-cqaado3u	149	37	-	-	HYPH
cord-334454-cqaado3u	149	38	guidelines	guideline	NNS
cord-334454-cqaado3u	149	39	.	.	.
cord-334454-cqaado3u	150	1	In	in	IN
cord-334454-cqaado3u	150	2	summary	summary	NN
cord-334454-cqaado3u	150	3	,	,	,
cord-334454-cqaado3u	150	4	this	this	DT
cord-334454-cqaado3u	150	5	review	review	NN
cord-334454-cqaado3u	150	6	reinforces	reinforce	VBZ
cord-334454-cqaado3u	150	7	the	the	DT
cord-334454-cqaado3u	150	8	beneficial	beneficial	JJ
cord-334454-cqaado3u	150	9	properties	property	NNS
cord-334454-cqaado3u	150	10	of	of	IN
cord-334454-cqaado3u	150	11	IFN	IFN	NNP
cord-334454-cqaado3u	150	12	therapy	therapy	NN
cord-334454-cqaado3u	150	13	opening	open	VBG
cord-334454-cqaado3u	150	14	new	new	JJ
cord-334454-cqaado3u	150	15	perspectives	perspective	NNS
cord-334454-cqaado3u	150	16	for	for	IN
cord-334454-cqaado3u	150	17	its	-PRON-	PRP$
cord-334454-cqaado3u	150	18	use	use	NN
cord-334454-cqaado3u	150	19	in	in	IN
cord-334454-cqaado3u	150	20	retroviral	retroviral	JJ
cord-334454-cqaado3u	150	21	infections	infection	NNS
cord-334454-cqaado3u	150	22	.	.	.
cord-334454-cqaado3u	151	1	Even	even	RB
cord-334454-cqaado3u	151	2	if	if	IN
cord-334454-cqaado3u	151	3	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	151	4	-	-	HYPH
cord-334454-cqaado3u	151	5	ω	ω	NN
cord-334454-cqaado3u	151	6	is	be	VBZ
cord-334454-cqaado3u	151	7	a	a	DT
cord-334454-cqaado3u	151	8	species	species	NN
cord-334454-cqaado3u	151	9	-	-	HYPH
cord-334454-cqaado3u	151	10	specific	specific	JJ
cord-334454-cqaado3u	151	11	compound	compound	NN
cord-334454-cqaado3u	151	12	,	,	,
cord-334454-cqaado3u	151	13	these	these	DT
cord-334454-cqaado3u	151	14	conclusions	conclusion	NNS
cord-334454-cqaado3u	151	15	can	can	MD
cord-334454-cqaado3u	151	16	be	be	VB
cord-334454-cqaado3u	151	17	extrapolated	extrapolate	VBN
cord-334454-cqaado3u	151	18	to	to	IN
cord-334454-cqaado3u	151	19	a	a	DT
cord-334454-cqaado3u	151	20	larger	large	JJR
cord-334454-cqaado3u	151	21	perspective	perspective	NN
cord-334454-cqaado3u	151	22	.	.	.
cord-334454-cqaado3u	152	1	Either	either	CC
cord-334454-cqaado3u	152	2	in	in	IN
cord-334454-cqaado3u	152	3	FIV	fiv	NN
cord-334454-cqaado3u	152	4	-	-	HYPH
cord-334454-cqaado3u	152	5	infected	infect	VBN
cord-334454-cqaado3u	152	6	cats	cat	NNS
cord-334454-cqaado3u	152	7	or	or	CC
cord-334454-cqaado3u	152	8	in	in	IN
cord-334454-cqaado3u	152	9	HIV	HIV	NNP
cord-334454-cqaado3u	152	10	individuals	individual	NNS
cord-334454-cqaado3u	152	11	,	,	,
cord-334454-cqaado3u	152	12	type	type	NN
cord-334454-cqaado3u	152	13	I	-PRON-	PRP
cord-334454-cqaado3u	152	14	IFNs	ifns	VBP
cord-334454-cqaado3u	152	15	seem	seem	VBP
cord-334454-cqaado3u	152	16	to	to	TO
cord-334454-cqaado3u	152	17	induce	induce	VB
cord-334454-cqaado3u	152	18	an	an	DT
cord-334454-cqaado3u	152	19	innate	innate	JJ
cord-334454-cqaado3u	152	20	immune	immune	JJ
cord-334454-cqaado3u	152	21	-	-	HYPH
cord-334454-cqaado3u	152	22	modulation	modulation	NN
cord-334454-cqaado3u	152	23	and	and	CC
cord-334454-cqaado3u	152	24	should	should	MD
cord-334454-cqaado3u	152	25	not	not	RB
cord-334454-cqaado3u	152	26	be	be	VB
cord-334454-cqaado3u	152	27	overlooked	overlook	VBN
cord-334454-cqaado3u	152	28	as	as	IN
cord-334454-cqaado3u	152	29	a	a	DT
cord-334454-cqaado3u	152	30	therapeutic	therapeutic	JJ
cord-334454-cqaado3u	152	31	option	option	NN
cord-334454-cqaado3u	152	32	in	in	IN
cord-334454-cqaado3u	152	33	retroviral	retroviral	JJ
cord-334454-cqaado3u	152	34	infections	infection	NNS
cord-334454-cqaado3u	152	35	.	.	.
cord-334454-cqaado3u	153	1	Clinical	clinical	JJ
cord-334454-cqaado3u	153	2	aspects	aspect	NNS
cord-334454-cqaado3u	153	3	of	of	IN
cord-334454-cqaado3u	153	4	feline	feline	JJ
cord-334454-cqaado3u	153	5	retroviruses	retrovirus	NNS
cord-334454-cqaado3u	153	6	:	:	:
cord-334454-cqaado3u	153	7	A	a	DT
cord-334454-cqaado3u	153	8	review	review	NN
cord-334454-cqaado3u	153	9	Clinical	clinical	JJ
cord-334454-cqaado3u	153	10	aspects	aspect	NNS
cord-334454-cqaado3u	153	11	of	of	IN
cord-334454-cqaado3u	153	12	feline	feline	JJ
cord-334454-cqaado3u	153	13	immunodeficiency	immunodeficiency	NN
cord-334454-cqaado3u	153	14	and	and	CC
cord-334454-cqaado3u	153	15	feline	feline	JJ
cord-334454-cqaado3u	153	16	leukemia	leukemia	NN
cord-334454-cqaado3u	153	17	virus	virus	NN
cord-334454-cqaado3u	153	18	infection	infection	NN
cord-334454-cqaado3u	153	19	Efficacy	Efficacy	NNP
cord-334454-cqaado3u	153	20	of	of	IN
cord-334454-cqaado3u	153	21	antiviral	antiviral	JJ
cord-334454-cqaado3u	153	22	chemotherapy	chemotherapy	NN
cord-334454-cqaado3u	153	23	for	for	IN
cord-334454-cqaado3u	153	24	retrovirus	retrovirus	NN
cord-334454-cqaado3u	153	25	-	-	HYPH
cord-334454-cqaado3u	153	26	infected	infect	VBN
cord-334454-cqaado3u	153	27	cats	cat	NNS
cord-334454-cqaado3u	153	28	:	:	:
cord-334454-cqaado3u	153	29	What	what	WP
cord-334454-cqaado3u	153	30	does	do	VBZ
cord-334454-cqaado3u	153	31	the	the	DT
cord-334454-cqaado3u	153	32	current	current	JJ
cord-334454-cqaado3u	153	33	literature	literature	NN
cord-334454-cqaado3u	153	34	tell	tell	VB
cord-334454-cqaado3u	153	35	us	-PRON-	PRP
cord-334454-cqaado3u	153	36	?	?	.
cord-334454-cqaado3u	154	1	Chapter	chapter	NN
cord-334454-cqaado3u	154	2	2	2	CD
cord-334454-cqaado3u	154	3	:	:	:
cord-334454-cqaado3u	155	1	Antiviral	antiviral	JJ
cord-334454-cqaado3u	155	2	and	and	CC
cord-334454-cqaado3u	155	3	Immmunomodulatory	Immmunomodulatory	NNP
cord-334454-cqaado3u	155	4	Chemotherapy	Chemotherapy	NNP
cord-334454-cqaado3u	155	5	Interferon	Interferon	NNP
cord-334454-cqaado3u	155	6	-	-	HYPH
cord-334454-cqaado3u	155	7	inducible	inducible	JJ
cord-334454-cqaado3u	155	8	antiviral	antiviral	JJ
cord-334454-cqaado3u	155	9	effectors	effector	NNS
cord-334454-cqaado3u	156	1	IFN	IFN	NNP
cord-334454-cqaado3u	156	2	-	-	HYPH
cord-334454-cqaado3u	156	3	alpha	alpha	NN
cord-334454-cqaado3u	156	4	regulates	regulate	VBZ
cord-334454-cqaado3u	156	5	TLR	TLR	NNP
cord-334454-cqaado3u	156	6	-	-	HYPH
cord-334454-cqaado3u	156	7	dependent	dependent	JJ
cord-334454-cqaado3u	156	8	gene	gene	NN
cord-334454-cqaado3u	156	9	expression	expression	NN
cord-334454-cqaado3u	156	10	of	of	IN
cord-334454-cqaado3u	156	11	IFN	IFN	NNP
cord-334454-cqaado3u	156	12	-	-	HYPH
cord-334454-cqaado3u	156	13	alpha	alpha	NN
cord-334454-cqaado3u	156	14	,	,	,
cord-334454-cqaado3u	156	15	IFN	IFN	NNP
cord-334454-cqaado3u	156	16	-	-	HYPH
cord-334454-cqaado3u	156	17	beta	beta	NN
cord-334454-cqaado3u	156	18	,	,	,
cord-334454-cqaado3u	156	19	IL-28	IL-28	NNP
cord-334454-cqaado3u	156	20	,	,	,
cord-334454-cqaado3u	156	21	and	and	CC
cord-334454-cqaado3u	156	22	IL-29	IL-29	NNP
cord-334454-cqaado3u	156	23	Plasmacytoid	Plasmacytoid	NNP
cord-334454-cqaado3u	156	24	dendritic	dendritic	JJ
cord-334454-cqaado3u	156	25	cells	cell	NNS
cord-334454-cqaado3u	156	26	in	in	IN
cord-334454-cqaado3u	156	27	immunity	immunity	NN
cord-334454-cqaado3u	156	28	Activity	activity	NN
cord-334454-cqaado3u	156	29	of	of	IN
cord-334454-cqaado3u	156	30	feline	feline	JJ
cord-334454-cqaado3u	156	31	interferon	interferon	NN
cord-334454-cqaado3u	156	32	-	-	HYPH
cord-334454-cqaado3u	156	33	omega	omega	NN
cord-334454-cqaado3u	156	34	after	after	IN
cord-334454-cqaado3u	156	35	ocular	ocular	JJ
cord-334454-cqaado3u	156	36	or	or	CC
cord-334454-cqaado3u	156	37	oral	oral	JJ
cord-334454-cqaado3u	156	38	administration	administration	NN
cord-334454-cqaado3u	156	39	in	in	IN
cord-334454-cqaado3u	156	40	cats	cat	NNS
cord-334454-cqaado3u	156	41	as	as	IN
cord-334454-cqaado3u	156	42	indicated	indicate	VBN
cord-334454-cqaado3u	156	43	by	by	IN
cord-334454-cqaado3u	156	44	Mx	Mx	NNP
cord-334454-cqaado3u	156	45	protein	protein	NN
cord-334454-cqaado3u	156	46	expression	expression	NN
cord-334454-cqaado3u	156	47	in	in	IN
cord-334454-cqaado3u	156	48	conjunctival	conjunctival	NN
cord-334454-cqaado3u	156	49	and	and	CC
cord-334454-cqaado3u	156	50	white	white	JJ
cord-334454-cqaado3u	156	51	blood	blood	NN
cord-334454-cqaado3u	156	52	cells	cell	NNS
cord-334454-cqaado3u	156	53	Interferons	interferon	NNS
cord-334454-cqaado3u	156	54	:	:	:
cord-334454-cqaado3u	156	55	Cell	cell	NN
cord-334454-cqaado3u	156	56	signalling	signalling	NN
cord-334454-cqaado3u	156	57	,	,	,
cord-334454-cqaado3u	156	58	immune	immune	JJ
cord-334454-cqaado3u	156	59	modulation	modulation	NN
cord-334454-cqaado3u	156	60	,	,	,
cord-334454-cqaado3u	156	61	antiviral	antiviral	JJ
cord-334454-cqaado3u	156	62	response	response	NN
cord-334454-cqaado3u	156	63	and	and	CC
cord-334454-cqaado3u	156	64	virus	virus	NN
cord-334454-cqaado3u	156	65	countermeasures	countermeasure	NNS
cord-334454-cqaado3u	156	66	Type	type	NN
cord-334454-cqaado3u	157	1	I	-PRON-	PRP
cord-334454-cqaado3u	158	1	interferon	interferon	NN
cord-334454-cqaado3u	158	2	responses	response	NNS
cord-334454-cqaado3u	158	3	in	in	IN
cord-334454-cqaado3u	158	4	rhesus	rhesu	NNS
cord-334454-cqaado3u	158	5	macaques	macaque	NNS
cord-334454-cqaado3u	158	6	prevent	prevent	VBP
cord-334454-cqaado3u	158	7	SIV	SIV	NNP
cord-334454-cqaado3u	158	8	infection	infection	NN
cord-334454-cqaado3u	158	9	and	and	CC
cord-334454-cqaado3u	158	10	slow	slow	JJ
cord-334454-cqaado3u	158	11	disease	disease	NN
cord-334454-cqaado3u	158	12	progression	progression	NN
cord-334454-cqaado3u	158	13	HIV-1	HIV-1	NNP
cord-334454-cqaado3u	158	14	and	and	CC
cord-334454-cqaado3u	158	15	interferons	interferon	NNS
cord-334454-cqaado3u	158	16	:	:	:
cord-334454-cqaado3u	159	1	Who	who	WP
cord-334454-cqaado3u	159	2	's	be	VBZ
cord-334454-cqaado3u	159	3	interfering	interfere	VBG
cord-334454-cqaado3u	159	4	with	with	IN
cord-334454-cqaado3u	159	5	whom	whom	WP
cord-334454-cqaado3u	159	6	?	?	.
cord-334454-cqaado3u	160	1	APOBEC3	APOBEC3	NNP
cord-334454-cqaado3u	161	1	G	g	NN
cord-334454-cqaado3u	161	2	upregulation	upregulation	NN
cord-334454-cqaado3u	161	3	by	by	IN
cord-334454-cqaado3u	161	4	alpha	alpha	NN
cord-334454-cqaado3u	161	5	interferon	interferon	NN
cord-334454-cqaado3u	161	6	restricts	restrict	VBZ
cord-334454-cqaado3u	161	7	human	human	JJ
cord-334454-cqaado3u	161	8	immunodeficiency	immunodeficiency	NN
cord-334454-cqaado3u	161	9	virus	virus	NN
cord-334454-cqaado3u	161	10	type	type	NN
cord-334454-cqaado3u	161	11	1	1	CD
cord-334454-cqaado3u	161	12	infection	infection	NN
cord-334454-cqaado3u	161	13	in	in	IN
cord-334454-cqaado3u	161	14	human	human	JJ
cord-334454-cqaado3u	161	15	peripheral	peripheral	JJ
cord-334454-cqaado3u	161	16	plasmacytoid	plasmacytoid	NNP
cord-334454-cqaado3u	161	17	dendritic	dendritic	JJ
cord-334454-cqaado3u	161	18	cells	cell	NNS
cord-334454-cqaado3u	162	1	HIV	HIV	NNP
cord-334454-cqaado3u	162	2	replication	replication	NN
cord-334454-cqaado3u	162	3	can	can	MD
cord-334454-cqaado3u	162	4	be	be	VB
cord-334454-cqaado3u	162	5	blocked	block	VBN
cord-334454-cqaado3u	162	6	by	by	IN
cord-334454-cqaado3u	162	7	recombinant	recombinant	JJ
cord-334454-cqaado3u	162	8	human	human	JJ
cord-334454-cqaado3u	162	9	interferon	interferon	NN
cord-334454-cqaado3u	162	10	beta	beta	NN
cord-334454-cqaado3u	162	11	Cohorts	Cohorts	NNPS
cord-334454-cqaado3u	162	12	for	for	IN
cord-334454-cqaado3u	162	13	the	the	DT
cord-334454-cqaado3u	162	14	study	study	NN
cord-334454-cqaado3u	162	15	of	of	IN
cord-334454-cqaado3u	162	16	HIV-1-exposed	hiv-1-exposed	JJ
cord-334454-cqaado3u	162	17	but	but	CC
cord-334454-cqaado3u	162	18	uninfected	uninfected	JJ
cord-334454-cqaado3u	162	19	individuals	individual	NNS
cord-334454-cqaado3u	162	20	:	:	:
cord-334454-cqaado3u	162	21	Benefits	benefit	NNS
cord-334454-cqaado3u	162	22	and	and	CC
cord-334454-cqaado3u	162	23	limitations	limitation	NNS
cord-334454-cqaado3u	162	24	Interferon	Interferon	NNP
cord-334454-cqaado3u	162	25	responses	response	NNS
cord-334454-cqaado3u	162	26	in	in	IN
cord-334454-cqaado3u	162	27	HIV	HIV	NNP
cord-334454-cqaado3u	162	28	infection	infection	NN
cord-334454-cqaado3u	162	29	:	:	:
cord-334454-cqaado3u	162	30	From	from	IN
cord-334454-cqaado3u	162	31	protection	protection	NN
cord-334454-cqaado3u	162	32	to	to	IN
cord-334454-cqaado3u	162	33	disease	disease	NN
cord-334454-cqaado3u	162	34	Pegylated	pegylate	VBN
cord-334454-cqaado3u	163	1	Interferon	interferon	NN
cord-334454-cqaado3u	164	1	alfa-2a	alfa-2a	NNP
cord-334454-cqaado3u	164	2	monotherapy	monotherapy	NN
cord-334454-cqaado3u	164	3	results	result	VBZ
cord-334454-cqaado3u	164	4	in	in	IN
cord-334454-cqaado3u	164	5	suppression	suppression	NN
cord-334454-cqaado3u	164	6	of	of	IN
cord-334454-cqaado3u	164	7	HIV	HIV	NNP
cord-334454-cqaado3u	164	8	type	type	NN
cord-334454-cqaado3u	164	9	1	1	CD
cord-334454-cqaado3u	164	10	replication	replication	NN
cord-334454-cqaado3u	164	11	and	and	CC
cord-334454-cqaado3u	164	12	decreased	decrease	VBD
cord-334454-cqaado3u	164	13	cell	cell	NN
cord-334454-cqaado3u	164	14	-	-	HYPH
cord-334454-cqaado3u	164	15	associated	associate	VBN
cord-334454-cqaado3u	164	16	HIV	HIV	NNP
cord-334454-cqaado3u	164	17	DNA	dna	NN
cord-334454-cqaado3u	164	18	integration	integration	NN
cord-334454-cqaado3u	164	19	Use	use	NN
cord-334454-cqaado3u	164	20	of	of	IN
cord-334454-cqaado3u	164	21	recombinant	recombinant	JJ
cord-334454-cqaado3u	164	22	interferon	interferon	NN
cord-334454-cqaado3u	164	23	omega	omega	NN
cord-334454-cqaado3u	164	24	in	in	IN
cord-334454-cqaado3u	164	25	feline	feline	JJ
cord-334454-cqaado3u	164	26	retrovirosis	retrovirosis	NN
cord-334454-cqaado3u	164	27	:	:	:
cord-334454-cqaado3u	164	28	From	from	IN
cord-334454-cqaado3u	164	29	theory	theory	NN
cord-334454-cqaado3u	164	30	to	to	TO
cord-334454-cqaado3u	164	31	practice	practice	VB
cord-334454-cqaado3u	164	32	Therapeutic	therapeutic	JJ
cord-334454-cqaado3u	164	33	effects	effect	NNS
cord-334454-cqaado3u	164	34	of	of	IN
cord-334454-cqaado3u	164	35	recombinant	recombinant	JJ
cord-334454-cqaado3u	164	36	feline	feline	JJ
cord-334454-cqaado3u	164	37	interferon	interferon	NN
cord-334454-cqaado3u	164	38	-	-	HYPH
cord-334454-cqaado3u	164	39	omega	omega	NN
cord-334454-cqaado3u	164	40	on	on	IN
cord-334454-cqaado3u	164	41	feline	feline	JJ
cord-334454-cqaado3u	164	42	leukemia	leukemia	NN
cord-334454-cqaado3u	164	43	virus	virus	NN
cord-334454-cqaado3u	164	44	(	(	-LRB-
cord-334454-cqaado3u	164	45	FeLV)-infected	felv)-infecte	VBN
cord-334454-cqaado3u	164	46	and	and	CC
cord-334454-cqaado3u	164	47	FeLV	FeLV	NNP
cord-334454-cqaado3u	164	48	/	/	SYM
cord-334454-cqaado3u	164	49	feline	feline	JJ
cord-334454-cqaado3u	164	50	immunodeficiency	immunodeficiency	NN
cord-334454-cqaado3u	164	51	virus	virus	NN
cord-334454-cqaado3u	164	52	(	(	-LRB-
cord-334454-cqaado3u	164	53	FIV)-coinfected	fiv)-coinfecte	VBN
cord-334454-cqaado3u	164	54	symptomatic	symptomatic	JJ
cord-334454-cqaado3u	164	55	cats	cat	NNS
cord-334454-cqaado3u	164	56	Immunomodulation	Immunomodulation	NNP
cord-334454-cqaado3u	164	57	and	and	CC
cord-334454-cqaado3u	164	58	therapeutic	therapeutic	JJ
cord-334454-cqaado3u	164	59	effects	effect	NNS
cord-334454-cqaado3u	164	60	of	of	IN
cord-334454-cqaado3u	164	61	the	the	DT
cord-334454-cqaado3u	164	62	oral	oral	JJ
cord-334454-cqaado3u	164	63	use	use	NN
cord-334454-cqaado3u	164	64	of	of	IN
cord-334454-cqaado3u	164	65	interferon	interferon	NN
cord-334454-cqaado3u	164	66	-	-	HYPH
cord-334454-cqaado3u	164	67	alpha	alpha	NN
cord-334454-cqaado3u	164	68	:	:	:
cord-334454-cqaado3u	164	69	Mechanism	mechanism	NN
cord-334454-cqaado3u	164	70	of	of	IN
cord-334454-cqaado3u	164	71	action	action	NN
cord-334454-cqaado3u	164	72	Susceptibility	susceptibility	NN
cord-334454-cqaado3u	164	73	of	of	IN
cord-334454-cqaado3u	164	74	feline	feline	JJ
cord-334454-cqaado3u	164	75	herpesvirus	herpesvirus	NN
cord-334454-cqaado3u	164	76	1	1	CD
cord-334454-cqaado3u	164	77	and	and	CC
cord-334454-cqaado3u	164	78	a	a	DT
cord-334454-cqaado3u	164	79	feline	feline	JJ
cord-334454-cqaado3u	164	80	calicivirus	calicivirus	NN
cord-334454-cqaado3u	164	81	to	to	IN
cord-334454-cqaado3u	164	82	feline	feline	JJ
cord-334454-cqaado3u	164	83	interferon	interferon	NN
cord-334454-cqaado3u	164	84	and	and	CC
cord-334454-cqaado3u	164	85	recombinant	recombinant	JJ
cord-334454-cqaado3u	164	86	human	human	JJ
cord-334454-cqaado3u	164	87	leukocyte	leukocyte	NN
cord-334454-cqaado3u	164	88	interferons	interferon	NNS
cord-334454-cqaado3u	164	89	Low	low	JJ
cord-334454-cqaado3u	164	90	-	-	HYPH
cord-334454-cqaado3u	164	91	dose	dose	NN
cord-334454-cqaado3u	164	92	interferon	interferon	NN
cord-334454-cqaado3u	164	93	-	-	HYPH
cord-334454-cqaado3u	164	94	alpha	alpha	NN
cord-334454-cqaado3u	164	95	treatment	treatment	NN
cord-334454-cqaado3u	164	96	for	for	IN
cord-334454-cqaado3u	164	97	feline	feline	JJ
cord-334454-cqaado3u	164	98	immunodeficiency	immunodeficiency	NN
cord-334454-cqaado3u	164	99	virus	virus	NN
cord-334454-cqaado3u	164	100	infection	infection	NN
cord-334454-cqaado3u	164	101	Inhibitory	inhibitory	JJ
cord-334454-cqaado3u	164	102	effects	effect	NNS
cord-334454-cqaado3u	164	103	of	of	IN
cord-334454-cqaado3u	164	104	ribavirin	ribavirin	NN
cord-334454-cqaado3u	164	105	alone	alone	RB
cord-334454-cqaado3u	164	106	or	or	CC
cord-334454-cqaado3u	164	107	combined	combine	VBN
cord-334454-cqaado3u	164	108	with	with	IN
cord-334454-cqaado3u	164	109	human	human	JJ
cord-334454-cqaado3u	164	110	alpha	alpha	NN
cord-334454-cqaado3u	164	111	interferon	interferon	NN
cord-334454-cqaado3u	164	112	on	on	IN
cord-334454-cqaado3u	164	113	feline	feline	JJ
cord-334454-cqaado3u	164	114	infectious	infectious	JJ
cord-334454-cqaado3u	164	115	peritonitis	peritonitis	NN
cord-334454-cqaado3u	164	116	virus	virus	NN
cord-334454-cqaado3u	164	117	replication	replication	NN
cord-334454-cqaado3u	164	118	in	in	IN
cord-334454-cqaado3u	164	119	vitro	vitro	FW
cord-334454-cqaado3u	165	1	Alpha	alpha	NN
cord-334454-cqaado3u	165	2	interferon	interferon	NN
cord-334454-cqaado3u	165	3	(	(	-LRB-
cord-334454-cqaado3u	165	4	2b	2b	LS
cord-334454-cqaado3u	165	5	)	)	-RRB-
cord-334454-cqaado3u	165	6	in	in	IN
cord-334454-cqaado3u	165	7	combination	combination	NN
cord-334454-cqaado3u	165	8	with	with	IN
cord-334454-cqaado3u	165	9	zidovudine	zidovudine	NN
cord-334454-cqaado3u	165	10	for	for	IN
cord-334454-cqaado3u	165	11	the	the	DT
cord-334454-cqaado3u	165	12	treatment	treatment	NN
cord-334454-cqaado3u	165	13	of	of	IN
cord-334454-cqaado3u	165	14	presymptomatic	presymptomatic	JJ
cord-334454-cqaado3u	165	15	feline	feline	JJ
cord-334454-cqaado3u	165	16	leukemia	leukemia	NN
cord-334454-cqaado3u	165	17	virus	virus	NN
cord-334454-cqaado3u	165	18	-	-	HYPH
cord-334454-cqaado3u	165	19	induced	induce	VBN
cord-334454-cqaado3u	165	20	immunodeficiency	immunodeficiency	NN
cord-334454-cqaado3u	165	21	syndrome	syndrome	NN
cord-334454-cqaado3u	165	22	Antiviral	antiviral	JJ
cord-334454-cqaado3u	165	23	potency	potency	NN
cord-334454-cqaado3u	165	24	of	of	IN
cord-334454-cqaado3u	165	25	interferon	interferon	NN
cord-334454-cqaado3u	165	26	omega	omega	NN
cord-334454-cqaado3u	165	27	against	against	IN
cord-334454-cqaado3u	165	28	selected	select	VBN
cord-334454-cqaado3u	165	29	canine	canine	JJ
cord-334454-cqaado3u	165	30	and	and	CC
cord-334454-cqaado3u	165	31	feline	feline	JJ
cord-334454-cqaado3u	165	32	viruses	virus	NNS
cord-334454-cqaado3u	165	33	Oral	oral	JJ
cord-334454-cqaado3u	165	34	Recombinant	recombinant	JJ
cord-334454-cqaado3u	165	35	Feline	Feline	NNP
cord-334454-cqaado3u	165	36	Interferon	Interferon	NNP
cord-334454-cqaado3u	165	37	-	-	HYPH
cord-334454-cqaado3u	165	38	Omega	Omega	NNP
cord-334454-cqaado3u	165	39	as	as	IN
cord-334454-cqaado3u	165	40	an	an	DT
cord-334454-cqaado3u	165	41	alternative	alternative	JJ
cord-334454-cqaado3u	165	42	immune	immune	JJ
cord-334454-cqaado3u	165	43	modulation	modulation	NN
cord-334454-cqaado3u	165	44	therapy	therapy	NN
cord-334454-cqaado3u	165	45	in	in	IN
cord-334454-cqaado3u	165	46	FIV	FIV	NNP
cord-334454-cqaado3u	165	47	positive	positive	JJ
cord-334454-cqaado3u	165	48	cats	cat	NNS
cord-334454-cqaado3u	165	49	:	:	:
cord-334454-cqaado3u	166	1	Clinical	clinical	JJ
cord-334454-cqaado3u	166	2	and	and	CC
cord-334454-cqaado3u	166	3	laboratory	laboratory	NN
cord-334454-cqaado3u	166	4	evaluation	evaluation	NN
cord-334454-cqaado3u	166	5	Relevance	relevance	NN
cord-334454-cqaado3u	166	6	of	of	IN
cord-334454-cqaado3u	166	7	feline	feline	JJ
cord-334454-cqaado3u	166	8	interferon	interferon	NN
cord-334454-cqaado3u	166	9	omega	omega	NN
cord-334454-cqaado3u	166	10	for	for	IN
cord-334454-cqaado3u	166	11	clinical	clinical	JJ
cord-334454-cqaado3u	166	12	improvement	improvement	NN
cord-334454-cqaado3u	166	13	and	and	CC
cord-334454-cqaado3u	166	14	reduction	reduction	NN
cord-334454-cqaado3u	166	15	of	of	IN
cord-334454-cqaado3u	166	16	concurrent	concurrent	JJ
cord-334454-cqaado3u	166	17	viral	viral	JJ
cord-334454-cqaado3u	166	18	excretion	excretion	NN
cord-334454-cqaado3u	166	19	in	in	IN
cord-334454-cqaado3u	166	20	retrovirus	retrovirus	NN
cord-334454-cqaado3u	166	21	infected	infect	VBN
cord-334454-cqaado3u	166	22	cats	cat	NNS
cord-334454-cqaado3u	166	23	from	from	IN
cord-334454-cqaado3u	166	24	a	a	DT
cord-334454-cqaado3u	166	25	rescue	rescue	NN
cord-334454-cqaado3u	166	26	shelter	shelter	NN
cord-334454-cqaado3u	166	27	Evaluation	Evaluation	NNP
cord-334454-cqaado3u	166	28	of	of	IN
cord-334454-cqaado3u	166	29	viremia	viremia	NNP
cord-334454-cqaado3u	166	30	,	,	,
cord-334454-cqaado3u	166	31	proviral	proviral	NNP
cord-334454-cqaado3u	166	32	load	load	NN
cord-334454-cqaado3u	166	33	and	and	CC
cord-334454-cqaado3u	166	34	cytokine	cytokine	NN
cord-334454-cqaado3u	166	35	profile	profile	NN
cord-334454-cqaado3u	166	36	in	in	IN
cord-334454-cqaado3u	166	37	naturally	naturally	RB
cord-334454-cqaado3u	166	38	feline	feline	JJ
cord-334454-cqaado3u	166	39	immunodeficiency	immunodeficiency	NN
cord-334454-cqaado3u	166	40	virus	virus	NN
cord-334454-cqaado3u	166	41	infected	infect	VBN
cord-334454-cqaado3u	166	42	cats	cat	NNS
cord-334454-cqaado3u	166	43	treated	treat	VBN
cord-334454-cqaado3u	166	44	with	with	IN
cord-334454-cqaado3u	166	45	two	two	CD
cord-334454-cqaado3u	166	46	different	different	JJ
cord-334454-cqaado3u	166	47	protocols	protocol	NNS
cord-334454-cqaado3u	166	48	of	of	IN
cord-334454-cqaado3u	166	49	recombinant	recombinant	JJ
cord-334454-cqaado3u	166	50	feline	feline	JJ
cord-334454-cqaado3u	166	51	interferon	interferon	NN
cord-334454-cqaado3u	166	52	omega	omega	NNP
cord-334454-cqaado3u	166	53	Monitoring	Monitoring	NNP
cord-334454-cqaado3u	166	54	acute	acute	JJ
cord-334454-cqaado3u	166	55	phase	phase	NN
cord-334454-cqaado3u	166	56	proteins	protein	NNS
cord-334454-cqaado3u	166	57	in	in	IN
cord-334454-cqaado3u	166	58	retrovirus	retrovirus	NN
cord-334454-cqaado3u	166	59	infected	infect	VBN
cord-334454-cqaado3u	166	60	cats	cat	NNS
cord-334454-cqaado3u	166	61	undergoing	undergo	VBG
cord-334454-cqaado3u	166	62	feline	feline	JJ
cord-334454-cqaado3u	166	63	interferon	interferon	NN
cord-334454-cqaado3u	166	64	-	-	HYPH
cord-334454-cqaado3u	166	65	ω	ω	VBG
cord-334454-cqaado3u	166	66	therapy	therapy	NN
cord-334454-cqaado3u	167	1	The	the	DT
cord-334454-cqaado3u	167	2	acute	acute	JJ
cord-334454-cqaado3u	167	3	-	-	HYPH
cord-334454-cqaado3u	167	4	phase	phase	NN
cord-334454-cqaado3u	167	5	protein	protein	NN
cord-334454-cqaado3u	167	6	response	response	NN
cord-334454-cqaado3u	167	7	to	to	IN
cord-334454-cqaado3u	167	8	human	human	JJ
cord-334454-cqaado3u	167	9	immunodeficiency	immunodeficiency	NN
cord-334454-cqaado3u	167	10	virus	virus	NN
cord-334454-cqaado3u	167	11	infection	infection	NN
cord-334454-cqaado3u	167	12	in	in	IN
cord-334454-cqaado3u	167	13	human	human	JJ
cord-334454-cqaado3u	167	14	subjects	subject	NNS
cord-334454-cqaado3u	168	1	Lipid	lipid	NN
cord-334454-cqaado3u	168	2	and	and	CC
cord-334454-cqaado3u	168	3	acute	acute	JJ
cord-334454-cqaado3u	168	4	-	-	HYPH
cord-334454-cqaado3u	168	5	phase	phase	NN
cord-334454-cqaado3u	168	6	protein	protein	NN
cord-334454-cqaado3u	168	7	alterations	alteration	NNS
cord-334454-cqaado3u	168	8	in	in	IN
cord-334454-cqaado3u	168	9	HIV-1	HIV-1	NNP
cord-334454-cqaado3u	168	10	infected	infect	VBD
cord-334454-cqaado3u	168	11	patients	patient	NNS
cord-334454-cqaado3u	168	12	in	in	IN
cord-334454-cqaado3u	168	13	the	the	DT
cord-334454-cqaado3u	168	14	early	early	JJ
cord-334454-cqaado3u	168	15	stages	stage	NNS
cord-334454-cqaado3u	168	16	of	of	IN
cord-334454-cqaado3u	168	17	infection	infection	NN
cord-334454-cqaado3u	168	18	:	:	:
cord-334454-cqaado3u	169	1	Correlation	correlation	NN
cord-334454-cqaado3u	169	2	with	with	IN
cord-334454-cqaado3u	169	3	CD4	CD4	NNP
cord-334454-cqaado3u	169	4	+	+	CC
cord-334454-cqaado3u	169	5	lymphocytes	lymphocyte	NNS
cord-334454-cqaado3u	169	6	.	.	.
cord-334454-cqaado3u	170	1	Braz	Braz	NNP
cord-334454-cqaado3u	170	2	Changes	change	NNS
cord-334454-cqaado3u	170	3	in	in	IN
cord-334454-cqaado3u	170	4	the	the	DT
cord-334454-cqaado3u	170	5	levels	level	NNS
cord-334454-cqaado3u	170	6	of	of	IN
cord-334454-cqaado3u	170	7	some	some	DT
cord-334454-cqaado3u	170	8	acute	acute	JJ
cord-334454-cqaado3u	170	9	-	-	HYPH
cord-334454-cqaado3u	170	10	phase	phase	NN
cord-334454-cqaado3u	170	11	proteins	protein	NNS
cord-334454-cqaado3u	170	12	in	in	IN
cord-334454-cqaado3u	170	13	human	human	JJ
cord-334454-cqaado3u	170	14	immunodeficiency	immunodeficiency	NN
cord-334454-cqaado3u	170	15	virus-1	virus-1	NN
cord-334454-cqaado3u	170	16	infected	infect	VBN
cord-334454-cqaado3u	170	17	patients	patient	NNS
cord-334454-cqaado3u	170	18	,	,	,
cord-334454-cqaado3u	170	19	following	follow	VBG
cord-334454-cqaado3u	170	20	interleukin-2	interleukin-2	IN
cord-334454-cqaado3u	170	21	treatment	treatment	NN
cord-334454-cqaado3u	170	22	Feline	feline	JJ
cord-334454-cqaado3u	170	23	immunodeficiency	immunodeficiency	NN
cord-334454-cqaado3u	170	24	.	.	.
cord-334454-cqaado3u	171	1	ABCD	ABCD	NNP
cord-334454-cqaado3u	171	2	guidelines	guideline	NNS
cord-334454-cqaado3u	171	3	on	on	IN
cord-334454-cqaado3u	171	4	prevention	prevention	NN
cord-334454-cqaado3u	171	5	and	and	CC
cord-334454-cqaado3u	171	6	management	management	NN
cord-334454-cqaado3u	171	7	Acute	acute	NN
cord-334454-cqaado3u	171	8	phase	phase	NN
cord-334454-cqaado3u	171	9	proteins	protein	NNS
cord-334454-cqaado3u	171	10	in	in	IN
cord-334454-cqaado3u	171	11	dogs	dog	NNS
cord-334454-cqaado3u	171	12	and	and	CC
cord-334454-cqaado3u	171	13	cats	cat	NNS
cord-334454-cqaado3u	171	14	:	:	:
cord-334454-cqaado3u	172	1	Current	current	JJ
cord-334454-cqaado3u	172	2	knowledge	knowledge	NN
cord-334454-cqaado3u	172	3	and	and	CC
cord-334454-cqaado3u	172	4	future	future	JJ
cord-334454-cqaado3u	172	5	perspectives	perspective	NNS
cord-334454-cqaado3u	173	1	The	the	DT
cord-334454-cqaado3u	173	2	feline	feline	JJ
cord-334454-cqaado3u	173	3	acute	acute	JJ
cord-334454-cqaado3u	173	4	phase	phase	NN
cord-334454-cqaado3u	173	5	reaction	reaction	NN
cord-334454-cqaado3u	174	1	The	the	DT
cord-334454-cqaado3u	174	2	innate	innate	JJ
cord-334454-cqaado3u	174	3	antiviral	antiviral	JJ
cord-334454-cqaado3u	174	4	immune	immune	JJ
cord-334454-cqaado3u	174	5	system	system	NN
cord-334454-cqaado3u	174	6	of	of	IN
cord-334454-cqaado3u	174	7	the	the	DT
cord-334454-cqaado3u	174	8	cat	cat	NN
cord-334454-cqaado3u	174	9	:	:	:
cord-334454-cqaado3u	175	1	Molecular	molecular	JJ
cord-334454-cqaado3u	175	2	tools	tool	NNS
cord-334454-cqaado3u	175	3	for	for	IN
cord-334454-cqaado3u	175	4	the	the	DT
cord-334454-cqaado3u	175	5	measurement	measurement	NN
cord-334454-cqaado3u	175	6	of	of	IN
cord-334454-cqaado3u	175	7	its	-PRON-	PRP$
cord-334454-cqaado3u	175	8	state	state	NN
cord-334454-cqaado3u	175	9	of	of	IN
cord-334454-cqaado3u	175	10	activation	activation	NN
cord-334454-cqaado3u	175	11	Comparative	comparative	JJ
cord-334454-cqaado3u	175	12	efficacy	efficacy	NN
cord-334454-cqaado3u	175	13	of	of	IN
cord-334454-cqaado3u	175	14	a	a	DT
cord-334454-cqaado3u	175	15	recombinant	recombinant	JJ
cord-334454-cqaado3u	175	16	feline	feline	JJ
cord-334454-cqaado3u	175	17	interferon	interferon	NN
cord-334454-cqaado3u	175	18	omega	omega	NN
cord-334454-cqaado3u	175	19	in	in	IN
cord-334454-cqaado3u	175	20	refractory	refractory	JJ
cord-334454-cqaado3u	175	21	cases	case	NNS
cord-334454-cqaado3u	175	22	of	of	IN
cord-334454-cqaado3u	175	23	calicivirus	calicivirus	JJ
cord-334454-cqaado3u	175	24	-	-	HYPH
cord-334454-cqaado3u	175	25	positive	positive	JJ
cord-334454-cqaado3u	175	26	cats	cat	NNS
cord-334454-cqaado3u	175	27	with	with	IN
cord-334454-cqaado3u	175	28	caudal	caudal	JJ
cord-334454-cqaado3u	175	29	stomatitis	stomatitis	NN
cord-334454-cqaado3u	175	30	:	:	:
cord-334454-cqaado3u	175	31	A	a	DT
cord-334454-cqaado3u	175	32	randomised	randomised	JJ
cord-334454-cqaado3u	175	33	,	,	,
cord-334454-cqaado3u	175	34	multi	multi	JJ
cord-334454-cqaado3u	175	35	-	-	JJ
cord-334454-cqaado3u	175	36	centre	centre	JJ
cord-334454-cqaado3u	175	37	,	,	,
cord-334454-cqaado3u	175	38	controlled	control	VBN
cord-334454-cqaado3u	175	39	,	,	,
cord-334454-cqaado3u	175	40	double	double	JJ
cord-334454-cqaado3u	175	41	-	-	HYPH
cord-334454-cqaado3u	175	42	blind	blind	JJ
cord-334454-cqaado3u	175	43	study	study	NN
cord-334454-cqaado3u	175	44	in	in	IN
cord-334454-cqaado3u	175	45	39	39	CD
cord-334454-cqaado3u	175	46	cats	cat	NNS
cord-334454-cqaado3u	176	1	The	the	DT
cord-334454-cqaado3u	176	2	research	research	NN
cord-334454-cqaado3u	176	3	work	work	NN
cord-334454-cqaado3u	176	4	that	that	WDT
cord-334454-cqaado3u	176	5	conducted	conduct	VBD
cord-334454-cqaado3u	176	6	to	to	IN
cord-334454-cqaado3u	176	7	the	the	DT
cord-334454-cqaado3u	176	8	mentioned	mention	VBN
cord-334454-cqaado3u	176	9	conclusions	conclusion	NNS
cord-334454-cqaado3u	176	10	was	be	VBD
cord-334454-cqaado3u	176	11	part	part	NN
cord-334454-cqaado3u	176	12	of	of	IN
cord-334454-cqaado3u	176	13	the	the	DT
cord-334454-cqaado3u	176	14	PhD	phd	NN
cord-334454-cqaado3u	176	15	project	project	NN
cord-334454-cqaado3u	176	16	of	of	IN
cord-334454-cqaado3u	176	17	Rodolfo	Rodolfo	NNP
cord-334454-cqaado3u	176	18	Oliveira	Oliveira	NNP
cord-334454-cqaado3u	176	19	Leal	Leal	NNP
cord-334454-cqaado3u	176	20	.	.	.
cord-334454-cqaado3u	177	1	This	this	DT
cord-334454-cqaado3u	177	2	project	project	NN
cord-334454-cqaado3u	177	3	was	be	VBD
cord-334454-cqaado3u	177	4	kindly	kindly	RB
cord-334454-cqaado3u	177	5	sponsored	sponsor	VBN
cord-334454-cqaado3u	177	6	by	by	IN
cord-334454-cqaado3u	177	7	FCT	FCT	NNP
cord-334454-cqaado3u	177	8	(	(	-LRB-
cord-334454-cqaado3u	177	9	Fundação	Fundação	NNP
cord-334454-cqaado3u	177	10	para	para	NNP
cord-334454-cqaado3u	178	1	a	a	DT
cord-334454-cqaado3u	178	2	Ciência	Ciência	NNP
cord-334454-cqaado3u	178	3	e	e	NN
cord-334454-cqaado3u	178	4	Tecnologia	Tecnologia	NNP
cord-334454-cqaado3u	178	5	-	-	HYPH
cord-334454-cqaado3u	178	6	PhD	PhD	NNP
cord-334454-cqaado3u	178	7	grant	grant	NN
cord-334454-cqaado3u	178	8	BD/62917/2009	BD/62917/2009	NNP
cord-334454-cqaado3u	178	9	)	)	-RRB-
cord-334454-cqaado3u	178	10	and	and	CC
cord-334454-cqaado3u	178	11	CIISA	CIISA	NNP
cord-334454-cqaado3u	179	1	(	(	-LRB-
cord-334454-cqaado3u	179	2	Centro	Centro	NNP
cord-334454-cqaado3u	179	3	de	de	FW
cord-334454-cqaado3u	179	4	Investigação	Investigação	NNP
cord-334454-cqaado3u	179	5	Interdisciplinar	Interdisciplinar	NNP
cord-334454-cqaado3u	179	6	em	-PRON-	NNP
cord-334454-cqaado3u	179	7	Sanidade	Sanidade	NNP
cord-334454-cqaado3u	179	8	Animal	Animal	NNP
cord-334454-cqaado3u	179	9	)	)	-RRB-
cord-334454-cqaado3u	179	10	of	of	IN
cord-334454-cqaado3u	179	11	the	the	DT
cord-334454-cqaado3u	179	12	FMV	FMV	NNP
cord-334454-cqaado3u	179	13	-	-	HYPH
cord-334454-cqaado3u	179	14	ULisboa	ULisboa	NNP
cord-334454-cqaado3u	179	15	and	and	CC
cord-334454-cqaado3u	179	16	Virbac	Virbac	NNP
cord-334454-cqaado3u	179	17	company	company	NN
cord-334454-cqaado3u	179	18	.	.	.
cord-334454-cqaado3u	180	1	Author	Author	NNP
cord-334454-cqaado3u	180	2	Contributions	contribution	NNS
cord-334454-cqaado3u	180	3	:	:	:
cord-334454-cqaado3u	180	4	This	this	DT
cord-334454-cqaado3u	180	5	review	review	NN
cord-334454-cqaado3u	180	6	was	be	VBD
cord-334454-cqaado3u	180	7	entirely	entirely	RB
cord-334454-cqaado3u	180	8	written	write	VBN
cord-334454-cqaado3u	180	9	by	by	IN
cord-334454-cqaado3u	180	10	Rodolfo	Rodolfo	NNP
cord-334454-cqaado3u	180	11	Oliveira	Oliveira	NNP
cord-334454-cqaado3u	180	12	Leal	Leal	NNP
cord-334454-cqaado3u	180	13	and	and	CC
cord-334454-cqaado3u	180	14	Solange	Solange	NNP
cord-334454-cqaado3u	180	15	Gil	Gil	NNP
cord-334454-cqaado3u	180	16	and	and	CC
cord-334454-cqaado3u	180	17	was	be	VBD
cord-334454-cqaado3u	180	18	based	base	VBN
cord-334454-cqaado3u	180	19	on	on	IN
cord-334454-cqaado3u	180	20	the	the	DT
cord-334454-cqaado3u	180	21	recent	recent	JJ
cord-334454-cqaado3u	180	22	conclusions	conclusion	NNS
cord-334454-cqaado3u	180	23	of	of	IN
cord-334454-cqaado3u	180	24	rFeIFNomega	rfeifnomega	JJ
cord-334454-cqaado3u	180	25	studies	study	NNS
cord-334454-cqaado3u	180	26	.	.	.
cord-334454-cqaado3u	181	1	Both	both	DT
cord-334454-cqaado3u	181	2	authors	author	NNS
cord-334454-cqaado3u	181	3	contributed	contribute	VBD
cord-334454-cqaado3u	181	4	equally	equally	RB
cord-334454-cqaado3u	181	5	to	to	IN
cord-334454-cqaado3u	181	6	the	the	DT
cord-334454-cqaado3u	181	7	writing	writing	NN
cord-334454-cqaado3u	181	8	of	of	IN
cord-334454-cqaado3u	181	9	this	this	DT
cord-334454-cqaado3u	181	10	review	review	NN
cord-334454-cqaado3u	181	11	.	.	.
cord-334454-cqaado3u	182	1	The	the	DT
cord-334454-cqaado3u	182	2	authors	author	NNS
cord-334454-cqaado3u	182	3	declare	declare	VBP
cord-334454-cqaado3u	182	4	no	no	DT
cord-334454-cqaado3u	182	5	conflict	conflict	NN
cord-334454-cqaado3u	182	6	of	of	IN
cord-334454-cqaado3u	182	7	interest	interest	NN
cord-334454-cqaado3u	182	8	.	.	.
cord-334454-cqaado3u	183	1	Virbac	Virbac	NNP
cord-334454-cqaado3u	183	2	did	do	VBD
cord-334454-cqaado3u	183	3	not	not	RB
cord-334454-cqaado3u	183	4	interfere	interfere	VB
cord-334454-cqaado3u	183	5	with	with	IN
cord-334454-cqaado3u	183	6	the	the	DT
cord-334454-cqaado3u	183	7	presented	present	VBN
cord-334454-cqaado3u	183	8	conclusions	conclusion	NNS
cord-334454-cqaado3u	183	9	.	.	.
cord-334454-cqaado3u	184	1	The	the	DT
cord-334454-cqaado3u	184	2	company	company	NN
cord-334454-cqaado3u	184	3	only	only	RB
cord-334454-cqaado3u	184	4	sponsored	sponsor	VBD
cord-334454-cqaado3u	184	5	the	the	DT
cord-334454-cqaado3u	184	6	above	above	RB
cord-334454-cqaado3u	184	7	mentioned	mention	VBN
cord-334454-cqaado3u	184	8	research	research	NN
cord-334454-cqaado3u	184	9	work	work	NN
cord-334454-cqaado3u	184	10	in	in	IN
cord-334454-cqaado3u	184	11	a	a	DT
cord-334454-cqaado3u	184	12	practical	practical	JJ
cord-334454-cqaado3u	184	13	manner	manner	NN
cord-334454-cqaado3u	184	14	by	by	IN
cord-334454-cqaado3u	184	15	donating	donate	VBG
cord-334454-cqaado3u	184	16	rFeIFN	rfeifn	NN
cord-334454-cqaado3u	184	17	-	-	HYPH
cord-334454-cqaado3u	184	18	ω	ω	JJ
cord-334454-cqaado3u	184	19	(	(	-LRB-
cord-334454-cqaado3u	184	20	Virbagen	Virbagen	NNP
cord-334454-cqaado3u	184	21	)	)	-RRB-
cord-334454-cqaado3u	184	22	which	which	WDT
cord-334454-cqaado3u	184	23	was	be	VBD
cord-334454-cqaado3u	184	24	administered	administer	VBN
cord-334454-cqaado3u	184	25	to	to	IN
cord-334454-cqaado3u	184	26	FIV	FIV	NNP
cord-334454-cqaado3u	184	27	cats	cat	NNS
cord-334454-cqaado3u	184	28	.	.	.